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Leukocyte immunoglobulin-like receptors are a family of inhibitory and activating 
receptors found on a wide variety of immune cells, and are thought to play a 
significant role in determining immune responses. Their known ligands are HLA 
Class I molecules; HLA-G is the prototypic ligand which has high affinity for two 
inhibitory members of the family and mediates its immunosuppressive functions 
through them. 
 
The hypothesis of this study is that polymorphisms in the non-coding regions are 
likely to influence both the expression and response of the LILRs to various stimuli. 
Published data supports this view in that polymorphisms in the LILRs are 
associated with various immunologically mediated diseases. In addition, these 
molecules represent a potential target for therapeutic manipulation and attempts to 
develop a therapy using this route were undertaken. 
 
Expression levels of various LILR molecules on APCs at baseline and after 
stimulation have shown significant variation between subjects. Genomic variation 
in the promoter regions of LILRB2 was established by sequencing. The relationship 
between LILRB2 SNPs and cell expression levels was tested both directly and in a 
luciferase assay, but no significant associations were found. Engagement of 
LILRB2 by monoclonal antibodies was shown to affect TLR-induced cytokine 
secretion, but no relationship was found between LILRB2 expression levels and the 




A synthetic construct (the “G-body”) utilising the LILR-HLA-G interaction has 
been developed for testing as a potential therapeutic molecule. This construct 
comprises two functional domains – an anti-HLA class I domain and an HLA-G 
domain. This construct would be expected to modulate allogeneic responses by 
localisation of an immunosuppressive signal (HLA-G) to the allogeneic HLA 
molecule; and (ii) potentially masking the allogeneic HLA class I molecule. Testing 
has shown that the construct suppresses lymphocyte proliferation with enhancement 
of this effect dependent on the presence of allogeneic HLA class I. 
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The primary subject of the research presented in this thesis is the group of 
molecules known as the leukocyte-immunoglobulin like receptors, or LILRs. 
Despite being first described in the late 1990s, there is still relatively little 
understanding of these molecules, and it is hoped that the data presented in this 
thesis goes some way towards addressing that. 
 
This document is divided into an introduction summarizing the current state of 
knowledge in the field, a chapter on the materials and methods used for the 
research, four results chapters describing the main findings in this project and an 
overall discussion of the project. The page numbers for the main chapter headings 
are listed in the table of contents at the beginning of the document. The list of page 
numbers of figures and tables, as well as a list of abbreviations used immediately 
follows this. The list of references and appendices are at the end of the document. 
 
Briefly, the four main areas investigated are (i) the characterisation of the 
expression of LILRs on healthy individuals, (ii) exploration of how genomic 
variation affects this expression (with respect to one specific member, as proof of 
principle), (iii) the development of a synthetic molecule to utilize the LILRs 
therapeutically and (iv) testing the effect of LILR ligation in various functional 
experiments. Each chapter contains the tables and figures associated with that 
chapter and are placed at the end of the chapter (apart from chapter 2 where they are 
in the text). Each results chapter also contains a discussion relating to the 
experiments described within. 
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Chapter 1: Introduction 
 
Leukocyte immunoglobulin-like receptors (LILRs) 
 
The leukocyte immunoglobulin-like receptors (LILRs, also known as 
immunoglobulin-like transcripts, ILTs; leukocyte Ig-like receptors, LIRs; myeloid 
inhibitory receptors, MIRs and CD85) are a family of receptors expressed on a wide 
variety of immune cells. They are thought to play a significant role in both innate 
and adaptive immunity and can broadly be divided into activating and inhibitory 
receptors based on the presence of either immunoreceptor tyrosine-based activating 
motifs (ITAMs) or immunoreceptor tyrosine-based inhibitory motifs (ITIMs) in the 
cytoplasmic tail. Their role can be seen as analogous to the TLRs which are innate 
immune receptors which recognise microbial patterns, whereas the LILRs are innate 




Due to the simultaneous discovery of many of these receptors, they have been 
ascribed various names with ILTs and LIRs being the most commonly used ones. 
For standardisation, these molecules are now referred to as LILRs with LILRA 
being those with short cytoplasmic tails thought to have activating properties and 








The LILRs are encoded on chromosome 19q13.4 in a region known as the 
leukocyte receptor complex (LRC), which also encodes the killer immunoglobulin-
like receptors (KIRs) expressed on NK and cytotoxic T cells. They are thought to 
have arisen due to large-scale inverted duplication with further loss/gain of genes. 
(2;3) In total, there are 13 members belonging to this family of genes, with 6 
activating LILRs, 5 inhibitory LILRs and 2 pseudogenes. The LILR molecules are 
considerably less polymorphic than the neighbouring KIR molecules with little 




LILRs are predominantly expressed in cells of the myeloid lineage; and some of the 
members of the family are found on plasmacytoid dendritic cells as well as 
lymphocytes (Table 1).  
 
Structure, ligands and binding interactions with ligands 
 
The LILR molecules share a similar structure with two or four extracellular 
immunoglobulin-like domains, a transmembrane region and a cytoplasmic tail. 
(Figure 1.1) LILRA molecules have a short cytoplasmic tail with no signalling 
domains but indeed possess a charged arginine residue to allow interaction with 
adaptor proteins for downstream signalling. LILRB molecules, on the other hand, 
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possess a cytoplasmic tail containing two to four immunoreceptor tyrosine-based 
inhibitory motifs (ITIMs), with sequences NxYxxV, VxYxx(L/V) or SxYxxV. 
 
In addition to the membrane-bound LILR molecules, some members of the LILR 
family can also be expressed both in a membrane-bound form or as a soluble 
molecule, or only as a soluble molecule (i.e. LILRA3 and LILRB2).  
 
The ligands for the LILRs have only been established for some members of the 
family and generally, have been shown to be HLA class I molecules. (Table 1.1) It 
has been suggested that LILRs can be divided into two groups based on the amino 
acid sequence similarity in the regions thought to bind to HLA. (4) Members of 
group 1 have high sequence similarity and are predicted to bind to Class I HLA 
molecules – members of this group include LILRB1, LILRB2, LILRA1, LILRA2 
and LILRA3. All of these have been shown to bind HLA Class I molecules apart 
from LILRA2. (5) Group 2 molecules (LILRB3, LILRB4, LILRB5, LILRA4, 
LILRA5 and LILRA6), on the other hand, had poor conservation of the same 
residues and are thought to bind a different group of ligands, most likely not MHC 
Class I molecules. (4) 
 
UL18, which is a human CMV protein that resembles HLA I has been shown to 
bind to LILRB1 in immunoprecipitation experiments and is thought to be one of the 
mechanisms by which the virus subverts the host immune response. In addition, 
LILRB2 has been shown to bind to CD1d, a member of a family of non-
polymorphic MHC I like proteins that have a role in presentation of lipid 
antigens.(6) The functional implications of this remained to be established as CD1d 
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is primarily expressed on APCs, which also express LILRB2. It is not certain 
whether LILRB2 acts in a self-regulatory capacity to regulate CD1d antigen 
presentation or whether it is LILRB2 expression on other cells that are responsible 
for the inhibitory effect, in view of the fact that LILRB2 interacts with classical 
HLA I molecules in a trans manner. 
 
In addition to viral particles, some of the LILR molecules have also been shown to 
bind to intact bacteria. LILRB1 and LILRB3 have been shown to bind S. aureus and 
LILRB1 binds E. coli, although neither of these receptors bound H. pylori unlike 
PIR-B. (7) In these experiments, NIH3T3 cells were infected with retrovirus 
expressing LILR (and PIR) cDNA; and incubated with fluorescently labelled live or 
heat-killed bacteria prior to analysis using flow cytometry or immunofluorescence 
microscopy. The differences in binding patterns to different bacteria suggests that 
these molecule may play an important role in the innate immune response against 
these organisms. Further functional work undertaken by the same group 
investigating the effects of PIR (the LILR orthologues) binding to bacteria is 
discussed below.  
 
HLA-G, a non-classical HLA class I molecule is the prototypic MHC ligand for the 
LILRs and has high affinity for LILRB1 and LILRB2. It is discussed further below. 
In addition to HLA-G, LILRB1 has also been shown to bind to non-classical HLA 
molecules HLA-E and HLA-F, and LILRB2 to HLA-F. (8-10) 
 
The structural interaction between HLA-G and LILRB1 and HLA-A2 and LILRB2 
has been explored in detail using co-crystal structures and by nuclear magnetic 
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resonance. (4;11;12) LILRB1 and B2 use the two membrane distal Ig-like domains 
(D1 and D2) to interact with their ligands. The contact sites on the MHC molecule 
lie in the α3 domain and β2m; with the D1 domain interacting with the α3 domain 
and the D1-D2 hinge interacting with β2m. However, LILRB1 preferentially binds 
β2m compared to LILRB2 which preferentially binds the α3 domain, as 
demonstrated by its ability to bind β2m free MHC molecules. (11) As the α3 
domain and β2m are the most conserved parts of the MHC molecule, this explains 
the wide spectrum of MHC I and MHC I-like molecules that can interact with the 
LILRs. In view of this, it has also been suggested that one of the functions the MHC 
molecules might be the generation of self-tolerance through binding of the LILRs 
and might play a role as important as antigen presentation to T cells. (13) 
 
Further data has demonstrated that four different Class I HLA alleles showed 
different binding affinities to LILRB1 and LILRB2. (14) Using surface plasmon 
resonance, Shiroishi et al analysed the interaction of soluble LILRB1 and LILRB2 
with HLA-A*1101 (with peptide AIFQSSMTK), HLA-B*3501 (with peptide 
IPLTEEAEL), HLA-Cw*0401 (with peptide QYDDAVYKL) and HLA-G1 (with 
peptide RIIPRHLQL). (14) This showed that LILRB1 and LILRB2 bound with a 
>20-fold difference in affinities (Kd of 2 – 45 μM) to the various HLA I molecules. 
LILRB1 bound with a 2 to 3 times greater affinity compared to LILRB2 for the 
same HLA molecule; with both LILRB1 and LILRB2 showing 3 to 4 times greater 
affinity for HLA-G compared to conventional class I HLA molecules. In this study, 
LILRB1 and LILRB2 were also shown to compete with CD8 for binding to HLA I, 
suggesting that LILRB1 might modulate CD8
+
 T cell activation by blocking CD8 




The crystal structure of the D1 domain of LILRA3 has also been researched and its 
binding to HLA-A2 and HLA-G1 shown in surface plasmon resonance studies. (15) 
Crystallography showed that LILRA3 contained the essential fold necessary for 
HLA class I binding, one or two amino acid changes in the binding region of 
LILRA3 reduced binding affinity compared to LILRB1 and LILRB2; and that there 
was a unique self interaction between Lys42 and Glu68 in the LILRA3 D1, which 
was thought to contribute to the lower LILRA3 binding to classical HLA class I 
molecules. 
 
Although previously thought that LILR interactions with their HLA ligands were 
relatively static, due to their interaction with the non-polymorphic parts of the 
molecule, more recent data has emerged to indicate that this might not be the case 
and that HLA structure could affect binding affinity. In part, previous binding 
studies had focused on the interaction of LILR molecules with the regions of the 
HLA molecule most proximal to the cell membrane. Variability in LILR binding 
affinity for different HLA alleles was demonstrated in data published by Jones et al, 
who undertook a study to more comprehensively evaluate the binding of LILR 
receptors to >90 HLA class I alleles. (5) They tested the binding by using a panel of 
>90 HLA class I single antigen beads, manufactured by One Lambda. (16) LILR-Fc 
fusion proteins were generated for LILRB1, LILRB2, LILRB3, LILRA1 and 
LILRA3 by cloning the extracellular portion of the LILR molecules into a vector 
containing the human IgG1
 
Fc domain. The fusion proteins were then used in assays 





They found that allelic variation in the HLA I molecules influenced the binding 
affinity of all the LILR molecules investigated. LILRB1 had lower affinity for 




, which corresponded to a known binding site 
for LILRB1. (4) However, the presence of the Val
194
 variation in the absence of 
other polymorphisms did not influence the binding affinity in other HLA molecules 
(i.e. several HLA-B alleles, B*35, B*51, B*58 and most HLA-C alleles). LILRB2 
showed more variable binding to HLA molecules, with strongest affinity for HLA-
A alleles and weakest affinity for certain HLA-B molecules, particularly B*2705 
and B5701. The investigators found that a cysteine residue at position 1 and/or 
aspartate residue at position 9 in HLA-C molecules correlated with stronger 
LILRB2 binding. These positions are known to influence peptide loading within the 
peptide binding groove. However, similar correlations were not found for HLA-A 
and HLA-B alleles, nor did variations in these positions influence LILRB1 binding. 
LILRA1 and LILRA3 were shown to have similar binding patterns suggesting that 
they recognised similar binding sites. 
 
Some of the LILR molecules have also been shown to interact with β2m-free forms 
of several HLA molecules. LILRB2 (but not LILRB1) and LILRA1 have been 
shown to bind HLA-B27 free heavy chain in flow cytometry experiments. (17;18) 
Crystallography and NMR binding studies has shown that LILRB2 can bind to 
β2m-free HLA-G, mainly through interactions with the hydrophobic site of the 
HLA-G α3 domain. (11) In their larger study, Jones et al confirmed that LILRA1, 
LILRA3 and LILRB2 (but not LILRB1) all bound to a wide variety of Class I HLA 
free heavy chains. (5) In addition, LILRA1 and LILRA3 were shown to have 
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increased affinity following removal of β2m, unlike LILRB2 which showed 
reduced binding. LILRB2 showed a preference for binding to the FHC of HLA-A 
whereas LILRA1 and LILRA3 showed a more marked preference for binding to 
HLA-C FHC. (5)  
 
Crystal structure studies initially showed LILR interaction with the non-
polymorphic regions of the HLA molecules, although subsequent work has also 
demonstrated that LILR binding to polymorphisms within the peptide groove affect 
overall affinity. The studies done to date also indicate that the different LILR 
molecules recognise different parts of the HLA structure. 
 
It has been hypothesized that the differences in LILR binding affinity to different 
HLA alleles may alter the overall balance between activating and inhibitory signals, 
predisposing to disease. In the study by Jones et al, they suggest that the weaker 
binding of LILRB2 to HLA-B*2705 might be relevant in autoimmune diseases 
associated with HLA-B27 (e.g. ankylosing spondylitis). (5) On the other hand, this 
weaker affinity with HLA-B*2705 (and B*5701) may be beneficial in infectious 
conditions – both these alleles are associated with delayed onset of AIDS in HIV 
infection. (19) HLA-B*3503 (which showed strong binding to LILRB2) has 
conversely been associated with greater inhibition, reduced DC responsiveness and 
more rapid onset in AIDS. (20)  
 
There is also data indicating that HLA-B27 homodimers and FHCs have stronger 
binding affinity for LILRB2 than classical class I HLA molecules; and that the 
membrane-distal D1 and D2 regions are critical for binding to B27 homodimers. 
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(21) This was not specifically described in the study by Jones et al. Relating this to 
the development of ankylosing spondylitis (AS), the authors suggested that as 
LILRB2 could inhibit osteoclast activity, (22) the increased strength of HLA-B27 
homodimer binding might result in inhibition of osteoclast activity resulting in new 
bone formation, that is seen in AS. In addition, HLA-B27 homodimers and FHCs 
could also interfere with immune tolerance by cis recruitment of LILRB2 on 
dendritic cells, preventing its interaction with HLA-G, which has been shown to 
induce a tolerogenic phenotype. (23;24) 
 
In view of the possible similarities in LILRA1 and LILRA3 binding sites, it has 
been suggested that LILRA3 (which is predicted to encode a soluble protein) may 
act as a competitive inhibitor of LILRA1 and reduce its activating function. (5) A 
similar phenomenon has been demonstrated for a soluble form of LILRB1. (25) In 
support of this hypothesis, LILRA3 deficiency has been described and is associated 
with the development of multiple sclerosis and Sjogren’s syndrome. (26-28) 
 
The binding of the so-called Group 2 LILR members is less clear. LILRA4 has been 
shown to bind to bone marrow stromal cell antigen 2 (BST2). (29) Engagement of 
LILRA4 on PDCs by its cognate ligand has been shown to result in strong 
inhibition of production of interferon and proinflammatory cytokines. Studies of the 
crystal structure of LILRB4, however, have suggested that it is both 
conformationally and electrostatically unsuitable for binding to MHC class I, 




LILRB2 has been shown to interact in cis with MHC class I on human basophilic 
leukaemia cell line, KU812 which expressed LILRB2, LILRRB3 and class I HLA 
molecules. (31) Masuda et al used confocal microscopy and FRET to confirm that 
LILRB2 was co-localised with HLA-A, B and C on KU812 cells unlike LILRB3. 
Although not confirmed in human cells, experiments in murine mast cells suggest 
that the in cis interaction increases the threshold for activation signalling. (31) The 
inhibitory NK cell receptor Ly49A has been shown to bind in cis to H-2D
d
 as well, 
(32) although conversely, it prevents binding of Ly49A to its target cells and 




The activating LILRA molecules possess short ITAM motifs that do not have 
docking sites for downstream signalling molecules. Instead, they possess single 
basic arginine residues which allow interaction with FcεRIγ. (34) So far, this is the 
only adaptor protein known to interact with LILRs, although it is possible that other 
adaptor proteins may share an interaction as well. Clustering of the activating 
receptors on the cell surface is thought to result in phosphorylation of a tyrosine 
residue within the ITAM sequence on FcεRIγ allowing recruitment of protein 
tyrosine kinase with Src2 homology (SH2), which then leads to intracellular 
signalling through Ca
2+
 mobilisation. (35) 
 
However, not all the so-called “activating” receptors have activating functions. 
LILRA2 activation can result in inhibition of GM-CSF induced DC differentiation, 
antigen presentation and response to TLR stimulation in a leprosy model. (36) 
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LILRA4 engagement has been shown to downregulate TLR stimulation of type I 
interferons and other cytokines by plasmacytoid DCs. (37) 
 
The inhibitory LILRB receptors possess long cytoplasmic tails that contain 2 to 4 
ITIM motifs that can recruit the protein tyrosine phosphatase SHP-1 to modulate 
downstream signalling. (38-40) LILRB1 has also been shown to bind C-terminal 
Src kinase (Csk), which phosphorylates Src kinases at the C-terminal tyrosine 
residue, and is thought to regulate its function. (41) In an experimental model with 
transfected rat basophilic leukaemia cells (RBL), LILRB2 and LILRB3 have been 
shown to inhibit serotonin release following FcεRI engagement. (40) There is also 
data to suggest that the inhibitory LILRs may modulate signalling through FcγRI, 
FcγRII, HLA-DR and the B cell receptor. (39;40;42-44) The interaction of LILRB1 
and LILRB2 with HLA Class I molecules may also modulate the secretion of 
cytokines and chemokines by CD40 stimulated monocytes. (43) 
 
Orthologues and homologues 
 
Homologous genes (or homologues) are two genes that are related by a common 
ancestral DNA sequence. If this is a result of a speciation event resulting in two 
different species, then the homologous genes are referred to as orthologues 
(compared to paralogues, which are homologous genes arising due to gene 
duplication). The paired immunoglobulin receptors (PIRs) in mice  have been 
identified as LILR orthologues. The PIRs were originally identified as being 
homologous to FcαRI, the human Fc receptor for IgA. (45) However, these 
molecules were shown to not have any interaction with IgA and subsequently, 
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based on similarity in expression, structure and genome location were thought to be 
orthologues for the LILRs. (45-47) In addition, a further homologue, LILRB4 
(previously known as gp49B1) in mice has also been found. (48;49) 
 
Orthologues for the LILRs have also been described in other species. Rat PIR-A 
and PIR-B which share similar structural sequences to the mice homologues have 
been described. (50) Similar genes in chickens (CHIR-A and CHIR-B), (51-53) 
chimpanzees, (54) gray seals (55) and cows (56) have also been identified. 
 
PIR genetics, expression and protein structure 
 
The PIR molecule are encoded at the proximal end of mouse chromosome 7, which 
is syntenic to the LRC on human chromosome 19q13.3-13.4. (46;47) PIR-A is 
encoded by at least 6 Pira genes and PIR-B (also known as LIR-3 and gp91) is 
encoded by Lilrb3 (also known as Pirb). (57) 
 
PIR-A and PIR-B are present on cells of the myeloid lineage (including mast cells, 
dendritic cells, macrophages, granulocytes and osteoclasts) and B cells (which 
express PIR-B but not PIR-A), but not on thymocytes, T cells or NK cells. 
(22;45;46;58) PIR-B has also been shown to be expressed transiently on early 
prethymic progenitors of T cells, NK cells and DCs although its exact role in this 
developmental stage remains unknown. (59) They are typically expressed in a pair-
wise fashion. (58) However, frequently there is greater cell surface expression of 
PIR-B compared to PIR-A. (31;58;60) Cell surface expression of PIR-B varies 
depending on the state of activation and differentiation of myeloid or B cells; 
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mature naïve B cells express PIR-B exclusively, and their levels are highest on 
marginal zone B cells. (58;60;61) Experiments looking at the expression of PIR-A 
and PIR-B on either Lilrb3 -/- or Fcrg -/- mice have shown dominant expression of 
PIR-B (compared to PIR-A) on splenic macrophages, splenic DCs and bone-
marrow derived cultured mast cells; with only PIR-B expression on splenic B cells. 
(60;62) Expression levels of PIR-A and PIR-B were also consistent with deletion of 
the other paired receptor, suggesting that the surface expression of the two 
molecules is fairly consistent for a given cell type in resting conditions, with PIR-B 
likely to have a dominant inhibitory effect through continuous interaction with the 
MHC. (63)  
 
PIR-A and PIR-B have very similar extracellular structures with 92% identity in 
their ectodomains. Both PIR-A and PIR-B are type I transmembrane glycoproteins 
with six extracellular immunoglobulin-like domains. PIR-B possesses a 
hydrophobic transmembrane region and four intracellular ITIM or ITIM-like 
sequences.(45;46) In contrast, PIR-A possesses a different pre-transmembrane, 
transmembrane regions and cytoplasmic sequences with ITAM motifs. (46) The 
transmembrane region in PIR-A has a positively charged arginine residue which 
allows association with homodimeric FcγR. This interaction with FcγR is necessary 
for expression of PIR-A on the cell surface and delivery of an activating signal. 
(58;64;65)  
 
Comparison of the extracellular sequences of PIR from several strains of mice 
(129/Sv, B10.A and BALB/c) show a high degree of sequence similarity, although 
multiple amino acid polymorphisms have been noted, similar to the LILR 
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molecules. (39;46) However, it has not yet been determined if these polymorphisms 
affect the binding affinity of the PIR molecule. 
 
Although PIR-B is thought to be related to LILRB1 and LILRB2, it only has about 
50% amino acid homology and has six Ig-like domains, unlike the 4 present in 
LILRB. (46;63) Similarly PIR-A also has six Ig-like domains unlike the four found 
in the orthologous LILRA2.  
 
Expression in neuronal tissue 
 
In addition to their role in the immune system, PIR-B has also been found to be 
broadly expressed in neuronal tissue. (66;67) Further work by Atwal et al has also 
shown that the PIR-B (and human LILRB2) can bind the myelin inhibitor neurite 
outgrowth inhibitor protein (Nogo66). (67) In addition, PIR-B also bound other 
myelin inhibitors, myelin-associated glycoprotein (MAG or Siglec-4) and 
oligodendrocyte myelin glycoprotein (OMgp). From these experiments, it was 
postulated that PIR-B (and possibly LILRB2, although there is little data on this) 





PIR-B (and most likely PIR-A) bind to murine H-2 (MHC I) molecules although the 
exact interaction with the MHC remains to be determined. In surface plasmon 
resonance experiments, PIR-B has been shown to bind monomeric H-2 molecules at 
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affinities of Kd= 1.9 to 5.6 x 10
-7
M. (68) These values are similar to the binding 
affinities between IgG and its low-affinity receptors, FcγRIIB and FcγRIII. (69) 
Recombinant PIR-B has also been shown to bind to murine β2m, (68) which 
suggests that the interaction is likely to be the same as that of the LILRB molecules, 
i.e. involving the constant α3 domain of the MHC and β2m. (14) In addition, the 
PIR molecules have also been shown to bind to human HLA-G. (68;70) 
 
In addition to MHC, the PIR molecules can also bind non-self ligands. Similar to 
pattern recognition receptors (e.g. TLRs, scavenger receptors and lectins), PIR-B 
can bind S. aureus, E. coli and H. pylori. (7) However, PIR-B was not able to bind 
B. subtilis, L. monocytogenes or P. aeruginosa. (7) In contrast, only one isoform of 
PIR-A, PIR-A1 was shown to bind to bacteria. The differential recognition of 





In a rat mast cell line (RBL-2H3) transfected with PIR-A, engagement of the 
receptor with antibodies results in calcium mobilisation and degranulation. (71) 
Activation signalling via PIR-A in this model was mediated through associated 
molecules including FcγR and the FcεRIβ chain; the residues Arg626 and Glu643 
are critical for PIR-A activating function and association with the FcR molecules. 
(64) In experiments with the ligand for PIRs, binding of H-2 tetramers induced 
phosphotyrosylation of FcRγ in peritoneal macrophages. (68) This 
phosphotyrosylation was further increased in mice that were PIR-B deficient, 
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suggesting that PIR-A could deliver an intracellular activation signal via FcRγ after 
engagement with its ligand, and that this signal was continuously blocked by 
interaction with PIR-B expressed on the same cell. (68) 
 
PIR-B exerts its inhibitory signalling effect by recruitment of the SH2-containing 
tyrosine phosphatases, SHP-1 and/or SHP-2 to the phosphorylated ITIM motifs. 
(72-74) Although in vitro experiments have shown binding of peptides in third and 
fourth ITIM to SHP-1, SHP-2 and SHIP-1, (47) inhibition experiments show loss of 
PIR-B function in SHP-1 and SHP-2 double negative DT40 chicken B cells, but not 
loss of function in SHIP-deficient cells. (75) This implied that PIR-B can negatively 
regulate B-cells through non-redundant functions in SHP-1 and SHP-2 but not 
SHIP. (75) It has also been noted that PIR-B is constitutively phosphorylated in 
macrophages and B cells regardless of the activation status of the cell, and that PIR-
B in splenocytes was constitutively associated with SHP-1 and Lyn. (76) This 
suggests that PIR-B inhibition does not require co-ligation with the B-cell receptor 
by a shared ligand. 
 
PIR-B has been shown to bind to MHC I in cis in fluorescence energy transfer 
(FRET) experiments done on mast cells. (31) Cis interactions have also been 
demonstrated on osteoclast precursor cells, B cells and DCs. (22;77) Mast cell 
stimulation by LPS or IgE cross-linking were shown to be suppressed by in cis 
binding of PIR to MHC I. (31) In addition, osteoclast development is regulated by 
the PIR-B cis interaction with MHC I on the surface of osteoclast precursor cells. 







The availability of PIR-B knockout mice has enabled better understanding of the 
functional effects of these molecules. In in vitro experiments, B cells, neutrophils 
and macrophages with a Pirb knockout have been shown to be hyper-responsive. 
Pirb -/- splenic B cells have increased proliferation when stimulated with anti-BCR 
antibodies, and this effect becomes more marked with the addition of blocking 
antibodies against FcγRIIB. (60) This was taken to indicate that the inhibitory effect 
of these molecules was additive, possibly because PIR-B recruited SHP-1 and 
FcγRIIB recruited SHIP. Pirb -/- B cells were also shown to have increased 
phosphorylation of proteins, suggesting that there was constitutive activation. (60) 
In keeping with this, Pirb-/- mice also had a greater increase in IgM when 
vaccinated with T-independent antigens (trinitrophenol-Ficoll and trinitrophenol-
LPS). (60) 
 
PIR-B is thought to be important in the regulation of neutrophil and macrophage 
integrin signalling. Pirb-/- neutrophils have been shown to have an increased 
respiratory burst, secondary granule release and hyperadhesive phenotype after 
engagement with integrin. (78) In addition, bone marrow derived macrophages form 
Pirb-/- mice also demonstrated a hyperadhesive phenotype and more rapid 
spreading after cross-linking with β2 integrins. (78) 
 
In terms of antibody responses, Pirb-/- mice demonstrate an increased response to 
vaccination with TNP-keyhole limpet haemocyanin or ovalbumin with alum as an 
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adjuvant. (60) There was both an elevated IL-4 and reduced IFN-γ cytokine 
response and increased production of IgG1 and IgE. The reason for this difference 
was thought to be due to the immature phenotype of DCs generated in Pirb-/- mice. 
Bone marrow derived DCs from the knockout mice showed an immature phenotype 
when assessed for surface MHC II, CD80 and CD86 expression, and had reduced 
production of IL-12 on antigen loading. Tyrosine phosphorylation of PIR-B was 
altered on exposure to GM-CSF and these profiles were different in Pirb-/- cells - 
suggesting that the H-2 interaction with PIR-B could be significant for DC 
maturation and control of humoral responses. (60) 
 
However, Pirb-/- DCs have been shown to generate greater activation in CD8
+
 T 
cells (77) despite their immature phenotype and inability to fully activate CD4
+
 T 
cells. (60)The reason for this phenomenon is thought to be due to PIR-B on DCs 
competing with CD8αα on T cells for interaction with MHC I on DCs (as 
demonstrated by surface plasmon resonance). (77) Hence, the absence of PIR-B 
results in greater activation of CD8
+
 T cells, and this has been shown to also result 
in greater rejection of skin grafts and tumours in vivo. (77) However, it is not 
certain whether PIR-B is more likely to interact in cis with the MHC on DCs or in 
trans with the MHC on T cells in the immunological synapse. 
 
In view of the interaction between human HLA-G and PIR-B, work has been done 
to determine the effects of this interaction, particularly as HLA-G is likely to play a 
significant role in feto-maternal tolerance by inhibiting NK cells. BMDC from 
HLA-G transgenic mice have poor maturation, with increased phosphorylation of 
PIR-B. Similarly, HLA-G tetramers have been shown to inhibit in vitro maturation 
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of murine BMDC. (70) Whether a similar phenomenon occurs in the mouse system 
with murine MHC Class Ib molecules (e.g. Qa-1) remains to be determined. 
 
Pirb-/- knockout mice have also been used to investigate the consequences on 
immune tolerance in a GVHD model. (68) Pirb-/- or wild type mice were irradiated 
and received allogeneic splenocytes intravenously. The Pirb-/- mice developed 
accelerated, lethal GVHD due to increased activation of recipient DCs, with 
upregulation of PIR-A, increased production of IFN-γ and proliferation of donor 
cytotoxic T cells. 
 
In a rat model of cardiac transplantation, Liu et al demonstrated the importance of 
CD8
+
 T suppressor cells for tolerance. (79) These CD8
+
 T suppressor cells induced 
upregulation of PIR-B in dendritic cells and heart endothelial cells, resulting in 
tolerance similar to the induction of LILRB2 and LILRB4 in human dendritic and 
endothelial cells by human CD8+ FOXP3+ T suppressor cells. Furthermore, when 
heart allografts with PIR-B positive endothelial cells were transplanted into a 
second allo-recipient, there was no rejection. 
 
It has been shown in eosinophils that PIR-B potentially has dual functionality and 
can perform both an activating and inhibitory role depending on the circumstances 
and signals resulting in activation. (80) Pirb was shown to be upregulated in an 
eosinophil dependent manner in the lungs of allergen-challenged and IL13-
overexpressing mice. Eosinophils had high levels of PIR-B expression and Pirb-/- 
knockout mice had increased eosinophils in the gastrointestinal tract. Eotaxin 
dependent eosinophil chemotactic responses were negatively regulated by PIR-B; 
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however, leukotriene B4 (LTB4) stimulation in Pirb-/- eosinophils resulted in 
decreased chemotactic responses. (80) Furthermore, it was shown that LTB4, but 
not eotaxin stimulation, resulted in PIR-B recruitment of multiple activating 
kinases; and that  Pirb-/- eosinophils activated by eotaxin had increased ERK1/2 
phosphorylation whereas LTB4 stimulation resulted in reduced ERK1/2 
phosphorylation. 
 
PIR-B has been shown to play a role in responses to bacteria, and this has been 
demonstrated in responses to Staphylococcus aureus and Salmonella enterica. 
(7;81) Pirb-/- knockout mice have greater susceptibility to Salmonella infection in 
part due to failure of Pirb-/- macrophages to control intracellular replication of the 
organism, thought to be due to imbalance in the signals generated by PIR-A and 
PIR-B in the response to bacteria. (81) Interference with PIR-B binding to S. aureus 
(either by blocking monoclonal antibodies or gene deletion) resulted in increased 
TLR-mediated inflammation in response to bacteria, although the significance of 
this finding is unclear. (7) Bone marrow derived macrophages produced higher 
levels of IL-6 and TNF-α with suppression of IL-10 in response to stimulation with 
S. aureus with either Pirb-/- knockout or blockade with monoclonal antibody. (7) 
Interference with PIR-B function did not make any difference to TLR responses on 
exposure to LPS or PAM3CSK4. There was a similar enhancement of IL-6 
production on exposure of Pirb-/- macrophages to H. pylori but not P. aeruginosa, 
again providing evidence that PIR-B discriminates between different bacteria. (7) 
 
PIR-B regulation is also relevant in the TLR9 system in B-1 cells. (61) PIR-B exerts 
its effects at the level of Btk; PIR-B phosphorylation is enhanced by activation of 
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Lyn (76) via the TLR9 pathway and this results in increased recruitment of SHP-1 
to the phosphorylated ITIMs of PIR-B resulting in Btk dephosphorylation, (82) 
which in turn attenuates the phosphorylation level of NF-κB p65RelA. (83;84) It 
has been suggested that this has potential implications in autoimmunity as B-1 cells 
are the main producers of rheumatoid factors and other autoantibodies; (85) and 
manipulating the PIR-B inhibitory system for therapeutic benefit while maintaining 




Murine LILRB4 is expressed on mast cells, neutrophils and macrophages and 
possesses two Ig-like domains as well as two intracellular ITIM motifs , similar to 
the PIR/other LILR molecules. (48;49;87) Its natural ligand has been identified as 
the integrin αvβ3. (88) It has been shown to inhibit in vitro activation of mast cells 
via IgE by recruitment of SHP1 to the cell membrane. (89) Lilrb4-/- knockout mice 
are more prone to severe IgE mediated mast cell dependent anaphylactic reactions 
compared to wild type mice (90) and also mast cell-dependent inflammation due to 
stem cell factor (SCF) interaction with Kit. (91) This indicates that LILRB4 can 
block inflammation both caused by Fc receptors signalling through ITIMs but also 
signalling through a receptor tyrosine kinase.   
 
Additionally, LILRB has been shown to play a role in modulating neutrophilic 
inflammation as well. Lilrb4 -/- mice demonstrate greater inflammatory responses 
in LPS and autoantibody induced neutrophilic inflammation. (92;93) Wild type 
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mice have a rapid upregulation of LILRB4 in response to LPS, suggesting that this 
may represent a regulatory response to prevent excessive inflammation. (92) 
 
Lilrb4 -/- mice are also more prone to develop eosinophilic pulmonary 
inflammation following inhaled sensitisation to ovalbumin and LPS, and ovalbumin 
airway challenge. (94) These mice had increased levels of ovalbumin-specific IgE 
and Th2 cytokines from ovalbumin restimulated cells from lymph nodes. Following 





bearing DCs in lymph nodes draining the lung. Conversely, in Lilrb4-/- mice, there 
were more mature DCs and IL4-producing lymphocytes in the draining lymph 
nodes. Adoptive transfer of OVA-pulsed Lilrb4-/- bone marrow derived DCs into 
Lilrb4+/+ mice resulted in increased allergic lung inflammation, compared to bone 
marrow derived DCs from Lilrb4+/+ mice. Taken together, these data suggest that 
upregulation of LILRB4 occurred in the maturation and migration of pulmonary 
DCs to the lymph nodes; and that LILRB4 ameliorated the ability of these DCs to 
generate pathological Th2 inflammation. (94)  
 
 
LILRs and influence on immune responses/functional effects 
 
Antigen presenting cells 
 
Dendritic cells are potent antigen presenting cells (APCs) which are capable of 
initiating primary immune responses and determining the subsequent outcome of 
the immune response. (95;96) DCs originate from haematopoietic stem cells in the 
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bone marrow and can broadly be divided into two major differentiation pathways 
depending on the expression of CD11c. (95) CD11c
+
 DC population includes blood 
myeloid DCs, Langerhans cells and interstitial DCs. The CD11c
-
 DC population are 
referred to as plasmacytoid DCs, and express CD123 (IL3Rα). 
 
The LILRs vary in their expression on various types of APCs. LILRA2, LILRB1, 
B2, B3 and B4 are found on myeloid DCs whereas LILRA4 appears to be restricted 
to PDCs. (37) It is also not known at present how engagement of multiple different 
LILRs on the cell would affect subsequent downstream events. However, there has 
been recent work exploring the contribution of some of these molecules towards DC 
function. 
 
The cell surface expression of LILRB1 (and to a far lesser extent, LILRB2 and 
LILRB4) has been shown to increase or be present during the differentiation 
process of monocytes into DCs in vitro. (97-99) Engagement of LILRB1 by 
monoclonal antibodies or the CMV protein, UL18 during the process results in 
failure of DC maturation and inability to stimulate primary and memory T cell 
responses. The CD80-CTLA4 costimulatory pathway was thought to play a role in 
this mechanism as blockade reversed the effect of LILRB2 engagement. (99) The 
cytokine profile and migratory capacity of the DCs were also affected. (97-99) 
 
LILRB2 and LILRB4 have also been shown to play a role in the context of 





suppressor (Ts) cells. (100;101) These DCs express high levels of LILRB2 and 
LILRB4 and show a phenotype with reduced levels of the costimulatory molecules 
41 
 
CD80 and CD86, as well as impaired ability to activate T cells. (100;101) In 







T cells converting them into regulatory T cells which can then further propagate the 
suppression cascade. LILRB2 and LILRB4 may produce their effects through 
different mechanisms; LILRB2 binding to its ligand results in failure of 
costimulatory molecule and MHC molecule upregulation (24;100) whereas LILRB4 
may provide its signal through its T cell ligand as there is data to suggest that 
soluble forms of the receptor are capable of providing inhibitory stimuli. (102;103) 
 
In addition to the inhibitory LILRB family members, some of the so-called 
“activating” LILRAs also have inhibitory effects on DCs as described above. 
LILRA2 has been shown to inhibit MoDC differentiation, antigen presentation and 
response to TLR stimulation (36) whereas LILRA4 engagement results in reduction 
of type I interferon secretion by PDCs. (37) 
 
Although engagement of some of the LILRs has been shown to affect cytokine 
production, conversely cytokines can influence LILR expression; IL10 and 
interferon-α have been shown to upregulate LILRB1, LILRB2 and LILRB4 to 
generate tolerogenic DCs. (23;104-107) 
 
The differential recognition of HLA molecules by LILR may represent part of the 
explanation how these molecules regulate and fine tune immune responses. For 
example, enhanced HLA FHC recognition by LILRA1 and LILRA3 may be 
relevant in an inflammatory context. Increased FHC expression is found with 
lymphocyte and APC activation; (108-113) HLA-C is prone to formation of FHC 
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due to its stability in the absence of β2m and this form is specifically upregulated on 
macrophages during differentiation. (114-117) Furthermore, class I HLA molecules 
clustering on activated T cells is influenced by increased FHC levels; (113;118;119) 
and this clustering can potentially enhance receptor recognition and downstream 
activity. (120) 
 
Human leukocyte antigen G (HLA-G) 
 
HLA-G is one of the non-classical HLA Class I molecules and shares a structure 
similar to the rest of them, with 3 α domains associated with β2m, although it has 
markedly less polymorphism. It was first discovered in the context of expression on 
cytotrophoblast cells, acting as a ligand for inhibitory receptors present on uterine 
NK cells, and thought to play a role in feto-maternal tolerance. (121) It differs from 
other MHC class I molecules by its lower degree of polymorphism, restricted tissue 
distribution, expression as 7 different isoforms due to alternative mRNA splice 
variants and its contribution as an immunosuppressive molecule. (122) 
 
HLA-G only has 14 different protein variants encoded by 44 alleles; many of which 
are silent mutations. (123) However, polymorphism in the noncoding regions has 
been shown to alter HLA-G expression with functional effects. (124) The 3’ UTR 
region which plays an important role in regulation of HLA-G expression has been 
shown to have 2 main polymorphic sites: a 14bp insertion associated with lower, 
but more stable mRNA production and a +3142 SNP, which is thought to act as a 
target for microRNA. (123) HLA-G polymorphisms have been shown to be 
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associated with rejection in heart transplants, inflammatory bowel disease, recurrent 
spontaneous abortion, pemphigus vulgaris and sarcoid. (123;125-128) 
 
HLA-G transcription can be found in most cells and tissues in healthy individuals, 
although translation is restricted to specific sites including trophoblast, thymus, 
cornea, nail matrix, pancreas and erythroid and endothelial precursors. (129) Neo-
expression of HLA-G has been seen following organ transplantation, or in 
malignancy, viral infections and autoimmune disease. (129) 
 
HLA-G can be expressed as 7 different isoforms as a result of alternative splicing of 
the primary mRNA transcript. (129) Four of these isoforms (G1 to G4) are 
membrane-bound and three (G5 to G7) are soluble. In addition, the membrane-
bound forms of HLA-G can be shed through proteolysis. HLA-G1 and G5 have a 
structure similar to the classical HLA molecules with 3 globular α domains that 
associate with β2m. The remaining isoforms lack one or more of the globular 
domains (although all contain the α1 domain) and should not associate with β2m or 
peptide. HLA-G (similar to HLA-B27) is also known to form homodimers (and 
potentially homotrimers) through disulphide bond formation between 2 unique 
cysteine residues at position 42 and 147. (130-132) HLA-G dimerisation has been 
shown to increase binding affinity to LILRB1 and LILRB2 potentially by 
generating an oblique orientation exposing these binding sites. (130) In addition, 





The principal ligands for HLA-G are LILRB1, LILRB2 and KIR2DL4.(39;40;134) 
In addition, HLA-G binding to CD8 has also been demonstrated. (135) LILRB1 is 
expressed on all monocytes/dendritic cells, B cells, some T cells and some NK cells 
(39) whereas LILRB2 is only expressed on monocytes/DCs. (40) KIR2DL4 is 
expressed on CD56
bright
 NK cells, which constitute the majority of uterine NK cells 
but only a minority of peripheral cells. (136-138) Through these receptors, HLA-G 
can effectively interact with a broad array of immune cells. 
 
The main physiological function of HLA-G is thought to be facilitation of maternal 
tolerance of the foetus. HLA-G has been shown to protect cytotrophoblast cells 
from maternal NK cells through interaction with inhibitory receptors on the NK 
cells. (121) In addition, HLA-G secretion by embryos appears to be necessary for 
implantation and pregnancy in in vitro fertilisation. (139;140) Given the broad 
expression of HLA-G ligands, its role in pathological scenarios, particularly in 
transplantation and oncology has also been investigated. HLA-G has been studied in 
the context of heart, kidney, liver, combined liver-kidney transplants and as would 
be expected, higher expression of HLA-G in the graft or in plasma was associated 
with better allograft acceptance. (141-147) Conversely, in malignancy, HLA-G 
expression would be expected to result in tumour tolerance and poorer outcomes. 
To date, HLA-G expression has been shown to protect tumour lesions from 
cytolysis (148-150), to be associated with malignant ascites in ovarian and breast 
carcinomas (151), to be upregulated in malignant melanoma (152), and to signify 
poorer outcomes and immunodeficiency in chronic lymphocytic leukaemia (153); 




HLA-G and LILRs 
 
β2m associated HLA-G is a high affinity ligand for LILRB1 and LILRB2, which is 
enhanced by dimerisation through disulphide bonds. (14) In view of this, it would 
be expected that situations where expression of HLA-G occurs would result in 
dominant immunosuppressive effects. In addition, HLA-G free heavy chains can 
bind to LILRB2 (but not LILRB1) and exert immunosuppressive effects as well. 
(155) It has also been shown that expression of HLA-G can upregulate LILRB1, 
LILRB2 and LILRB4 expression; (156) and that IL10 upregulates both LILRB 
molecules and HLA-G. (104;106;157;158) 
 
Potential therapeutic implications 
 
The widespread distribution of the LILRs on multiple immune cells suggests that 
they are likely to play a role in many disease processes. Although data is beginning 
to accumulate, several studies have demonstrated the association and influence of 
LILRs in transplantation, autoimmune disease, infection and tumour evasion 
(summarised in Table 1.2).  
 
Consequently, the development of therapeutic manipulation utilising the inhibitory 
LILRs for immunosuppressive effects, for example through its natural ligands, 
including HLA-G or by artificial constructs such as monoclonal antibodies could be 
beneficial in various scenarios including transplantation, autoimmune and 
inflammatory disease. Conversely, engagement of the activating LILRs could be 
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used in various scenarios where enhancement of the immune system would be 
beneficial, for example, malignancy and infectious diseases.  
 
This represents an exciting area for development in that there is much that remains 
to be discovered about this family of molecules, with potentially significant benefits 




The main hypothesis of the project is that genetic polymorphisms (both coding and 
non-coding) in the LILR molecules are likely to affect their expression levels and 
the function of immune cells. At present, there is some although very limited data to 
indicate that polymorphisms in the LILRs (similar to other immune system genes) 
can influence individual susceptibility to rheumatological disease and no work on 
the role of polymorphisms in the context of antigen presenting cells, particularly 
monocytes and dendritic cells which play important roles in determining the nature 
of immune responses. 
 
Consequently, it is hoped that a greater understanding of the basic science will 
enable development of therapeutic modalities. To this end the other part of the 
project has also focused on the development of a therapeutic molecule, the “G-
body” and testing its use in alloimmune responses. The G-body was conceived as a 
bifunctional molecule with two “business ends” to exploit the potential 
immunosuppressive properties of the LILRs for use in an allogeneic setting. One 
business end would comprise HLA-G, the known highest affinity ligand for 
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LILRB1 and LILRB2 to exploit the immunosuppressive potential of these 
molecules. The other business end would comprise an anti-HLA mAb portion or 
whole molecule (HLA-A2 was used in this project for proof of concept) to allow 
localisation of the G-body to targets bearing the allogeneic HLA. This combined 
molecule would allow localisation of the immunosuppressive signal delivered 
through the LILRs by HLA-G to allogeneic cells bearing foreign MHC molecules; 




Aims and Objectives 
 
The project has two broad aims: 
 
(i) to explore the basic science underlying how genetic polymorphisms affected the 
expression of LILR molecules and the functional consequences of this; particularly 
in the context of antigen presenting cells; and 
 
(ii) to develop a therapeutic molecule which targets LILRs (the G-body) and test its 
effect on functional responses. 
 
The specific objectives of the project are: 
 
1. Establish baseline levels of expression of various LILR molecules on 
antigen presenting cells 
2. Test the function of antigen presenting cells with and without engaging the 
LILRs 
3. Obtain genomic DNA for genetic polymorphism typing of the LILRs 
4. Compare the expression levels and functional results with the 
polymorphisms to determine if any correlations exist 
5. To construct the G-body molecule and confirm its characteristics 







Members of the leukocyte immunoglobulin-like receptor (LILR) family. 
Members are divided into activating ‘A’ receptors with a short cytoplasmic tail 
and charged arginine residue in the transmembrane region, or inhibitory ‘B’ 
receptors with a long cytoplasmic tail and two to four ITIM domains. 
Members of the LILR family have also been divided into Group 1 and Group 2 
receptors on the basis of conserved residues shared with LILRB1. Group 1 



































































































































A summary of the various LILRs, their alternative names, the number of immunoglobulin (Ig) domains, cytoplasmic tail and ligands 
they possess and their cellular distribution 
 
 Alternative names Number of Ig 
domains 
Ig domains and 
tail 
Ligands Expression 
LILRA1 LIR6, CD85i 4 Arginine+TM HLA Class I, with increased 
affinity for free heavy chains 
Macrophages 
LILRA2 ILT1, LIR7, CD85h 4 Arginine+TM HLA Class I Monocytes, macrophages, dendritic 
cells, NK cells, basophils, eosinophils 
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 Alternative names Number of Ig 
domains 
Ig domains and 
tail 
Ligands Expression 
LILRA3 ILT6, LIR4, 
CD85e, HM43, 
HM31 
4 Soluble form only HLA Class I, with increased 
affinity for free heavy chains 
Only expressed in soluble form, 
produced by monocytes 
LILRA4 ILT7, CD85g,  4 Arginine+TM Bone marrow stromal cell 
antigen 2 (BST2)  
Plasmacytoid dendritic cells 
LILRA5 ILT11, LIR9, 
CD85f, LILRB7 
4 Arginine+TM Unknown CD14
+
 monocytes 
LILRA6 ILT8, CD85b, 
LILRB6 
4 Arginine+TM Unknown Unknown 
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 Alternative names Number of Ig 
domains 
Ig domains and 
tail 
Ligands Expression 
LILRB1 ILT2, LIR1, CD85, 
CD85j, MIR7 
4 4 ITIM, Csk  HLA-A, HLA-B, HLA-F, 
HLA-G 
HCMV UL18 protein 
S. aureus, E. coli 
Monocytes, macrophages, dendritic 
cells, osteoclasts, eosinophils, B cells, 
T cells, NK cells, placental stromal 
cells 
LILRB2 ILT4, LIR2 CD85d, 
MIR10 
4 3 ITIM HLA-A, HLA-B, HLA-F, 
HLA-G 
CD1d 
Monocytes, macrophages, dendritic 
cells, osteoclasts, basophils, 
eosinophils, placental vascular smooth 
muscle 
LILRB3 ILT5, LIR3, 
CD85a, HL9 
4 4 ITIM S. aureus Monocytes, macrophages, dendritic 




 Alternative names Number of Ig 
domains 
Ig domains and 
tail 
Ligands Expression 
LILRB4 ILT3, LIR5, 
CD85k, HM18 
2 3 ITIM Unknown Monocytes, macrophages, dendritic 
cells, osteoclasts 
LILRB5 LIR8, CD85c 4 2 ITIM Unknown Unknown 
LILRP1 ILT9, CD85b, 
LILR6AP 
4 Pseudogene 





Known disease associations of various LILRs 
 
LILR Disease association 
LILRA1 The defective function of DCs in patients with progressive HIV infection is 
correlated with downregulation of LILRA1 (159) 
LILRA2 LILRA2 Delta 419-421 isoform associated with increased  risk of SLE and 
microscopic polyangiitis in Japanese individuals (160)  
 LILRA2 expression correlates with lepromatous leprosy; functionally 
LILRA2 suppressed innate defences by skewing monocyte cytokine 
production from IL12 to IL10 and by blocking TLR induced antimicrobial 
activity(161) 
 LILRA2, B2 and B3 levels in RA synovium was upregulated and decreased 
in patients who responded to treatment (162) 
LILRA3 Homozygous LILRA3 deficiency more prevalent in patients with multiple 
sclerosis (7.1%) than in healthy blood donors (3.8%) (27) Increase 
prevalence of LILRA3 deficiency in multiple sclerosis confirmed in further 
study in Spanish patients. (28) 
 Homozygous LILRA3 deficiency is more prevalent in patients with 
Sjogren’s syndrome (8%) compared to healthy controls (3%) (26) 
LILRB1 In CMV positive lung transplant recipients, increase in percentage of 
peripheral blood lymphocytes expressing LILRB1 preceded detection of 
CMV DNA (163) 
 Likely to play a role in HLA-G mediated allograft tolerance (142;164) 
 B cells in patients with SLE have reduced expression of LILRB1; in 
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 LILRB1 found to be coexpressed with HLA-G in brain lesions of patients 
with multiple sclerosis (166) 
 Increased expression of LILRB1 on NK cells and CD8
+
 cells in HIV 
infection (167;168) 
 Proportion of B cells expressing LILRB1 is increased in patients with 
severe malaria (169) 
 Likely to be involved in the mechanism of HLA-G mediated tumour 
evasion (149;170;171) 
 LILRB1 polymorphisms are associated with susceptibility to RA in HLA-
DRB1 shared epitope negative subjects in a Japanese population (172) 
 HIV-1 ‘elite controllers’ have unique upregulation of LILRB1 and 
LILRB3, higher than HIV-1 progressors or uninfected subjects (159) 
LILRB2 Increased expression on DCs involved in the T cell suppression cascade 
related to allograft tolerance (23;100) 
 Likely to be involved in HLA-G mediated suppression of allo-responses 
(142;173) 
 LILRA2, B2 and B3 levels in RA synovium was upregulated and decreased 
in patients who responded to treatment (162) 
 LILRB2 present in synovial monocytes and T and B cells of patients with 
spondyloarthritis, and their role as ligands for HLA-B27 homodimers might 
be relevant to the disease (18) 
 LILRB2 upregulated on monocytes in patients with HIV and thought to be 
due to increased IL10 levels (107) 
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 HIV-1 viral escape mutant results in increased MHC-peptide binding to 
LILRB2 and a tolerogenic phenotype of myelomonocytic cells (174) 
 LILRB2 and LILRB4 expression increased in B cells of patients with 
chronic lymphocytic leukaemia and may play a role in T cell suppression 
(175) 
 37.1% of tumour tissue samples from patients with non-small cell lung 
cancer expressed LILRB2 (176) 
 Likely to be involved in the mechanism of HLA-G mediated tumour 
evasion (149;170;171) 
 Infection with Salmonella typhimurium or TLR stimulation with 
Salmonella components results in upregulation of LILRB2 and LILRB4 
(177) 
 HLA-B*35 Px subtypes increase the rate of HIV-1 disease progression via 
LILRB2-dependent functional inhibition of DCs (20) 
LILRB3 HIV-1 ‘elite controllers’ have unique upregulation of LILRB1 and 
LILRB3, higher than HIV-1 progressors or uninfected subjects (159) 
LILRB4 Increased expression on DCs involved in the T cell suppression cascade 
related to allograft tolerance (23;100) 
 LILRB2 and LILRB4 expression increased in B cells of patients with 
chronic lymphocytic leukaemia and may play a role in T cell suppression 
(175) 
 LILRB4-Fc construct prevented islet cell allograft rejection in a 
NOD/SCID mouse model (103) 
 Patients with melanoma, and carcinomas of the colon, rectum, and pancreas 
produce soluble LILRB4 which results in generation of CD8
+
 T suppressor 
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cells and impairs T cell responses in mixed lymphocyte reactions (102) 
 Infection with Salmonella typhimurium or TLR stimulation with 





Chapter 2: Materials and methods 
 
In addition to the research materials and experimental protocols used in the project, 
this chapter also contains results of experiments designed to optimise the assays 




The THP-1 (178) cell line was used in both the qPCR and luciferase assays. It is an 
acute monocytic leukaemia cell line obtained from ATCC. The cells were 
maintained in RPMI-1640 supplemented with 10% FCS, 300 mg/l L-glutamine and 
100U/ml penicillin/ 0.1mg/ml streptomycin (all cell culture media from Sigma). 
 
COS7 (179) and 293T (180) cell lines were used for transient transfection 
experiments. Both were obtained from ATCC, maintained in DMEM supplemented 
with 10% FCS, 300 mg/l L-glutamine and 100U/ml penicillin/ 0.1mg/ml 
streptomycin and passaged with Trypsin-EDTA (Sigma) just prior to reaching 
confluence. Additionally, COS7 cells were adapted to serum free medium growth 
by gradual reduction of serum concentration and replacement with VPSFM media 
(Invitrogen). These cells were passaged using TrypLE (Invitrogen). 
 
The K562 (181;182) cell line is a myelogenous leukaemia cell line growing in 
suspension obtained from HPA Cultures. Cells were maintained in RPMI 1640 
supplemented with 10% FCS, 300 mg/l L-glutamine and 100U/ml penicillin/ 
0.1mg/ml streptomycin. K562 cells transfected with HLA-A2, HLA-A24 and HLA-
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B8 in a pcDNA3.1(+) vector and selected with G418 at 700 μg/ml were a kind gift 
from Mark Peakman. Additionally, K562 cells were stably transfected with 
pcDNA3.1(+) and LILRB1, LILRB2 and HLA-G to be used in further experiments. 
 
The JEG3 cell line (183) is an adherent human placental choriocarcinoma cell line 
obtained from HPA Cultures and was used as a source of HLA-G mRNA for 
cloning experiments. It was cultured in EMEM supplemented with 10% FCS, 300 
mg/l L-glutamine, non-essential amino acids and 100U/ml penicillin/ 0.1mg/ml 
streptomycin; and passaged with Trypsin-EDTA (Sigma) just prior to reaching 
confluence. 
 
BB7.2 (184), W6/32 (185), ZM3.8 (42) and 42D1 (40) are hybridomas producing 
monoclonal antibodies against HLA-A2, pan-HLA Class I, LILRB4 and LILRB2 
respectively. These were maintained in DMEM supplemented with 10% FCS, 300 
mg/l L-glutamine and 100U/ml penicillin/ 0.1mg/ml streptomycin. For generation 
of antibody, hybridomas were left to proliferate in medium for 7 days prior to the 
supernatant being harvested for antibody purification. BB7.2 and W6/32 were 
obtained from ATCC. ZM3.8 and 42D1 were a kind gift from Marco Colonna. 
 
Generation of stable K562 transfectants with LILRB1, LILRB2 and pcDNA3.1(+) 
 
K562 cells were transfected with pcDNA3.1(+) vectors containing LILRB1, 
LILRB2 or empty vector alone as a control using the Attractene transfection reagent 
(Qiagen) following the manufacturer’s instructions. The Attractene reagent is a 
nonliposomal lipid transfection reagent. Briefly, 3x10
5
 cells were incubated in 2 ml 
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of RPMI 1640 medium supplemented with 10% FCS, 300 mg/l L-glutamine and 
100U/ml penicillin/ 0.1mg/ml streptomycin in 6-well plates. 1.2 μg of plasmid 
DNA was mixed with 4.5 μl of the Attractene reagent, incubated for 10 to 15 
minutes and added to the cells. After 48 hours, the cells were transferred to medium 
containing G418 700 μg/ml for selection and maintained until the appearance of 
colonies. 
 
Additionally for LILRB1 and LILRB2 transfectants, cells with a high level of 
expression were sorted using a BD FACS ARIA cell sorter and single clone 
colonies were grown by limiting dilution cloning. Briefly, transfectants were diluted 
to a concentration of 2.5 cells/ml and 200 μl of the cell suspension was transferred 
to individual wells in 96-well plates. Wells with single colonies were then expanded 
after several weeks of culture, and cells were assessed for expression of the 
transfected protein, for selection of the best clones. 
 
Purification of monoclonal antibody from hybridoma supernatant 
 
Monoclonal antibodies were isolated from hybridoma supernatant using the 
MAbTrap kit (GE Life Sciences) following the manufacturer’s instructions. Briefly, 
this utilised a protein-G column for binding of antibody and subsequent elution. 
Filtered hybridoma supernatant was injected manually into the column, washed and 
eluted using a low pH buffer (1M glycine-HCl, pH 2.7) into a neutralising buffer 








Human PBMCs were separated from whole blood or buffy coat (National Blood 
Service, Tooting) by using Lymphoprep (Axis Shield). Whole blood or buffy coat 
was diluted 1:1 with RPMI or PBS, layered on Lymphoprep and centrifuged at 
800G for 20 minutes at 20
o
C. The PBMC layer was then harvested and washed with 







Monocytes were purified from PBMCs using anti-CD14 magnetic beads (Miltenyi 
Biotec) for positive selection, according to the manufacturer’s instructions. Briefly, 
PBMCs were labelled with anti-CD14 beads, washed and run through a magnetic 
separation column (LS columns, Miltenyi Biotec) according to the manufacturer’s 
instructions. Monocyte purity was checked by staining with anti-CD14 APC (clone 
61D3, eBioscience) and analysis using flow cytometry. 
 
Generation of MoDCs 
 
Monocytes separated from PBMCs by adherence to plastic were used for generation 
of MoDCs.  Prior to use, frozen PBMCs were thawed at 37
o
C and allowed to adhere 
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in a 100 mm dish for 2 hours. Non-adherent cells were then removed and frozen in 
liquid nitrogen prior to subsequent use. 
 
Fresh culture medium, RPMI 1640 (Invitrogen) supplemented with 10% heat-
inactivated FCS (Invitrogen or Sigma), 2mM L-glutamine (Sigma), 100U/ml 
penicillin and 0.1 mg/ml streptomycin (Sigma) was added to the adherent cells. 
Cells were cultured in a final concentration of IL-4 (R&D Systems) at 20 ng/ml and 
GM-CSF (R&D Systems) at 3.33 ng/ml. Cytokines were refreshed on day 2 or 3 of 
cultures by addition of the same amount of cytokine added on day 0. On day 5 of 
culture, the dendritic cells were washed and resuspended in medium with fresh 
cytokines at a concentration of 0.5x10
6
 cells/ml in 6-well plates. On day 6 of 
culture, a maturation stimulus consisting of a final concentration of 5 ng/ml TNF-α, 
5ng/ml IL-1β, 150 ng/ml IL-6 and 1 μg/ml prostaglandin E2 was added to the DCs. 
Dendritic cells were harvested and counted on day 7 for use in downstream 
experiments. 
 
General molecular biology techniques 
 
The general molecular biology techniques used in different parts of the project are 
described below: 
 
Transformation of competent E. Coli 
 
Competent E coli (TOP10 from Invitrogen or NEB10beta from New England 
Biolabs) were transformed with plasmid DNA according to manufacturer’s 
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instructions. E coli were thawed on ice, incubated with plasmid DNA for 30 
minutes, heat shocked at 42
o
C for 30 seconds and the incubated on ice for a further 
2 to 5 minutes. 250 or 950 μl of SOC medium (for TOP10 and NEB10beta 
respectively) were then added to the E coli and the mixture incubated at 37
o
C in a 
shaking incubator for 60 minutes. Subsequently, 20 and 200 ul of the mixture were 






DNA minipreps were obtained by plating or streaking transformed TOP10 or 
NEB10 beta E Coli on LB agar plates with selective medium (carbenicillin 100 
μg/ml) and incubating overnight at 37oC. Single colonies were then incubated in 6 
ml LB broth with carbenicillin and the culture incubated overnight at 37
o
C in a 
shaking incubator. 4 ml LB culture was then centrifuged and plasmid DNA was 
extracted from the pellet using the Qiagen Qiaprep Miniprep kit. The DNA was 
eluted in dH2O, the concentration measured using a Nanodrop ND-1000 
spectrophotometer and stored at -20
o




DNA midipreps/maxipreps were obtained by plating or streaking transformed 
TOP10 or NEB10 beta E Coli on LB agar plates with selective medium 
(carbenicillin 100 μg/ml) and incubating overnight at 37oC. Single colonies were 
then incubated in a starter culture of 5 ml LB broth with carbenicillin and the 
culture incubated for 8 hours at 37
o
C in a shaking incubator. 1 or 5 ml LB culture 
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was then added to 50 or 250 ml LB broth with carbenicillin (for midi and maxipreps 
respectively) and incubated overnight at 37
o
C in a shaking incubator. The LB broth 
was centrifuged and plasmid DNA was extracted from the pellet using the Sigma 
GenElute HP Midiprep or Maxiprep kit. The DNA was eluted in dH2O, the 
concentration measured using a Nanodrop ND-1000 spectrophotometer and stored 
at -20
o
C until needed for use. 
 
DNA gel extraction 
 
All DNA extractions from agarose gels was performed using the Qiagen Qiaquick 
Gel Extraction kit. The manufacturer’s instructions were followed. The gel slice 
was solubilised using proprietary buffers, bound in a spin column, washed and 
eluted with dH2O or 10 mM Tris-HCL buffer, pH 8.5. 
 
Purification of PCR products 
 
When necessary, PCR products were purified using the Qiagen Qiaquick PCR 
Purification kit. In principle, the Qiaquick system uses a proprietary silica 
membrane to bind DNA in a spin-column technology format. Different buffers are 
used for efficient recovery of DNA and removal of contaminants. DNA is adsorbed 
to the silica membrane in the presence of high concentrations of salt while 
contaminants pass through the column. Subsequently contaminants are washed 
away, and pure DNA is eluted. The manufacturer’s instructions were followed. PCR 
products were diluted in the supplied proprietary buffer, bound in a spin column, 




Restriction enzyme digestion 
 
Restriction enzymes used for experiments included ApaI, BamHI, BspEI, HindIII, 
NheI and XhoI (all from New England Biolabs). Restriction enzymes were used as 
per manufacturer’s instructions and mixed with the DNA to be digested in the 









All DNA ligation was done using T4 DNA ligase and T4 DNA ligase buffer (from 
New England Biolabs). Ligation reactions were incubated overnight at 16
o
C. A 




Total RNA extraction from either PBMCs or cell lines was extracted using the 
Qiagen RNEasy Mini extraction kit. In principle, the technology utilised the 
combination of selective binding of RNA to a silica-based membrane with 
microspin technology. A proprietary high-salt buffer system allowed up to 100 μg 
of RNA > 200 bases to bind to the RNeasy silica membrane. 
 
Cells were initially lysed and homogenized in a highly denaturing guanidine-
thiocyanate–containing buffer. This was to immediately inactivate RNases to ensure 
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purification of intact RNA. Ethanol was then added to provide appropriate binding 
conditions, and the sample applied to a spin column, where the total RNA binds to 
the membrane and contaminants are washed away. The RNA is then eluted in 50 μl 




Reverse transcription of mRNA into cDNA was done using the Qiagen Omniscript 
Reverse transcription reagent. Template RNA was incubated with Omniscript RT, 
dNTPs, anchored oligo-dT primers and RNase inhibitor according to the 
manufacturer’s instructions at 37oC for 60 minutes. Reaction products were 




All DNA sequencing was done by a commercial company, Geneservice who use 
Applied Biosystems 3730 DNA analyzers for their work. Standard sequencing 




PCR reactions were undertaken using the Phusion High-Fidelity PCR kit (New 
England Biolabs), which uses an enzyme incorporating a novel Pyrococcus-like 
enzyme with a processivity-enhancing domain, engineered for high fidelity PCR 
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work. Proprietary buffers and reagents were supplied with the kits, and the 
manufacturer’s recommendations for their use were followed. 
 
Reactions were undertaken in either 20 μl or 50 μl volumes, with a final 
concentration of 0.5μM forward and reverse primers, 200μM dNTPs, proprietary 
buffer and template DNA. 
 
DNA Agarose electrophoresis 
 
Agarose electrophoresis for DNA was done on agarose gels, using 0.5X Tris-
borate-EDTA buffer to cast the gel and in the tank. DNA was visualized using an 
ultraviolet transilluminator. 
 
Development of assays to measure variance in LILRs 
 
Measurement of LILR levels on DCs and other immune cells 
 
Whole blood (collected in sodium heparin tubes) was stained with anti-CD1c FITC 
(AD5-8E7, Miltenyi), anti-ILT1 PE (135.4, eBioscience) or anti-ILT4 PE (42D1, 
eBioscience), anti-CD14-ECD (RMO52, IOTest, Beckman), anti-ILT2 APC (HP-
F1, eBioscience) or anti-ILT3 APC (eBioscience, ZM4.1) and anti-CD19 PC7 (J3-
119, IOTest, Beckman). Isotype matched controls were IgG2a (mouse) FITC 
(S43.10, Miltenyi), IgG2a (rat) PE (eBioscience), IgG2a (mouse) ECD (7T4-1F5, 
IOTest, Beckman), IgG1 (mouse) APC (eBioscience) and IgG1 (mouse) PC7 
(679.1Mc7, IOTest, Beckman). After incubation at 4
o
C for 30 minutes, stained 
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blood was lysed with BD PharmLyse solution (Becton Dickinson). Cells were 
washed twice with wash buffer (PBS/1%BSA/0.1%  azide) and fixed with BD 
CellFix (Becton Dickinson) prior to being analysed on the flow cytometer 
(Cytomics FC500, Beckman Coulter). 
 
Analysis of the data was done with FlowJo software (Tree Star, USA). Gates for the 
DC, monocyte and B cell populations were drawn as shown in Figure 1. The FL2 
and FL4 median fluorescence intensity (MFI) values for these populations were 
then obtained and normalized to units of molecules of equivalent fluorochrome 
(MEF) using normalising fluorospheres (Rainbow Calibration Particles-30-5A, 
Spherotech) according to manufacturer’s protocol. Briefly, normalising 
fluorospheres were run on each day, and MFI values plotted against the 
manufacturer provided MEF values to draw a ‘standard curve’ which was used to 
convert unknown MFI values into MEF values. This allowed longitudinal 
comparison of LILR levels on samples taken on different days. (186) To further 
reduce variation in LILR measurement, all antibodies used were from the same 
batch. This single batch of antibodies was specifically allocated to the part of the 
project assessing the variation of the LILRs between different individuals. 
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Figure 2.1  
Flow cytometry plots showing (top row from left to right): forward scatter vs. 
side scatter (with white cell gate), FL3 (CD14 ECD) vs. side scatter (with the 
white cell gate applied, and showing the monocyte gate), FL5 (CD19 PC7) vs. 
FL1 (Cd1c FITC) (showing DC and B cell gates). FL2 and FL4 histogram plots 
for monocytes, DCs and B cells were drawn to obtain median fluorescence 
intensity. The FL2 and FL4 overlay histograms are shown for monocytes in the 
bottom row. The FL2 overlay histogram plot (bottom left) shows the 
fluorescence intensity for the PE IMC (red), LILRA2 (blue) and LILRB2 
(orange) on monocytes. The FL4 overlay histogram plot (bottom right) shows 
the fluorescence intensity for the APC IMC (red), LILRB1 (blue) and LILRB4 





Effect of cytokine stimulation on LILR expression 
 
In optimisation experiments, whole blood was incubated at 37
o
C for various 
intervals with or without the addition of IL10, an IL1β/TNFα/PGE2/IL6 cocktail, 
IL1β, TNFα, IL6 alone or TGF-β was analysed with this assay to determine the 
effect of LILR expression after whole blood stimulation. The concentration of the 
cytokines in the cocktail were IL1β 10ng/ml, TNFα 10 ng/ml, PGE2 2μg/ml and 
IL6 300 ng/ml. 
 
For determination of the change in LILR expression for correlation with genomic 
variation, whole blood was incubated at 37
o
C for 21 hours with or without the 
addition of 50 ng/ml IL-1β or 20 ng/ml TGF-β (both cytokines from Miltenyi 
Biotec, Germany), and LILR cell surface levels were measured. Culture was 
performed with undiluted whole blood in loosely capped 12x75 mm polypropylene 
tubes in a humidified incubator with supplemental 5% CO2. The endotoxin level in 
all cytokines used in cell culture were certified to be <0.1 ng/μg cytokine by the 
manufacturer. For some experiments, the “modulation index” was calculated as the 
ratio of MEF with cytokine stimulation divided by MEF under baseline conditions. 
 




Total genomic DNA was extracted from whole blood using the QIAamp DNA Mini 
Kit (Qiagen) according to the manufacturer’s instructions. Briefly, 200 μl of whole 
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blood was lysed, incubated at 56
o
C for 10 minutes and mixed with ethanol. The 
mixture was run though a spin format column and washed with the proprietary 
buffers provided; and eluted in 200 μl of Tris EDTA buffer (10 mM Tris Cl, 0.5 
mM EDTA, pH 9.0). The concentration of the DNA was measured using a 
Nanodrop ND-1000 spectrophotometer and stored at -20
o
C until needed for use. 
 
PCR to amplify the LILRB2 promoter region 
 
Primers to amplify a region of 2306 base pairs containing the putative promoter 
region for LILRB2 were designed using the PrimerZ web application. (187) The 
amplified PCR product was designed to be –1925 to +380 bp from the ATG start 
codon of the LILRB2 sequence (Genome Reference Consortium Human genome 
build 37, GRCh37:19:54784103-54786408). 
 
PCR reactions were done with the Phusion High-Fidelity PCR kit (New England 
Biolabs), which uses an enzyme incorporating a novel Pyrococcus-like enzyme 
with a processivity-enhancing domain, engineered for high fidelity PCR work. 
Proprietary buffers and reagents were supplied with the kits, and the manufacturer’s 
recommendations for their use were followed. Reactions were done in 50 μl 
volumes, with a final concentration of 0.5μM forward and reverse primers, 200μM 
dNTPs, proprietary buffer and template genomic DNA. 
 
The amplification primers used were the forward primer, PRO1F 
(TGCCATGCACTCCATATTGT) and reverse primer, EX2R 





C for 30 seconds, followed by 35 cycles of denaturation at 98
o
C for 10 
seconds, annealing at 65
o
C for 30 seconds and elongation at 72
o
C for 75 seconds; 
with a final elongation step at 72
o
C for 8 minutes. 
 
The PCR reactions were then run on an 0.8% agarose gel in 0.5X TBE buffer at 
100V for 60 minutes. The 2306 bp band corresponding to the amplified region 
containing the LILRB2 promoter region was then extracted using the Qiagen 
QiaQuick Gel Extraction kit according to the manufacturer’s instructions. 
 
Sequencing of the amplified PCR fragment 
 
The amplified DNA region was then sent to a commercial company, Geneservice 
for sequencing using the custom primers designed with the PrimerZ application. 
The custom primers are detailed below in Table 2.1. 
 
Table 2.1 Primers used for sequencing of amplified LILRB2 promoter region 
 
Primer name Primer sequence 











EX2R CTGGGGACAGACTCACCTGT  
 
Analysis of LILRB2 polymorphisms 
 
The sequenced LILRB2 regions were then analysed using Variant Reporter 
software (version 1.1, Applied Biosystems) to overlay PCR amplicons, compare to 
the reference sequence and identify SNPs. 
 
Real time PCR to quantify LILRB2 mRNA levels 
 
Cell types used and experimental conditions 
 
Purified monocytes or THP-1 cells were exposed to various stimuli to confirm that 
LILRB2 mRNA could be transcriptionally regulated. 5 x 10
5
 monocytes or 2.5 x 
10
5
 THP-1 cells were incubated in 500 μl volumes with  IL10 600 ng/ml , an 
inflammatory cytokine mixture (17.5 ng/ml TNFα, 17.5 ng/ml IL1β, 525 ng/ml IL6 
and 3.5 μg/ml PGE2) or LPS 1 μg/ml for 6 or 22 hours prior to having total RNA 







RNA extraction and genomic DNA removal 
 
Total RNA was extracted using the RNAqueous-4PCR kit (Applied Biosystems). 
Briefly, cells were lysed and the lysate run through a spin column to extract the 
RNA. The RNA underwent wash steps and was subsequently eluted. 
 
Eluted RNA was incubated with DNase 1 (Applied Biosystems) at 37
o
C to for 15 to 
30 minutes to remove any trace of contaminating genomic DNA. The DNase 1 was 
then inactivated and the RNA converted to cDNA. 
 
Conversion of RNA to cDNA 
 
Total RNA was converted to cDNA using the High Capacity RNA-to-cDNA kit 
(Applied Biosystems) according to the manufacturer’s instructions. Briefly, purified 
RNA was incubated with the proprietary reverse transcriptase enzyme and buffers 
for 60 minutes at 37
o
C. The mixture was then incubated at 95
o
C to inactivate the 
enzyme and stored at -20
o
C prior to use in further experiments. 
 
Real time PCR reaction 
 
The primers used to quantify the amount of LILRB2 mRNA were those 
recommended by Applied Biosystems (Hs01629548_s1, FAM/MGB probe) with a 
human GAPD (GAPDH) Endogenous Control (FAM/MGB Probe) primer. An 
equal amount of cDNA was loaded with each primer set and a no-template control 




All samples were run in 20μl volumes in triplicates. The real-time PCR reaction 
was performed on an Applied Biosystems StepOnePlus
TM
 Real-Time PCR System 
with the following cycling parameters: 50
o
C for 2 minutes, 95
o
C for 10 minutes, 
followed by 40 cycles of 95
o
C for 15 seconds and 60
o
C for 1 minute. 
 
Data was analysed using DataAssist software v3.0 (Applied Biosystems). The ΔΔCt 
method of relative quantification was used to compare the different samples. (188) 
Briefly, this method allows comparison of the amount of DNA or RNA present in 
different samples by normalization against a housekeeping gene (GAPDH in these 
experiments). The Ct (or threshold cycle) value is the number of cycles at which 
fluorescence based detection of DNA exceeds a pre-set limit above background. 
The difference between the Ct of the gene of interest and the housekeeping gene 
gives the ΔCt value. The amount of DNA or RNA present in different samples 
(normalized to an endogenous reference) can then be compared by calculating the 
difference between the ΔCt of the target sample and that of a reference sample, 
giving the ΔΔCt value. The relative quantitation (RQ) is calculated using the 
formula 2
-ΔΔCt
, allowing the amount of DNA or RNA in the sample (normalized to 





Dual luciferase assays were undertaken to determine if the different SNPs identified 
in the LILRB2 promoter region affected transcriptional regulation of the protein. 
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Briefly, a 1000 bp region upstream of the ATG start codon of the LILRB2 region 
was cloned into a promoterless firefly luciferase plasmid (pGL4.10, luc2, Promega). 
This was co-transfected with a Renilla luciferase plasmid with an SV40 promoter 
(pGL4.73, hRluc/SV40, Promega) into THP-1 cells to allow normalisation of firefly 
luciferase activity. 
 
Cloning of LILRB2 region upstream of start codon into promoterless luciferase 
vector for sequencing 
 
A 1000-bp region upstream of the LILRB2 ATG start codon was PCR cloned from 
the amplified 2306 bp region. NheI and XhoI restriction enzyme sites were added to 
the start of the PCR primers to allow cloning into the multiple cloning region of the 
pGL4.10 vector. The primers used were the forward primer ILT4P_1000_NHEF 
(ATAGCTAGCACCTACAGAATGTGGAGTCC) and reverse primer 
ILT4P_NOATG_XHOR (ATACTCGAGGGGGTGTTGTCATCTGCAGC); 
underlined sequences represent the restriction enzyme sites. 
 
PCR reactions were done with the Phusion High-Fidelity PCR kit (New England 
Biolabs) in 50 μl volumes. Reaction conditions were: initial denaturation at 98oC 
for 30 seconds, followed by 35 cycles of denaturation at 98
o
C for 10 seconds and 
elongation at 72
o
C for 30 seconds; with a final elongation period at 72
o





The PCR products were run on an 0.8% agarose gel in 0.5X TBE buffer at 100V for 
60 minutes. Bands of approximately 1000 bp were excised and extracted from the 
gel using the Qiagen QiaQuick Gel Extraction kit. 
 
The promoterless firefly luciferase vector pGL4.10 and the cloned 1000 bp region 
of the putative LILRB2 promoter were digested with NheI and XhoI restriction 
enzymes at 37
o
C for 60 minutes. The digested product was then run on an agarose 
gel to confirm that no additional bands were present and then purified using the 
Qiagen QiaQuick PCR purification kit. 
 
The linearized pGL4.10 vector and digested LILRB2 promoter region were then 
ligated together overnight at 16
o
C with T4 DNA ligase (New England Biolabs), at a 
vector:insert ratio of 1:3. Ligated products were then transformed into NEB10beta 
competent E coli (New England Biolabs). Selected colonies were screened for 
presence of the insert by restriction enzyme digestion with NheI and XhoI prior to 
sequencing to determine the LILRB2 promoter haplotype. 
 
Sequencing of cloned 1000 bp LILRB2 region upstream of start codon 
 
pGL4.10 plasmids containing the 1000 bp LILRB2 promoter region insert were sent 
to Geneservice for sequencing to determine the haplotype/SNPs contained in the 
plasmid. The sequencing primers used were RVprimer3 
(CTAGCAAAATAGGCTGTCCC) and GLprimer4 




Gene synthesis of LILRB2 promoter region for use in luciferase assay 
 
Based on the haplotypes obtained from sequencing of the cloned 1000 bp LILRB2 
region, five different haplotypes of a 633 bp region [-533 to +74 from the putative 
promoter site identified by Nakajima et al (189)] were synthesized and cloned into 
pGL4.10 plasmids by a commercial company (Genscript). These five different 
plasmids were used in further luciferase transfection experiments to determine if 
SNPs in the LILRB2 promoter affected expression levels. 
 
Transfection of THP-1 cells with luciferase plasmids 
 
THP-1 cells were transfected in 96-well flat-bottom plates. Cells were resuspended 
in OptiMEM medium (Invitrogen) with 10% FCS and seeded at a density of 10
5
 
cells per well prior to transfection. 
 
The THP-1 cells were then co-transfected with LILRB2 promoter/luc2 and 
pGL4.73 plasmids using Lipofectamine 2000 (Invitrogen) according to the 
manufacturer’s instructions. Briefly plasmid DNA and Lipofectamine 2000 were 
mixed with 25 μl of OptiMEM medium (Invitrogen) each and combined after 5 
minutes. Plasmid-lipofectamine complexes were allowed to form for 20 minutes 
prior to being added to cells. 
 
Cells were harvested after 24 or 48 hours for use in the luciferase assay. 
Additionally 1 μg/ml LPS was also added to cells at specific time points to 




Measurement of luciferase activity 
 
Measurement of firefly and renilla luciferase activity was undertaken using the Dual 
Luciferase Reporter system (Promega) according to the manufacturer’s instructions. 
Briefly, transfected cells were lysed with the proprietary lysis buffer. 20 μl of lysate 
was then incubated with 100 μl of luciferase assay reagent and measured on the 
luminometer. 100 μl of Stop&Glo reagent was then added to quench firefly 
luciferase activity and allow measurement of renilla luciferase activity. All readings 
were done on a Biotek FLX800 luminometer. 
 
The ratio of firefly to renilla luciferase was then calculated to allow for comparison 
between different LILRB2 haplotypes. 
 
 
Functional assays with anti-LILRB2 antibodies 
 
Functional assays to determine the effect of LILRB2 ligation were undertaken on 
anti-CD14
+
  purified peripheral blood monocytes, isolated with magnetic beads as 
described in the Section 2.2 on isolation and manipulation of primary cells. 
 
Stimulation with TLR ligands 
 
Purified monocytes were incubated with various TLR ligands including LPS, 
imiquimod, ssRNA/Lyovec, Pam3CSK4, polyI:C and CpG DNA ODN2006 (LPS 
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from Sigma, all remaining TLR ligands from Invivogen). Additionally anti-LILRB2 
antibodies (clone 42D1 purified from hybridoma supernatant) or a rat IgG2a kappa 
isotype matched control (clone eBR2a, eBioscience) were added to determine if 
there would be any functional effect. After overnight incubation at 37
o
C, 
supernatant was harvested and frozen at -20
o
C prior to analysis for cytokine 
concentration. 
 
ELISA for cytokine secretion 
 
The concentrations of IL6, IL8, IL10 and TNFα in the supernatants of stimulated 
monocytes were measured using Ready-SET-Go! ELISA kits from eBioscience 
according to the manufacturer’s instructions. Briefly, Corning Costar plates were 
incubated overnight at 4
o
C with the appropriate capture antibody. The following 
day, plates were washed, incubated with blocking buffer, washed and then 
incubated overnight with supernatant diluted to allow concentration of the cytokines 
to come within the range of the standard curve. 
 
Following this, plates were washed and incubated with the biotinylated detection 
antibody. After a further wash step, plates were incubated with HRP-avidin as the 
detection reagent and washed again. The TMB substrate was then added and 
sulphuric acid used as the stop reagent. Plates were then read at 450 nm using a 





Development and testing of the G-Body 
 
Two main approaches were taken to create the bifunctional G-body molecule 
comprising a HLA-G domain for interaction with the immunosuppressive LILRB1 
and LILRB2 and an anti-HLA-A2 domain for localisation to allogeneic cells 
expressing HLA-A2: 
(i) a recombinant DNA approach; and 
(ii) a chemical conjugation approach using the biotin-streptavidin 
interaction 
 




Hybridoma sequencing was performed by a commercial company (Fusion 
Antibodies Ltd). Briefly, mRNA was extracted from the hybridoma pellets using 
the company’s in-house RNA extraction protocol. cDNA was created from the 
RNA by reverse-transcription with an oligo(dT) primer. PCR reactions using 
variable domain primers were used to amplify both the VH and VL regions of the 
monoclonal antibody DNA. The VH and VL products were cloned into the 
sequencing vector pCR2.1 (Invitrogen) and transformed into TOP10 cells 
(Invitrogen) for positive transformants. Selected colonies were picked and analyzed 
through sequencing. 
 





DNA was chemically synthesised by a commercial company (Genscript, USA) 
using undisclosed methods. The synthesized gene was then cloned into a pUC57 
vector and subcloned into a pcDNA3.1(+) vector (Invitrogen). 
 
Generation of plasmids for transfection 
 
The general molecular biology techniques used to generate various plasmids for 
different versions of the recombinant G-body and control materials are described 
previously. 
 
Briefly, the original recombinant G-body was designed in a modular fashion to 
allow replacement of various segments using appropriate restriction enzymes. 
Subsequent modifications to the original recombinant G-body were undertaken 
using a combination of PCR cloning and/or gene synthesis of the segments to be 
changed. 
 
Minipreps were generated to allow confirmation by gene sequencing that the 
intended sequence was present. Subsequently, midipreps or maxipreps were 
generated for transfection purposes. 
 
For control materials, various genes including HLA-G, LILRB1 and LILRB2 were 
obtained from RNA extracted from PBMCs. These were converted to cDNA, 
83 
 
amplified by PCR and cloned into the pcDNA3.1+ expression vector prior to being 
used in various transfection experiments. 
 
Transient transfection of cell lines 
 
Transient transfection experiments were undertaken using the Attractene 
transfection reagent (Qiagen), a proprietary non-liposomal lipid based reagent. The 
manufacturer’s instructions were followed. Briefly, the cells to be transfected were 
seeded 24 hours before transfection, to achieve 40 – 80% confluence at the time of 
transfection. Plasmid DNA (inserts were cloned into a pcDNA3.1+ expression 
vector) and the transfection reagent were mixed in medium according to 
manufacturer’s instructions and incubated for 10 to 15 minutes at room temperature. 
When co-transfections with two separate plasmids were performed, the amount of 
DNA used for each plasmid was halved. Subsequently, the mixture was added to 
the cells to be transfected. Supernatant and cells were harvested at 48 to 72 hours 
post-transfection for further experiments. 
 
Generation of chemically conjugated G-body 
 
Conjugation of streptavidin to BB7.2 
 
BB7.2 was conjugated to streptavidin using the EZ-Lightning Link kit (Innova 
Biosciences); at a molar ratio of approximately 1:3. 100 μg of purified mAb in PBS 
was added to 100 μg of streptavidin after addition of the proprietary reagents. The 
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conjugate was incubated for 3 hours and then a proprietary quenching reagent was 
used to stop the reaction. 
 
Measurement of endotoxin levels 
 
Biotinylated HLA-G monomers were purchased from the Fred Hutchinson Cancer 
Research Centre and tested for endotoxin contamination with the QCL-1000 
limulus amebocyte lysate endotoxin measurement kit (Lonza). Briefly, the kit 
measures endotoxin levels by measuring the colorimetric change after addition of 
limulus amebocyte lysate (LAL) to samples. 
 
Endotoxin purification of biotinylated HLA-G 
 
bHLA-G monomers were purified using the ToxinEraser Endotoxin Removal Kit 
(Genscript). Briefly, samples were run through a modified polymixin B resin in a 
pre-packed column which removed endotoxin. Samples were then buffer exchanged 
into PBS using the Vivaspin 2 ultrafiltration device (Sartorius). Endotoxin levels 




Protein concentrations were measured using a bicinchoninic acid (BCA) kit 
(Pierce). Briefly, standards and samples were added to the BCA reagents and 
absorbance measured at 562 nm after incubation at 37
o




Conjugation of biotinylated HLA-G monomers to streptavidin-conjugated BB7.2 
 
The biotinylated HLA-G was mixed with streptavidin-conjugated BB7.2 at various 
molar ratios and incubated at room temperature for 30 minutes before being ready 
for use. 
 
Generation of controls for chemically conjugated G-body 
 
Controls for the cG-body were generated using the same processes above but 
substituting BB7.2 with MPC11 (mouse IgG2b isotype matched control) and 
bHLA-G with biotinylated BSA (Pierce) in various combinations. 
 




30 μl of streptavidin agarose or protein G sepharose beads (Sigma Aldrich) were 
washed with 1 ml of PBS and incubated with 1 μg of biotinylated HLA-A2 
(purchased from the Fred Hutchinson Cancer Research Centre) or 1 μg mAb in 250 
μl PBS for 1 hour and washed twice with PBS. Beads were then incubated with 
culture supernatant or lysates for 3 hours and then washed a further 3 times. The 
beads were then used for SDS-PAGE and Western blotting. The primary antibodies 
used for immunoprecipitation included the conformational anti-HLA-G antibodies 
87G (BioLegend) and MEM-G/9 (AbD Serotec), and the pan-HLA I antibody 






The Laemmli buffer system with discontinuous polyacrylamide gels and Tris-
glycine-SDS buffer was used for SDS-PAGE experiments. Gels were cast in house 
with the Bio-Rad Mini Protean gel casting stands. Samples were run using the Bio-
Rad Mini-Protean Tetra cell. Laemmli reducing buffer was added to the samples 
and boiled for 5 minutes at 95 to 100
o





Protein transfer from SDS-PAGE gels to PVDF membranes (Hybond-P, GE Life 
Sciences) was performed using the Bio-Rad Trans-Blot SD Semi-Dry 
Electrophoretic Transfer Cell. The Bjerrum and Schafer-Nielsen transfer buffer was 
used (48 mM Tris. 39 mM glycine, 20% methanol). Transfer times were as the 
manufacturer’s recommendations. 
 
Membranes were then incubated in TBS-T (Tris buffered saline-Tween) buffer with 
5% skimmed milk for 60 minutes, followed by a wash, and then incubated 
overnight at 4
o
C with the primary antibody in TBS-T/2.5%BSA. The membranes 
were then washed 2 times with TBS-T and incubated with the secondary antibody 
[goat anti-mouse IgG (Fc specific) HRP (Sigma)] in TBS-T for 60 minutes at room 




ECL reagent (GE Life Sciences) was then added to the membrane for 1 minute 
before the membrane was exposed to autoradiography film (Hyperfilm ECL, GE 
Life Sciences). Exposure times ranged between 2 to 60 minutes to obtain the best 
quality images and the film was developed in an automated film processor. 
 
Primary antibodies used for Western blotting included anti-denatured HLA-G 
(4H84, Santa Cruz Biotech), anti-β2m (B2M-01, Abcam), anti-His(C-term) and 
anti-myc ( both from Invitrogen). 
 
For some Western blotting experiments, biotinylated anti-denatured HLA-G (4H84, 
Abcam) was used as the primary antibody with streptavidin-HRP (eBioscience) as 
the secondary layer. This was done for immunoprecipitation experiments where a 
monoclonal antibody was bound to protein G sepharose beads to avoid detection of 




The amount of HLA-G or G-body present in the supernatant of transfected cells was 




LILRB2 and HLA-A2 transfected K562 cells were used as targets to test G-body 
binding to its ligands. Cells were incubated with the chemical G-body or 
supernatant from G-body transfected cells for 30 to 60 minutes at 4
o
C. Cells were 
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then washed twice and incubated with a secondary layer, either goat-anti-mouse 
IgG FITC (Invitrogen) or anti-HLA-G (87G-PE, eBioscience) for 30 to 60 minutes 
at 4
O
C. Cells were then washed twice and fixed prior to flow cytometric analysis. 
 
Functional testing of G-Body 
 
Lymphocytes proliferation experiments 
 
PBMCs were incubated with anti-CD3/28 beads (Invitrogen), anti-CD3 (OKT3, 
eBioscience) or SEB (Sigma-Aldrich) in the presence of the chemically conjugated 
G-body (at a concentration containing  2.5μg/ml of the mAb component) or its 
controls to determine if there was any effect on proliferative responses as measured 
by tritiated thymidine incorporation. 10
5
 PBMCs were incubated with anti-CD3/28 
beads at a ratio of 1 bead:5 cells, or anti-CD3 at a concentration of 0.5 μg/ml, or 
SEB at a concentration of 1 ng/ml in 96-well round bottom plates in 200 μl total 
volume. 
 
PBMCs were incubated for 4 days and pulsed with 0.5μCi of tritiated thymidine18 
hours prior to harvesting or freezing for later harvest. Cells were harvested with a 
Perkin Elmer Filtermate harvester. The filter membranes were then dried and 






Mixed lymphocyte reactions 
 
MoDCs or isolated PBMCs were used as stimulator cells. MoDCs were used “as is” 
after generation and PBMCs were treated with mitomycin-C (MMC) (Merck 
Chemicals) to prevent proliferation. PBMCs were incubated at a concentration of 
2x10
6/ml with 25 μg/ml MMC for 1 hour at 37oC. PBMCs were washed three times 
with medium prior to being used for experiments. PBMCs from another donor were 
used as responder cells. 
 
MoDCs or MMC-treated PBMCs were incubated with 10
5
 allogeneic PBMCs per 
well in 250 μl total volume in 96-well round bottom plates at a ratio of 1:10 or 1:1 
for 5 to 7 days with various concentrations of the chemically conjugated G-body or 
its controls. 75μl of supernatant was removed for cytokine measurement and cells 
were pulsed with 0.5μCi of tritiated thymidine18 hours prior to harvesting or 
freezing for later harvest. 
 
Cells were harvested with a Perkin Elmer Filtermate harvester. The filter 





IFN-γ, IL2, IL4 and IL10 were measured in culture supernatants using the 
FlowCytomix kit (Bender Medsystems), which used a bead-based flow cytometric 
method. Briefly, various cytokine capture beads and a biotin conjugate antibody 
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were incubated with culture supernatants, washed and incubated with PE-
streptavidin. Cytokine capture beads were differentiated by light scatter and FL4 





Statistical analysis was undertaken using either Sigmastat (Systat Software Inc) or 
SPSS (IBM) software. The student’s t-test, paired t-test, one-way ANOVA, 
ANOVA by ranks, Mann-Whitney U test or Kruskal-Wallis test were used to test 
for differences between various groups as appropriate depending on whether the 
data was parametric or non-parametric and whether two group or multiple group 
comparison was being undertaken. Correlation analyses were undertaken using 




Generation of control materials 
 
Cloning of green fluorescent protein (GFP) into pcDNA3.1 for use as transfection 
control 
 
An EGFP (enhanced GFP) containing vector was used as a positive transfection 
control to determine if the transfection process was effective. An EGFP insert 
extracted using a BamHI/XhoI digest (a kind gift from Lucas Chan) was cloned into 
pcDNA3.1(+) linearized with BamHI/XhoI. The ligated insert and vector were 
transformed into TOP10 cells. The sequence of the EGFP (GenBank reference 
AM181664.2) was confirmed by gene sequencing. 
 
When transfected into COS7 cells, these showed GFP expression confirming 




Figure 2.2  
Histograms showing expression of GFP in vector transfected COS7 cells 





Cloning of full-length HLA-G, soluble HLA-G, β2-microglobulin into pcDNA3.1 for 
use as experimental controls   
 
To generate controls for the recombinant G-body, HLA-G and β2m were all cloned 
into the same expression plasmid used for the G-body. 
 
Full-length HLA-G (NCBI reference sequence NM_002127.5) was PCR cloned 
from cDNA extracted from JEG3 cells. The primers used were 5’- 
CACCATGGTGGTCATGGCACCCCG and 3’- 
TCAATCTGAGCTCTTCTTCCTCC. The PCR product was run on an agarose gel 
and extracted before being cloned into pcDNA3.1 using the directional TOPO 
cloning system (Invitrogen). TOP10 cells were transformed with the vector, and the 
sequence for the gene confirmed by DNA sequencing and maxipreps generated. 
 
Soluble HLA-G was PCR cloned from the recombinant G-body plasmid using the 
primers 5’- ATAGGATCCACCATGGTGGTCATGGC and 3’- 
ATACTCGAGTCAGGAAGACTGCTTCC which had 5’-BamHI and 3’-XhoI 
restriction sites (underlined) built in to allow cloning into pcDNA3.1. The PCR 
products and the pcDNA 3.1 vector were digested with BamHI/XhoI. PCR products 
were purified using the Qiagen Qiaquick PCR purification kit and the digested 
pcDNA3.1 was extracted after agarose electrophoresis. The vector and insert were 
ligated, and TOP10 cells were transformed to allow DNA sequencing and maxiprep 




β2 microglobulin (NCBI reference sequence NM_004048.2)was PCR cloned using 
from the β2M Mammalian Gene Collection (ATCC) clone. Primers 5’- 
AAAGGATCCACCATGTCTCGCTCCGTG and 3’- 
AAACTCGAGTTACATGTCTCGATCCC were designed with 5’-BamHI and 3’-
XhoI restriction enzyme sites (underlined) and subsequently cloned into pcDNA3.1 
using the same process as the soluble HLA-G clone. 
 
DNA sequencing confirmed that all the clones had the correct sequence. 
 
Cloning of LILRB1 and LILRB2 for use in ligand binding experiments 
 
LILRB1 and LILRB2 were cloned as these are the natural ligand for HLA-G and 
were meant for the purpose of testing binding of the G-body. 
 
LILRB1 and LILRB2 receptors were PCR cloned using cDNA extracted from 
human PBMCs. A 2-stage nested PCR process was used. For LILRB1, the first set 
of primers were 5’- GCTCATCCATCCACAGAGC and 3’- 
ATGGAGTGTGGGGTCTGC; for LILRB2 the first set of primers were 5’- 
CTCATCCATCCGCAGAGC and 3’- GAGTGTGGAGTCTGCGTACC; and the 
second set of primers were 5’- ATAAAGCTTGACGCCATGACCCCC and 3’- 
ATACTCGAGCTAGTGGATGGCCAG with 5’-HindIII and 3’-XhoI restriction 
sites (underlined) at either ends. The PCR products were then inserted into 
pcDNA3.1 using the same process as described for soluble HLA-G with HindIII 
and XhoI enzymes. Gene sequencing confirmed the PCR products as LILRB1, 
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transcript variant 2 (NCBI reference NM_001081637.1) and LILRB2, transcript 
variant 2 (NCBI reference NM_001080978.1). 
 
The pcDNA3.1 plasmids with LILRB1 and LILRB2 were then stably transfected 
into K562 cells with G418 selection. Single clones were generated with limiting 
dilution cloning as described and FACS analysis confirmed expression of the 
transfected gene. (Figure 2.3a and 2.3b) This was to generate a stable clone of cells 




Histogram overlay showing staining of a K562-LILRB1 transfectant after 
sorting and limiting dilution cloning stained with anti-LILRB1 mAb. The pink 
histogram represents the isotype matched control and the green histogram is 










Histogram overlay showing staining of a K562-LILRB2 transfectant after 
sorting and limiting dilution cloning stained with anti-LILRB2 mAb. The red 
histogram represents the isotype matched control and the blue histogram is 














In view of the hypothesis that the expression level of LILR molecules is (at least in 
part) influenced by genetic variation, and could affect immunological responses, the 
first step in the project was to develop a method for accurately quantifying 
expression levels on different cell types. This forms the prelude to further 
experiments to determine if genetic variation does affect LILR expression and also 
if the differences in LILR levels have functional consequences. 
 
Furthermore, in view of the data suggesting that expression levels of some of the 
LILR molecule are associated with certain haplotypes, (172) which in turn have an 
association with certain diseases, the development of a straightforward, robust flow 
cytometric assay to characterise these molecules would also be a useful tool to 
study their expression in various disease states. The same tool could be used to 
compare changes before and after treatment which could give an idea how these 
molecules are affected by various therapeutic modalities.  
 
In this chapter, the development of 5-colour flow cytometric method to quantify 
cellular surface protein expression of LILRA2, LILRB1, LILRB2 and LILRB4 on 
CD1c
+
 DCs, monocytes and B cells is described. This is then used to quantify the 
LILR levels in 26 healthy individuals at baseline and after stimulation with different 
cytokines. In addition, these results are also normalized over time to allow 
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comparison between samples obtained on different days. The differences between 
various individuals, various cell types and response to different stimuli are then 
analysed for statistical differences. 
 
Optimisation of whole blood LILR expression assay 
 
Determination of antibody concentrations to be used 
 
Initial optimisation experiments were performed to determine the correct amount of 
antibody required for staining for LILR expression as well as to determine the 
inherent variability of the assay. 
 
Saturating amounts of the anti-LILR antibodies were determined by titration 
experiments staining 50μl whole blood and with different amounts of staining 
antibody - at 2x, 1x, 0.5x and 0.25x the amount recommended by the manufacturer 
(Figure 3.1a and 3.1b). At double the manufacturer recommended amount, there 
was still a degree of increase in MFI; however, these amounts of antibody were 
used as the optimum balance between detection and economy. The manufacturer 
recommended amount of antibody was 20μl for the PE conjugated antibodies (anti-
LILRA2 0.5μg in 20μl, 0.025 mg/ml and anti-LILRB2 1μg in 20μl, 0.05 mg/ml) 
and 5μl for the APC conjugated antibodies (anti-LILRB1 0.25μg in 5μl, 0.05 mg/ml 
and anti-LILRB4 0.125μg in 5μl, 0.025 mg/ml). Figure 3.1a and 3.1b use antibody 





Determination of assay characteristics 
 
The inherent variation of the assay was then determined by analysing 5 repeat 
measurements of the same sample. This showed that intra-assay variability for the 
MFIs for the various LILRs was very good, with the highest coefficient of variation 
being less than 6%. (Table 3.1) 
 
These findings suggest that the assay is highly reproducible and that differences 
observed between individuals are likely to result from inherent differences rather 
than being due to assay variability. It also suggests that the assay would be a useful 
tool for measuring LILR expression for correlation with SNP differences. 
 
Intra-individual variation was also determined by measuring LILR levels on 2 
different individuals at 5 distinct time points. This showed that the greatest 
variability was seen in LILRB2 (CV of 44% and 37% for DCs and monocytes, 
respectively), whereas other molecules showed little variation from day to day, e.g. 
the other LILRs expressed on DCs and monocytes had a CV range between 9.6 to 
16% and 4.4 to 13.4% respectively (Table 3.2). 
 
Optimisation of whole blood stimulation assay to measure LILRs 
 
In addition to testing basal expression levels of the LILRs, a functional assay was 
developed to further determine if regulatory genetic polymorphisms could affect not 
just basal levels, but also the LILR response to stimulation with different cytokines. 
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A whole blood assay was developed in the first instance to allow a relatively quick 
tool to test large numbers of subjects for genotype-expression correlation. 
 
Experiments incubating whole blood overnight at 37
o
C without addition of any 
stimuli showed changes in the expression level of the LILRs on monocytes and 
DCs. (Figure 3.2) There were marked increases in the expression levels of LILRB1, 
LILRB4 and LILRB2 on monocytes, which increased the longer the cells were 
incubated at 37
o
C. There was also a rise in the expression of LILRB1 and LILRB2 
on DCs although not as marked. LILRA2 levels increased slightly on monocytes 
although there was no change on DCs. In contrast, expression levels of LILRB1 on 
B cells did not change. 
 
Subsequently, various different cytokines were tested to identify one cytokine each 
that could result primarily in upregulation or downregulation of the LILR 
molecules. This was to allow correlation with genotype to determine if any 
variation was related to the magnitude of change in LILR expression levels. 
 
A mixture of inflammatory cytokines (IL1β, IL6, TNFα and PGE2), IL10 or TGFβ 
were added to whole blood to determine their effect on LILR expression levels of 
APCs. This showed that the inflammatory cytokines and IL10 generally resulted in 
upregulation of the LILRB molecules (particularly on monocytes but also LILRB2 
and LILRB4 on DCs) whereas TGFβ prevented the upregulation associated with 




To allow for better discrimination during subsequent correlation with genotype, 
IL1β, IL6 and TNFα were individually tested in the overnight whole blood 
stimulation assay. (Figure 3.4) This showed that all the individual inflammatory 
cytokines increased LILRB expression although to varying degrees. From this data, 
IL1β at a dose of 50 ng/ml was chosen as the stimulus for use in the genetic 
correlation part of the project. 
 
LILR expression levels in 26 healthy individuals at baseline and after 
stimulation with cytokines 
 
Differential LILR cell surface patterns on monocytes and DCs at baseline 
 
After optimisation work was complete, LILR expression levels on antigen-
presenting cells in 26 healthy individuals were measured. This showed different 
patterns of expression of the four receptors tested (Figure 3.5, monocytes and DCs 
express all the LILRs tested whereas B cells only express LILRB1). In addition, 
different cell types expressed different levels of individual LILRs. DCs expressed 
higher levels of LILRB4 compared to monocytes (p<0.001). Conversely monocytes 
had higher expression of LILRB2 compared to DCs (p<0.001). DCs and monocytes 
had similar expression levels of LILRA2 and LILRB1, although B cells had 
significantly lower levels of expression of LILRB1. As the whole blood assay 
showed good reproducibility with an intra-assay CV between 1.7 and 5.7%, most of 
the variability seen is likely to arise due to difference between individuals or cell 




Incubation of whole blood ex vivo alters LILR expression on monocytes and DCs 
 
For the same 26 individuals, whole blood was incubated for 21 hours at 37
o
C 
without any manipulation to determine the amount of change without stimulation. 
Monocytes upregulated all the LILR molecules tested (Figure 3.7) whereas DCs 
only upregulated LILRB1 and LILRB2 to a lower extent (Figure 3.6). Conversely, 
DCs downregulated LILRA2 and LILRB4 expression (Figure 3.6). 
 
Monocytes were then compared to DCs with respect to their ability to modulate 
LILR levels. When cultured in whole blood ex vivo, there were significant 
differences in the change of LILRs between DCs and monocytes for all molecules 
tested (Figure 3.8). Monocytes always upregulated all four LILRs tested to a greater 
extent than DCs. In contrast, DCs showed a slight downregulation of LILRA2 and 
LILRB4, but upregulated both of LILRB1 and LILRB2. 
 
LILRs are upregulated on monocytes and DCs by inflammatory cytokines 
 
The change in LILR expression in response to the inflammatory cytokine, IL1-β 
was then tested in the group of 26 healthy individuals. This showed a marked 
increase of LILRB1, LILRB2 and LILRB4 on monocytes above the levels seen 
without stimulation (Figure 3.10). On DCs, only LILRB2 showed marked 
upregulation, whereas the other two molecules showed less upregulation, although 
still statistically significant (Figure 3.9). The activating receptor LILRA2 did not 
show much change on either monocytes or DCs (Figures 3.9 and 3.10). Monocytes 
significantly upregulated LILRB1 and LILRB4 more than dendritic cells. A 
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significant difference in the change of LILRA2 expression levels between 
monocytes and DCs was observed as well, although the magnitude of difference 
was less. Both monocytes and DCs upregulated LILRB2 to a similar degree  (Figure 
3.11). 
 
LILRs are downregulated on monocytes and DCs by stimulation with TGF-β 
 
Subsequently, the response to the inhibitory cytokine TGF-β at a dose of 20 ng/ml 
was tested to determine the responses in the 26 individuals. This showed significant 
downregulation in all molecules tested on monocytes and DCs. The downregulation 
was most pronounced for LILRA2 on DCs and LILRB2 on DCs and monocytes 
(Figures 3.12 and 3.13). There was a more moderate downregulation in the 
remaining LILRs. Comparison of the modulation index showed significant 
differences in the degree of downregulation seen in all 4 LILRs tested between DCs 
and monocytes (Figure 3.14). Monocytes showed greater downregulation of 
LILRB1 and LILRB2 compared to DCs whereas the converse was true for LILRA2 
and LILRB4. These findings again further confirm that LILRs are regulated 




These findings show that the LILRs, despite being relatively non-polymorphic 
express some variation between different individuals and on different cell types. 
This appears to be true for LILR baseline as well as IL-1β and TGF-β mediated 
changes (a summary of all results is found in Table 3.3). However, the pattern of 
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LILR regulation is remarkably similar between the 26 individuals studied. Such 
variation may play a significant functional role as published data have demonstrated 
that expression of some of the inhibitory LILRs on cells in vitro has resulted in 
functional consequences such as the generation of tolerogenic DCs. (23;101) 
 
It is possible that the variation of the different LILRs on the cells surface may just 
represent natural biological variation and be of no functional consequence. There is 
relatively little data on how much variability normally exists for most cell surface 
molecules, so it is difficult to be certain what the significance of the variation in 
LILR levels is. However, with the advent of genome-wide association studies, there 
has been increasing need to assess genotype-phenotype correlations. One approach 
has been to use standardised flow cytometry to compare protein expression levels 
with genetic variation. (190) Dendrou et al compared alleles in the IL2RA (or 
CD25) gene (that has been shown to have an association with type 1 diabetes and 
multiple sclerosis) with CD25 expression on CD4+ T cells. (190) They found that 
subjects with the a certain protective allele (against type 1 diabetes, rs12722495) 
had 27% higher mean CD25 expression on CD4+ memory T cells, compared to 
patients with susceptibility alleles or other protective alleles. Although there was 
variability in CD25 expression for subjects with different alleles, there was a 
significant difference in mean expression levels. In addition, they noted a gene 
dosage effect with heterozygous and homozygous individuals having a 22% and 
33% higher mean CD25 level respectively. This data examining a different cell 
surface molecule does lend support to the hypothesis that variation in cell surface 





The phenomenon of LILR upregulation primarily on monocytes but not DCs with 
incubation ex vivo is intriguing. The function of these molecules is still not 
completely understood, although it is likely that they represent some form of sensor 
for ‘self’ given that they bind to MHC class I. One possible explanation could be 
that monocytes ex vivo respond to deprivation of an in vivo suppressive signal, 
perhaps from vascular endothelial cells. Another possible explanation for LILR 
upregulation on monocytes ex vivo could be the presence of stimulatory 
unidentified factor(s) in culture. Endotoxin contamination has been ruled out (see 
materials and methods). 
 
It is also interesting to note the direction of change of the so-called ‘inhibitory’ 
LILRB molecules in response to stimulation with IL1-β and other ‘inflammatory’ 
cytokines. It would be expected that an inflammatory stimulus would depress levels 
of inhibitory molecules; whereas the converse occurred. In keeping with the 
expectation that inhibitory cytokines should upregulate inhibitory LILRB 
molecules, IL-10 has been shown to upregulate LILRB1, LILRB2 and LILRB4 on 
monocyte-derived dendritic cells in vitro (23;104) and in these experiments as well. 
Addition of inflammatory cytokines resulted in increase of all of the LILRB 
molecules on monocytes but mainly LILRB2 on DCs. LILRB1 and LILRB4 
showed less change on DCs. Interestingly, levels of the ‘activating’ LILRA2 did not 
show much change in response to IL-1β. 
 
The reduction in most of the LILRs on monocytes and DCs (and particularly 
LILRB2 on monocytes) with incubation with TGF-β also stands in contrast to the 
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findings with IL-10, indicating that different ‘inhibitory’ cytokines can regulate the 
LILR molecules in different ways. Although it would be predicted that an inhibitory 
cytokine would reduce the levels of the activating LILRA2, the reduction in the 
inhibitory LILRB molecules as well is worthy of further attention. 
 
These findings clearly indicate that the regulation of these molecules is likely to be 
more complex than just simple inhibition or activation of immune cells. It is also 
possible that differential expression of the LILRs could result in variable cell 
signals quantitatively and/or qualitatively. This might provide a potential 
mechanism to explain the diversity of interaction between APCs and ‘self’. 
 
The similar direction of change in the LILRs in response to stimuli seen in different 
healthy individuals implies that they are tightly regulated and further suggests that 
these molecules could have evolved to discriminate between innate self and non-
self and play a fundamental role in determining the way immune responses develop. 
 
It should be noted that there is the possibility that the effect of overnight culture or 
cytokines on LILR expression may be due to other cells being affected and 
subsequently influencing DCs and monocytes to modify their expression of the 
LILRs.  
 
In summary, the whole blood assay to measure LILR levels on antigen-presenting 
cells is robust and can be used to accurately quantify these molecules in different 
individuals. This could represent a useful tool for translational research as LILRs 
are likely to gain greater prominence. At present, there are multiple studies showing 
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an association of various LILRs with rheumatologic diseases, infection, 
autoimmunity, transplantation and malignancy. (1) Various in vitro and in vivo 
attempts have been made to harness HLA-G (the highest affinity natural ligand for 
LILRB1 and LILRB2) and other stimuli that affect LILRB levels for therapeutic 
purposes. (24;133;191;192) These have made a difference and proposals for 
potential use in patients have been suggested. 
 
Potentially, the expression levels of these molecules in vivo might have functional 
consequences as well. Consequently, the use of the whole blood assay clinically 
could be important for two reasons: (i) as understanding of the LILRs increases, 
their contribution to many diseases will be better delineated and (ii) a reliable 
method for assessing their expression levels will be useful for translation of this 
knowledge into useful clinical application. LILR levels could be used to accurately 
categorise high or low-risk patients for a particular outcome based on their LILR 
expression levels; to more precisely direct therapy by selecting patients who would 
be more likely to benefit from interventions using the LILRs; or for monitoring 
disease progression. 
 
As yet, the whole blood assay has not been used to compare healthy individuals 
with those with diseases states; or between individuals before and after some form 
of therapeutic intervention. There is some data suggesting that LILRB2 and 
LILRB4 levels can be altered with venom immunotherapy (193) although there is 
limited other data looking at LILR levels during various immunological 
manipulations. Consequently, this represents an area (in addition to characterizing 






Mean, standard deviation and coefficient of variation of the MFI of LILRA2, LILRB1, LILRB4 and LILRB2 on DCs, monocytes and B 
cells for 5 replicates of one sample 
 


















Mean 5.63 11.9 12.2 1.21 8.60 11.3 11.7 3.27 2.63 
SD 0.095 0.471 0.369 0.060 0.488 0.264 0.285 0.138 0.074 






Intra-individual variation in LILRs in 2 different individuals sampled at 5 different time points. The coefficient of variation for the 4 
LILR molecules tested is shown. 
 
  B cells DCs Monocytes 
  LILRB1 LILRA2 LILRB1 LILRB2 LILRB4 LILRA2 LILRB1 LILRB2 LILRB4 
Individual 1 
Mean 3.04 16.6 7.60 3.23 2.79 12.4 5.34 5.77 1.05 
SD 0.117 1.59 0.937 0.475 0.220 0.914 0.234 1.78 0.0814 
CV 3.85 9.6 12.3 14.7 7.9 7.3 4.4 30.8 7.8 
Individual 2 
Mean 3.41 17.9 8.50 1.89 4.48 17.2 7.57 4.48 1.73 
SD 0.165 1.82 1.36 0.838 0.673 1.45 0.871 1.65 0.232 





Change in LILR levels at 21 hours of culture on different APCs following stimulation with IL-1β or TGF-β compared to baseline.  
 
 B cells DCs Monocytes 
 LILRB1 LILRA2 LILRB1 LILRB2 LILRB4 LILRA2 LILRB1 LILRB2 LILRB4 
Cultured vs. baseline NC NC NC ↑ NC ↑ ↑ ↑↑ ↑ 
IL-1β vs. medium alone NC NC ↑ ↑↑ NC NC ↑↑ ↑↑ ↑↑↑ 
TGF-β vs. medium alone NC ↓ NC ↓ ↓ NC NC ↓↓↓ NC 
 
NC (no change) = between 50% increase and 33% reduction compared to baseline/unstimulated cells, ↑ = 50 to 200% increase compared to 
baseline/unstimulated cells, ↑↑ = 200 to 400% increase compared to baseline/unstimulated cells, ↑↑↑ = > 400% increase compared to 
baseline/unstimulated cells, ↓ = 33% to 66% reduction compared to baseline/unstimulated cells, ↓↓ = 66% to 80% reduction compared to 






Median fluorescence intensity of monocyte staining with various amounts of 










































Median fluorescence intensity of monocyte staining with various amounts of 










































Change in the levels of LILR molecules on B cells, DCs and monocytes at 
baseline, 3, 6 and 22 hours incubation at 37
o
C in whole blood without addition 










































































































Differential response of LILRs after addition of inflammatory cytokines MCM 
(IL1β, IL6, TNFα and PGE2), IL10 or TGFβ on B cells, monocytes and 
dendritic cells. Modulation index (ratio of the median fluorescence intensity of 
LILR expression after 21 hours incubation at 37
o
C with stimulus over LILR 
expression at 21 hours without stimulation) for B cells, DCs and monocytes. B 













































































































Modulation index (ratio of the median fluorescence intensity of LILRB1, 
LILRB4 and LILRB2 expression after 21 hours incubation at 37
o
C with 
stimulus over expression at 21 hours without stimulation) for monocytes, after 
stimulation with a cocktail of inflammatory cytokines (MCM = IL1β, IL6, 
TNFα and PGE2) or individually with IL1β, IL6 or TNFα at 3 different doses. 
 














































Differential baseline LILR expression between monocytes and dendritic cells. 
Molecules of equivalent fluorochrome (MEF) of LILRA2, LILRB1, LILRB2 
and LILRB4 on B cells (grey circles), DCs (white circles) and monocytes (black 
circles) on healthy individuals (n=26). B cells only express LILRB1. The 
diamonds represent the mean value and error bars represent 1 standard 
deviation. 




































Change in LILR expression on dendritic cells by ex vivo incubation in healthy 
individuals (n=26). Difference in molecules of equivalent fluorochrome (MEF) 






















































Change in LILR expression on monocytes by ex vivo incubation in healthy 
individuals (n=26). Difference in molecules of equivalent fluorochrome (MEF) 
















































Differential upregulation of LILRs by ex vivo incubation between monocytes 
and dendritic cells. Modulation indices (ratio of the molecules of equivalent 
fluorochrome of LILR staining after 21 hours incubation at 37
o
C over LILR 
expression at 0 hours) for B cells (grey circles), DCs (white circles) and 
monocytes (black circles) of 26 healthy individuals are shown. B cells only 
express LILRB1. The diamonds represent the mean and the error bars 
represent 1 standard deviation. 
 









































Change in LILR expression on dendritic cells by stimulation with IL-1β in 
healthy individuals (n=26). Difference in molecules of equivalent fluorochrome 
(MEF) of LILRs on B cells and DCs  between cells at 21 hours incubation at 
37
o
C unstimulated and cells incubated with 50 ng/ml IL-1β.  
 












































































Change in LILR expression on monocytes by stimulation with IL-1β in healthy 
individuals (n=26). Difference in molecules of equivalent fluorochrome (MEF) 
of LILRs on monocytes between cells at 21 hours incubation at 37
o
C 
unstimulated and cells incubated with 50 ng/ml IL-1β.  
 































































Differential upregulation of LILRs by IL-1β between monocytes and dendritic 
cells. Modulation index (ratio of the molecules of equivalent fluorochrome of 
LILR expression after 21 hours incubation at 37
o
C with 50 ng/ml IL-1β over 
LILR expression at 21 hours without stimulation) for B cells (grey circles), 
DCs (white circles) and monocytes (black circles) of 26 healthy individuals. B 
cells only express LILRB1. The diamonds represent the mean and the error 
bars represent 1 standard deviation. 
 









































Change in LILR expression on dendritic cells by stimulation with TGF-β in 
healthy individuals (n=26).  Difference in molecules of equivalent fluorochrome 
(MEF) of LILRs on B cells and DCs between cells at 21 hours incubation at 
37
o
C unstimulated and cells incubated with 20 ng/ml TGF-β.  
 














































































Change in LILR expression on monocytes by stimulation with TGF-β. 
Difference in molecules of equivalent fluorochrome (MEF) of LILRs on 
monocytes between cells at 21 hours incubation at 37
o
C unstimulated and cells 
incubated with 20 ng/ml TGF-β.  
 

































































Differential downregulation of LILRs by TGF-β between monocytes and 
dendritic cells. Modulation index (ratio of the molecules of equivalent 
fluorochrome of LILR expression after 21 hours incubation at 37
o
C with 20 
ng/ml TGF-β over LILR expression at 21 hours without stimulation) for B cells 
(grey circles), DCs (white circles) and monocytes (black circles) of 26 healthy 
individuals. B cells only express LILRB1. The diamonds represent the mean 
and the error bars represent 1 standard deviation. 
 













































There is a limited amount of previously published data showing that LILR 
polymorphisms are associated with either expression levels on the cell surface or 
with various immunological diseases. The most well described example of a LILR 
deficiency being associated with disease is homozygous LILRA3 deficiency which 
has been shown to have an association with multiple sclerosis and Sjogren's 
syndrome. (26;27) A polymorphism in LILRA2 resulting in an isoform lacking 3 
amino acids in the linker region (Delta 419-421) has been shown to be more 
prevalent in microscopic polyangiitis and systemic lupus. (160) In addition to the 
data showing that polymorphisms in the LILR molecules can affect expression or be 
linked to disease, there is data showing that polymorphisms in HLA molecules, the 
ligands for some of the LILRs can affect both binding affinity to the LILRs and 
have an association with disease. (5) 
 
Most of the other studies showing differences in LILR levels in various pathological 
conditions have not investigated whether this is due to genetic polymorphism or 
other disease-related or non-genetic factors. There are two published studies that 
have looked at the effect of polymorphisms on expression levels of the LILRs; and 
one of these studies looked at the association of polymorphisms with a disease 
(rheumatoid arthritis). However, some of the polymorphisms described affected the 
coding region of the LILR molecules and potentially might have effects on the 
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binding/functional properties of the molecules (rather than their expression levels) 
to account for their association with disease states. 
 
Kuroki et al have shown that for LILRB1, a certain haplotype (described as 
LILRB1.PE01) with two SNPs present in the promoter region (not present in the 
other 2 haplotypes described) was associated with lower level of LILRB1 by flow 
cytometry both on lymphocytes and monocytes .(172) No differences were noted in 
crystal structure, binding affinities or thermostability in any of the three haplotypes 
described. It should be noted, however, that there were also non-synonymous 
polymorphisms present in the coding regions of the molecule, although they did 
show that this did not affect the affinity of the detection antibody used in the flow 
cytometric assay. They did not find a significant association with rheumatoid 
arthritis or systemic lupus. However, on analysis of patients who did not carry the 
RA-associated HLA-DRB1 shared epitope, patients homozygous for 
LILRB1.PE01/01 were more likely to have rheumatoid arthritis (with an odds ratio 
of 2.05). These data suggest that LILRB1 promoter polymorphisms can affect 
expression levels of the molecule and subsequently increase propensity to 
rheumatoid arthritis (at least in the absence of an HLA type strongly associated with 
the disease). 
 
Hirayasu et al identified 3 LILRB2 polymorphisms (two in the 5’-UTR and one in 
the signal sequence region, c.59A→G, p.H20R) which had an effect on expression 
levels on monocytes. (194) Individuals with the c.59GG phenotype had a 
significantly lower level of cell surface expression of LILRB2 compared to those 
with the c.59AA phenotype. The remaining two polymorphisms c.-169A and c.-
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153A showed the same effect but were in absolute linkage disequilibrium with 
c.59G. Hence, it is possible that the signal sequence region polymorphism is solely 
responsible for the differences in expression levels. Their study did not investigate 
whether any of these alleles were more likely to be associated with any particular 
diseases. 
 
Consequently, the data on whether promoter region polymorphisms affect the 
expression levels of the LILR molecules (and potentially affect susceptibility to 
illness) is not conclusive. To test the hypothesis, the putative LILRB2 promoter 
region was chosen for sequencing to focus effort and resources; in particular, given 
that there was availability of large amounts of anti-LILRB2 antibody from 
hybridoma stock to allow for further functional testing of this particular molecule. 
 
In this chapter, the sequencing results of the LILRB2 promoter region in the 26 
individuals had previously had LILR expression levels measured are described. The 
different polymorphisms are then compared to determine if any of these have an 
effect on LILRB2 expression levels. Transcriptional regulation of LILRB2 in 
response to various stimuli is confirmed both in monocytes and the human acute 
monocytic leukaemia cell line, THP-1. Finally, a 607 bp region (-533 to +74) 
around the putative transcription initiation site for  LILRB2 (189) is cloned into the 
pGL4.10/luc2 firefly luciferase vector to determine if any effect for the promoter 





Sequencing of the putative LILRB2 promoter region 
 
PCR amplification of 2306 bp region containing the LILRB2 promoter 
 
Genomic DNA was extracted from heparinised whole blood of the 26 individuals 
(designated C1 to C26) who had previously had their LILR expression levels 
measured. This yielded a genomic DNA concentration in the range of 11.8 to 43.6 
ng/μl. (Table 4.1) A 2306 bp region corresponding to –1925 to +380 bp from the 
ATG start codon (with A being designated as position 0) was then amplified with 
primers designed using the PrimerZ web application. (195) In the Genome 
Reference Consortium Human genome build 37 this corresponds to 
GRCh37:19:54784103-54786408. Agarose gel electrophoresis demonstrated 
successful amplification of the product (Figure 4.1). The 2306 bp band was then 
extracted from the gel and sent off for sequencing. 
 
Sequencing of amplified PCR product and identification of SNPs contained in the 
amplified PCR region 
 
The amplified PCR product was then sequenced with 5 overlapping primer pairs 
(Figure 4.2) and the sequence data analysed with Variant Reporter 1.1 software 
(Applied Biosystems). Individual traces showing the various polymorphisms for the 
26 healthy individuals tested is shown are Figure 4.3. This identified 15 SNPs 
present in the 26 individuals that were sequenced. (Table 4.2) The public SNP 
database (dbSNP build 135) was then checked to determine if these SNPs had been 
previously identified. 13 of these SNPs had previously been identified; the dbSNP 
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ID and GRCh37 chromosome 19 positions for the SNPs identified are noted in 
Table 4.2. Two new SNPs were identified – GRCh37 chromosome 19, position 
54786194 with a G/A polymorphism in one individual (C9) and position 54784798 
with a C/T polymorphisms in another individual (C22). 
 
Relationship between SNPs identified and LILRB2 protein expression levels 
 
The expression levels of LILRB2 protein on flow cytometry (Figures 2.1, 3.5, 3.8, 
3.11 and 3.14) were then compared for differences between groups of individuals 
with different SNPs. Figure 4.4 shows the values for LILRB2 expression (at 
baseline and as a modulation index after incubation with or without cytokines at 22 
hours) divided by genotype. Although there was some variation in expression levels 
by different genotype, no statistically significant differences were found between 
the different groups. The statistical tests used for parametric data was the t-test 
(when there were 2 genotypes for the SNP)  or one way ANOVA with the 
Bonferroni correction (when there were 3 genotypes for the SNP). Non-parametric 
data was compared using the Mann-Whitney U test (when 2 SNP genotypes were 
present) or the Kruskal-Wallis test (when 3 SNP genotypes were present). 
 
Previously published data has shown that individuals with a homozygous haplotype 
of AA at the rs448092 and rs448083 SNPs (associated with G at the rs383369 SNP) 
have lower levels of LILRB2 expression on monocytes. (194) Unfortunately, it was 
not possible to demonstrate this as there was only one individual with the AA 
haplotype at the rs448092 SNP present in the 26 individuals tested. (Table 4.2) 




Demonstration of the transcriptional regulation of LILRB2 
 
In order to confirm that expression levels of LILRB2 are transcriptionally regulated, 
real time PCR was performed on purified monocytes (Figure 4.5a) and THP1 cells 
(Figure 4.5b) at baseline and after stimulation with IL10, an inflammatory cytokine 
mixture (MCM =  IL1β, IL6, TNFα and PGE2) or unstimulated. 
 
Published data had shown that addition of IL10 resulted in upregulation of LILRB2 
mRNA in THP-1 cells (196) and that addition of Salmonella thyphimurium LPS 
results in upregulation of LILRB2 (and LILRB4) mRNA in in vitro cultured 
macrophages. (177) 
 
The experiments were performed to confirm some of these findings and also to 
determine if the changes in the LILRB2 protein expression seen in monocytes in the 
whole blood stimulation assay could possibly occur due to transcriptional regulation 
of LILRB2. 
 
Real time PCR for LILRB2 in monocytes and THP1 cells with different stimuli 
 
Total mRNA was harvested from both purified monocytes and THP-1 cells at 
baseline and after 6 and 24 hours with or without stimulation with IL10, MCM or E 
Coli LPS. Following conversion of the mRNA to cDNA, the samples were then run 
through a real time PCR reaction. The monocyte experiments were done on two 




For purified monocytes, the greatest amount of increase in LILRB2 mRNA was 
seen at 6 hours after stimulation with LPS (with a relative quantitation, RQ value of 
17.9, using the ΔΔCt method of calculation). (Figure 4.5a) There was a more 
modest increase in IL10 (RQ of 6.7) and with inflammatory cytokines at 6 hours 
(RQ of 3.1). By 24 hours, the amount of increase in LILRB2 mRNA had almost 
returned to baseline. 
 
For THP-1 cells, there was an increase in LILRB2 mRNA with both LPS and 
inflammatory cytokines (RQ of 9.4 and 6.7 respectively), with similar change at 
both 6 and 24 hours after addition of stimuli (RQ of 4.8 and 5.1 respectively). 
(Figure 4.5b) There was a more modest increase with addition of IL10. (RQ of 4.2 
at 6 and 24 hours) 
 
These findings confirm that the change in expression levels of LILRB2 is, at least in 
part, transcriptionally regulated. 
 
Dual luciferase reporter assay to determine if LILRB2 promoter SNPs affect 
protein expression levels 
 
In view of the fact that no significant differences were found in LILRB2 expression 
levels in individuals with different SNPs, cloning of individual LILRB2 promoter 
haplotypes into a firefly luciferase plasmid was undertaken. This was done in case 
other factors could have masked any significant effect the individual SNPs would 
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have had on expression levels in primary cells; potential reasons for this are 
discussed further below. 
 
Cloning of the 1000 bp region upstream of the ATG start codon to determine 
individual LILRB2 promoter region haplotypes 
 
A 1000 bp region upstream of the ATG start codon was PCR cloned into the 
pGL4.10/luc2 promoterless firefly luciferase plasmid (Promega). This was done 
from the amplified 2306 bp region containing the LILRB2 promoter from 5 out of 
the 26 individuals (C2, C3, C11, C13 and C25) to obtain a selection of LILRB2 
promoter haplotypes for testing in the luciferase assay.  
 
PCR cloning was done using primers which had the addition of NheI at the 5' end 
and XhoI at the 3' end of the sequence to allow directional cloning into the pGL4.10 
vector. Four clones from each individual were selected for sequencing to allow 
identification of both haplotypes present in each individual; DNA agarose gel of the 
restriction enzyme digest of each of the clones is shown in Figure 4.6. 
 
Sequencing of cloned promoter regions and identification of the LILRB2 promoter 
haplotype 
 
Sequencing of the 1000 bp region upstream of the ATG start codon for each of the 5 
clones from each of the 5 individuals was undertaken by a commercial sequencing 




Gene synthesis of a region from -533 to +74 from the putative transcription 
initiation site for LILRB2 and cloning into pGL4.10/luc2 vector 
 
Previously work undertaken by Nakajima et al. indicated that the transcription 
initiation site for LILRB2 most likely lay 600 bp upstream of the ATG start codon. 
(189) Based on the data obtained from sequencing of the 1000 bp region, a region 
from -533 to +74 of the putative transcription initiation site identified by Nakajima 
et al. was sent for gene synthesis and subcloning into the pGL4.10/luc2 vector for 
use in the luciferase assay. (Figure 4.7) This region encompassed the first 482 bp of 
the sequenced 1000 bp region and a further 125bp upstream of this which did not 
contain any SNPs on sequencing of the amplified PCR product. 
 
This region was chosen as it included a more than sufficient amount of the promoter 
region for expression of luciferase (189) as well as a short segment after the 
putative transcription initiation site that was particularly rich in SNPs, to increase 
the probability of identifying polymorphisms that might affect protein expression.  
 
Effect of LILRB2 promoter SNPs on luciferase expression 
 
The LILRB2p/pGL4.10 plasmids were transfected into THP-1 cells based on the 
data that LILRB2 was transcriptionally regulated and behaved in a similar way to 
monocytes. In addition, there was also published data indicating that THP-1 cells 




Luciferase expression between the 5 different haplotypes showed a degree of 
variation although the differences did not meet statistical significance. (Figure 4.8) 
The greatest variation was seen between haplotype C2-2 and C3-1, with a 2.15-fold 
difference. However, the coefficient of variation for the assay was large with values 
between 10 and 59% for the luciferase:renilla ratios, despite quadruplicate data. 





The purpose of the experiments described in this chapter is primarily to demonstrate 
that genomic variation (including SNPs) in LILR promoter regions can affect their 
transcriptional regulation and the expression levels of the molecules on the cell 
surface.  For practical considerations, LILRB2 was used in this exercise as there 
was comparatively more (if limited) data published on the molecule and a 
suggestion from one study that genomic variation (within the 5' UTR and signal 
sequence) could affect its expression levels. (194) In addition, experiments in the 
previous chapter had shown greater variability in LILRB2, which would hopefully 
have made it easier to identify genomic differences resulting in variation in 
expression levels. Availability of the anti-LILRB2 hybridoma also influenced the 
choice of molecule investigated as this provided large amounts of antibody for use 
in subsequent functional experiments to determine if there was any relationship 
between LILRB2 expression levels and functional responses to LILRB2 




Sanger sequencing of the 2306 bp upstream of the LILRB2 ATG start codon 
identified 15 SNPs in this region, of which 2 had not previously been documented 
in the reference database (dbSNP build 135). The identification of 13 previously 
known SNPs served to confirm the validity of the sequencing data. Although the 2 
previously unidentified SNPs require confirmation, their identification in a group of 
26 individuals does indicate that the non-coding regions for LILRB2 (and 
potentially the other LILR molecules as well) are not extensively mapped. This 
represents an area for future potential research, especially as these molecules are 
known to be linked to disease and more detailed mapping could identify further 
linkages with immunological disease. 
 
Despite the number of SNPs identified, there was no statistically significant 
difference between the various SNP genotype founds when compared with LILRB2 
expression levels. This included the differences seen in the haplotype previously 
described by Hirayasu et al. (194) They described a c.59GG homozygous genotype 
(corresponding to dbSNP reference  rs383369 and position 2279 on the 2306 bp 
sequence described in this data) which had lower expression levels of LILRB2 
compared to the c.59AA and c.59AG genotypes. The c.59GG genotype was 
particularly common in North East Asian populations. (194) However, in this study, 
there were 23 participants with the AA genotype, 3 with the AG genotype; and none 
with the GG genotype shown to have lower LILRB2 expression levels, possibly due 
to the different ethnic composition of subjects. This is the most likely explanation as 





In addition to this, Hirayasu et al. also found that two other SNPs, which they 
describe as c.-153 and c.-169 (corresponding to rs448083/position 1489 and 
rs448092/position  1473) were in absolute linkage disequilibrium with c.59 in their 
sample of subjects tested for LILRB2 expression. They concluded that these 
additional SNPs might also be responsible for the differences in LILRB2 expression 
seen although this was not tested in their study. Again, there were no statistically 
significant differences between the different genotypes for these two SNPs seen in 
the data described here.  
 
Some of the possible reasons why there were no statistically significant differences 
identified between the different LILRB2 genotypes include: 
1. Insufficient numbers of each genotype to demonstrate a significant difference - 
although there were SNPs identified, the proportion of each genotype present often 
resulted in small numbers of the variant genotype 
2. Other genetic factors (outside of the LILRB2 promoter region) having a greater  
effect on LILRB2 expression levels and masking any effect of promoter genomic 
variation 
3. Other non-genetic factors that could have influenced LILR levels - e.g. 
subclinical infection or other undeclared disease states in the subjects tested 
4. The effect of heterozygosity vs. homozygosity for each genotype, as differences 
might have been more obvious with sufficient numbers of two different 





To attempt to address some of the issues that might have resulted in no significant 
differences between the various genotypes when assessed in human subjects, a dual 
luciferase reporter assay was performed with cloning of different haplotypes of 
LILRB2 promoter regions into a luciferase vector for transfection into cell lines. 
This would help eliminate most of the difficulties described above. Initially, qPCR 
experiments were performed to confirm that LILRB2 expression could be 
transcriptionally regulated. Exposure of monocytes and the THP-1 cell line to 
different cytokines and LPS did indeed confirm this. In addition, it also 
demonstrated that monocytes and the THP-1 cell line responded to the same stimuli 
in a similar fashion, indicating that the THP-1 cell line would be reasonable to use 
in this experimental model. 
 
However, although there were some differences in luciferase activity between the 
various promoter haplotypes seen in the experiment, these were not statistically 
significant. It is possible that this indicates that there is no actual difference between 
the difference promoter haplotypes; however, it should be noted that the luciferase 
assay demonstrated a marked amount of variability (despite the experiments being 
run in quadruplicate) which could have accounted for the lack of statistical 
significance. In addition, addition of the LPS failed to result in augmentation of 
luciferase activity in THP-1 cells despite the fact that LPS resulted in an increase in 
LILRB2 mRNA in both monocytes and THP-1 cells. For future work, further 
optimisation of this experimental system would be undertaken to improve the 
performance characteristics of this assay as well as determine the optimum time to 




In summary, these experiments have demonstrated that there is significant genomic 
variability in the non-coding regions of the LILRB2 gene. There were also 
differences in expression of LILRB2 levels seen when these were separated by 
genotype as well as luciferase activity by LILRB2 promoter haplotype. However, 
none of the correlations between genomic variation and LILRB2 expression were 
statistically significant, which is most likely a result of insufficient numbers to 
achieve this, although a lack of a true difference cannot be ruled out. 
 
To take forward the work in this chapter, next generation sequencing of the 
genomic regions for all the LILRs measured in the previous chapter (i.e. LILRA2, 
LILRB1, LILRB2 and LILRB4) should be performed on a larger sample of the 
population. The large amount of data generated could then be subjected to more 
thorough bioinformatics analysis to determine what effect genomic variation in both 
the non-coding and coding regions of the LILR molecules would have on their 
expression levels. In addition, it would also serve to confirm some of the SNPs 
identified in this small scale pilot study as well as help determine whether genomic 
variation in one LILR molecule can affect expression of another LILR molecule. 
 
It would also be important to obtain a larger sample size of subjects to allow 
enrichment of rarer LILR SNPs to allow more meaningful comparison of different 
genotypes. With regard to the luciferase assay as a means to demonstrate in vitro 
that genomic variation in the LILR promoters could affect expression levels, it 
might be useful to clone a longer region of the LILR promoter region in case SNPs 
further upstream might play a role in determining expression levels. In addition, 
further optimisation of the luciferase assay (e.g. with different transfection 
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conditions or reagents) might provide less intra-assay variability making it easier to 
demonstrate any true differences in luciferase activity due to genomic variation in 







Concentration of genomic DNA from 26 healthy controls (C1 to C26). 200 μl 
blood was processed, resulting in 200 μl of solution containing the DNA. 
 
Individual Concentration of 
genomic DNA 
(ng/μl) 
 C1  12.15 
 C2  11.91 
 C3  20.42 
 C4  29.07 
 C5  34.74 
 C6  20.79 
 C7  17.14 
 C8  38.45 
 C9  21.02 
 C10  21.56 
 C11  23.76 
 C12  27.76 
 C13  33.28 
 C14  35.3 


















SNPs identified in the putative LILRB2 promoter region of the 26 individuals sequenced. Yellow boxes indicate where the genotype is 


































































































































































215 54786194  G G G G G G G G G R G G G G G G G G G G G G G G G G G 
387 54786022 rs4112253 C C C C S S C C C G C S S S S S C S S C S C C C S C S 
546 54785863 rs113412095 G G G G G G G G K G G G G G G G G G G G G G G G G G G 
630 54785779 rs7260261 G G G R G G R G A R G G G G G G A G G R R G R R G G R 
816 54785593 rs380573 T Y C Y Y Y Y T C C Y C C C C Y C Y T Y C C C Y Y C C 
1444 54784965 rs73938625 G G G G G G G G G G G G G G G G G G G G G G G G G S G 
1473 54784936 rs448092 G G A G G G G G G G R R R R G G G G G G G G G G G R G 
1481 54784928 rs13347079 A R A R A A R A G A A A A A A A G A R R R A R R A A R 
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1487 54784922 rs13347078 A R A R A A R A G A A A A A A A G A R R R A R R A A R 
1489 54784920 rs448083 G G A G G G G G G G R R R R G G G G G G G G G G G G G 
1501 54784908 rs13345069 G K G K K K K G T T G K K K T K T K T K T G K K K G T 
1511 54784898 rs13345054 T K T K K K K T G G T K K K G K G K G K G T K K K T G 
1611 54784798  C C C C C C C C C C C C C C C C C C C C C C Y C C C C 
1788 54784621 rs188025641 G G G G G G G G G G G G G G G G G G G G G G G R G G G 










SNP haplotypes identified in the 1000 bp region upstream of the ATG start codon of LILRB2 
 
Position of SNP on 2306 bp product 1444 1473 1481 1487 1489 1501 1511 
Reference sequence G G A A G G T 
C2-1, C2-2, C2-3, C2-4, C11-3, C11-4, C13-1, C13-2, C13-3 G A A A A G T 
C3-1 G G G G G T G 
C3-2, C3-3, C3-4, C25-2 G G A A G G T 
C11-1, C11-2, C13-4 G G A A G T G 






Agarose gel showing PCR products of the 2306 bp region containing the 
putative LILRB2 promoter region. The 2306 bp product is visible between 
the 2.0 and 3.0 kb markers on the ladder in all 26 healthy individuals (C1 to 
C26). The cloning primers used to amplify the 2306 bp region were the 
forward primer, PRO1F (TGCCATGCACTCCATATTGT) and reverse 











































































































Diagram showing the regions covered by the 5 primer pairs used to 
sequence the 2306 bp region upstream of the LILRB2 ATG start codon. The 
green bars (labelled PRO1, PRO2, PRO3, PRO4 and EX1+2) represent the 
areas of the 2306 bp product covered by the 5 primer pairs. The blue arrows 
represent the direction and length of sequence obtained from each 
individual primer and the yellow areas represent areas where data from 
both forward and reverse primers overlap. This data is shown for all 
subjects in the study (C1 to C26). The sequencing primers used are detailed 









DNA sequencing data showing the individual SNPs identified in the 26 healthy subjects (C1 to C26). The numerical positions identified 
correspond to that on the 2306 bp region upstream of the LILRB2 ATG start codon, with the reference nucleotide identified first, 
followed by the SNP present. Green peaks represent adenine, red peaks represent thymidine, blue peaks represent cytosine and black 






































Graph showing mean LILRB2 expression levels (in molecules of equivalent fluorochrome of LILR staining, MEF) at 0 hours, and 
modulation indices without addition of cytokines (ratio of the MEF after 21 hours incubation at 37
o
C over LILR expression at 0 hours), 
with addition of IL-1β (ratio of the MEF after 21 hours incubation at 37oC with 50 ng/ml IL-1β over LILR expression at 21 hours 
without stimulation) or addition of TGF-β (ratio of the MEF after 21 hours incubation at 37oC with 20 ng/ml TGF-β over LILR 
expression at 21 hours without stimulation). Monocytes are represented by the red bars and dendritic cells  by the blue bars; expression 
levels are shown for each individual genotype present at different loci along the 2306 bp sequence upstream of the LILRB2 ATG start 
codon. There was no statistical difference found between any of the groups. The error bars represent one standard deviation; where no 
error bars are shown, there was only one subject with that particular genotype. The genotype symbols used are International Union of 




 LILRB2 at 0 hours 
LILRB2 index at 21h without 
addition of cytokines 
LILRB2 index after stimulation 
with IL-1β at 21h 
LILRB2 index after stimulation 



























































































 LILRB2 at 0 hours 
LILRB2 index at 21h without 
addition of cytokines 
LILRB2 index after stimulation 
with IL-1β at 21h 
LILRB2 index after stimulation 

























































































 LILRB2 at 0 hours 
LILRB2 index at 21h without 
addition of cytokines 
LILRB2 index after stimulation 
with IL-1β at 21h 
LILRB2 index after stimulation 

























































































 LILRB2 at 0 hours 
LILRB2 index at 21h without 
addition of cytokines 
LILRB2 index after stimulation 
with IL-1β at 21h 
LILRB2 index after stimulation 





























































































 LILRB2 at 0 hours 
LILRB2 index at 21h without 
addition of cytokines 
LILRB2 index after stimulation 
with IL-1β at 21h 
LILRB2 index after stimulation 

























































































 LILRB2 at 0 hours 
LILRB2 index at 21h without 
addition of cytokines 
LILRB2 index after stimulation 
with IL-1β at 21h 
LILRB2 index after stimulation 

























































































 LILRB2 at 0 hours 
LILRB2 index at 21h without 
addition of cytokines 
LILRB2 index after stimulation 
with IL-1β at 21h 
LILRB2 index after stimulation 























































































 LILRB2 at 0 hours 
LILRB2 index at 21h without 
addition of cytokines 
LILRB2 index after stimulation 
with IL-1β at 21h 
LILRB2 index after stimulation 

























































































 LILRB2 at 0 hours 
LILRB2 index at 21h without 
addition of cytokines 
LILRB2 index after stimulation 
with IL-1β at 21h 
LILRB2 index after stimulation 































































































LILRB2 mRNA in monocytes at 0 hours, and after 6 and 24 hours 
incubation at 37
o
C with no cytokines, IL10, an inflammatory cocktail of 
cytokines (MCM = IL-1β, TNF-α, IL-6 and PGE2) or LPS. mRNA was 
quantified using qPCR and the ΔΔCt method to obtain relative quantitation 
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LILRB2 mRNA in THP-1 cells at 0 hours, and after 6 and 24 hours 
incubation at 37
o
C with no cytokines, IL10, an inflammatory cocktail of 
cytokines (MCM = IL-1β, TNF-α, IL-6 and PGE2) or LPS. mRNA was 
quantified using qPCR and the ΔΔCt method to obtain relative quantitation 
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Agarose gel showing restriction enzyme digest of a 1000 bp product region  
upstream of the LILRB2 ATG start codon, cloned into pGL4.10 vector. 4 
clones for each of the healthy subject C2, C3, C11, C13 and C25 were sent 


























































































DNA sequences of the 5 different haplotypes (C2-2, C3-1, C3-2, C13-4 and 
C25-3) used for cloning into pGL4.10/luc2 for dual luciferase experiments. 
The sequence is -533 to +74 bp from the putative promoter start site for 
LILRB2. Green characters represent SNPs in the DNA sequence with C3-2 
























































































Dual luciferase assay data showing luciferase and renilla activity and the 
luciferase:renilla ratio for THP-1 cells transfected with the pGL4.10 firefly 
luciferase vector containing 5 different haplotypes (C2-2, C3-1, C3-2, C13-4 
and C25-3) of the LILRB2 promoter region. Luciferase activity was 
measured 24 hours after transfection with or without the addition of LPS at 
6 hours. The bars show the mean of quadruplicate experiments and the 
error bars indicate 1 standard deviation from the mean. There were no 





































































In view of the immunosuppressive properties of the LILRB molecules, their 
potential use in therapeutic applications has been considered. In particular, HLA-
G, the high-affinity natural ligand for LILRB1 and LILRB2 has been suggested 
as a potential therapeutic molecule. Engagement of the LILRB molecules in vitro 
by HLA-G has been shown to result in various tolerogenic or 




 T cells, antigen 
presenting cells as well as whole PBMC fractions and endothelial cells. In 
addition, HLA-G also binds to KIR2DL4, CD8 and CD160, and mediates some 
of its functions through these molecules. 
 
HLA-G has been shown to inhibit NK cell cytotoxicity, (121;197) NK cell 
proliferation (198) and transendothelial cell migration via LILRB2. (199) In 
addition, through its interaction with KIR2DL4, HLA-G also inhibits NK 
cytotoxicity. (121;197) Conversely, interaction with KIR2DL4 results in 
increased proliferation and IFN-γ production by uterine NK cells. (200;201) 
Binding to endocytosed KIR2DL4 results in increased secretion of pro-
angiogenic factors. (202) HLA-G induces apoptosis in CD8
+
 T cells and NK 
cells (135;203) and inhibits cytotoxic T cell activity through interaction with 
CD8. (135) Indirectly, HLA-G can also inhibit NK cell cytotoxicity through 
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stabilisation of HLA-E via CD94/NKG2A. (204) Expression of HLA-G by target 
cells prevents polarization of cytolytic granules at the immune synapse. (205) 
 
HLA-G inhibits alloreactivity via LILRB1 and LILRB2 in CD4
+
 helper T cells, 




 T cells. 
(208;209) HLA-G inhibits the cytotoxic function of CD8
+
 T cells (210;211) and 




 regulatory T cells. (146;206) 
 
Dendritic cells exposed to HLA-G have reduced maturation, antigen presenting 
ability and trafficking (by downregulation of chemokine receptors), and result in 
the induction of regulatory T cells. (24;212)  HLA-G also upregulates inhibitory 
receptors LILRB1, LILRB2, LILRB4 and KIR2DL4 in APCs, NK and T cells. 
(156) PBMCs exposed to HLA-G in vitro secrete Th2 cytokines. (213) 
 
In addition to its effect on immune cells, HLA-G has also been shown to result in 
apoptosis of endothelial cells via CD160. (214) More recently, it has been 
demonstrated that HLA-G can also be acquired from other cells via trogocytosis 
resulting in a novel means of immunological escape. (198;209) 
 
There is more limited data on in vivo use of HLA-G resulting in a tolerogenic 
effect, although there is some evidence in mouse models that exogenous 
administration of HLA-G results in benefit in transplantation and autoimmunity. 
In allogeneic skin transplants in mice, both HLA-G transgenic mice and injection 
of microbeads coated with tetrameric HLA-G (or other HLA-G fusion proteins) 
resulted in delayed skin allograft rejection. (70;215;216) Some of the HLA-G 
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fusion proteins shown to improve allograft tolerance included β2m linked to 
HLA-G1-IgG Fc, β2m linked to HLA-G5 and the HLA-G α1 domain linked to 
IgG Fc. (216) 
 
HLA-G5-β2m microbeads have also been used in a mouse model of lupus 
nephritis (MRL/lpr mice). (217) Injection of microbeads for 10 weeks (from 
week 12 of age) resulted in attenuation of disease with reduced renal 
inflammation, reduced CXCR3
+
 T cells in the kidney, reduced IFN-γ producing 
cells, reduced infiltration and activation of DCs and macrophages in the kidney; 
and lower levels of rheumatoid factor, IL12p40, TNF-α and IL17. 
 
Most of the immunosuppressive effects of HLA-G have been studied with either 
the full HLA-G molecule (either as membrane bound HLA-G1, shed HLA-G1 or 
soluble HLA-G5). However, there is less data on the function of the other HLA-
G isoforms (which lack some of the α domains). HLA-G2, G3 and G4 have been 
shown to inhibit NK and cytotoxic T cell cytolysis in vitro. (210) 
 
In view of its multiple immunosuppressive and tolerogenic effects, the use of 
HLA-G as a therapeutic molecule represents an attractive option with potential 
use in transplantation and autoimmune disease. However, theoretically there 
would be little specificity with the use of HLA-G and this would carry with it the 





As a result, the G-body was developed to determine if the known 
immunosuppressive properties of the LILRs could be manipulated for therapeutic 
purposed by combining one of their natural ligands with another molecule to 
allow localisation to an allogeneic target. Both a more “elegant” recombinant 
product and a chemically conjugated molecule comprising both “business ends” 
that would make up the G-body were generated. 
 
Conceptually, the G-Body was designed as a bifunctional molecule to be used in 
the setting of transplantation and alloimmune responses. It would consist of two 
parts; one “business end” would be HLA-G, used for its known 
immunosuppressive properties and the other “business end” would enable 
specific localization of the HLA-G to donor cells/tissues to prevent alloimmune 
responses and generate allospecific tolerance. To this end, HLA-A2 was used as 
the allogeneic target for a proof-of concept model. This would allow localisation 
of HLA-G to donor HLA-A2 positive cells in a HLA-A2 negative recipient for 
suppression of alloimmune responses. 
 
Two approaches were concurrently taken to develop the G-body. This was to 
allow more rapid development of a product that would be suitable for functional 
testing and proof-of-concept. The first was a more elegant recombinant 
technology approach that sought to combine HLA-G and the ScFv fragment of 
an anti-HLA-A2 monoclonal antibody within a single expression plasmid, and 
transfected into mammalian cells for protein production. This approach, although 
likely to take longer and be more complex was used with the longer term view of 




The second approach involved chemically conjugating biotinylated HLA-G 
monomers to an anti HLA-A2 monoclonal antibody that had been labelled with 
streptavidin. Although this approach would result in a mixture of molecular 
species, it was expected that this method would more quickly generate a 
bifunctional product that could be used in functional studies for proof of concept. 
 
Design of the recombinant G-body 
 
The recombinant G-body was intended to be created as two polypeptide chains; 
one with the HLA-G heavy chain and the VL fragment of a monoclonal antibody 
directed against HLA-A2 and one with β2m and the VH fragment of the same 
monoclonal antibody. Each of the parts of the two separate molecule would be 
linked by using a repeating (G4S)n=1-3 linker (Figure 5.1), to allow a degree of 
flexibility for the portions of the two polypeptide chains to fold correctly, 
resulting in a HLA-G/β2m molecule and an anti-HLA-A2 ScFv on two separate 
ends of the recombinant molecule. Four different recombinant constructs were 
designed to achieve this goal. (Figures 5.2 to 5.4) 
 
Recombinant G-Body version 1 (ORIGBv1) 
 
The recombinant G-body was first designed as a single polypeptide chain with a 
furin cleavage site in the middle that would allow generation of the two 
polypeptide chains (Figure 5.2). In addition, c-myc and 6x His tags were added 




The HLA-G sequence (NCBI reference sequence NM_002127.5) was truncated 
to remove the intracytoplasmic tail to allow the protein product to be secreted 
into supernatant. The genetic sequence for the anti-HLA-A2 ScFv was obtained 
by sequencing of the BB7.2 hybridoma by a commercial company. The two 
sequences were then combined such that the genetic sequences were in the 
following order: HLA-G signal peptide, HLA-G heavy chain, (G4S)1 linker, VL 
mAb fragment, c-myc tag, furin cleavage site, VH mAb fragment, (G4S)3 linker, 
β2m. Synonymous substitutions were made in the coding DNA to generate 
specific restriction enzyme sites to allow subsequent modular modification of the 
molecule as necessary. (Figure 5.5) The gene was synthesized and cloned into 
the pcDNA3.1+ expression vector by Genscript. 
 
COS7 cells were chosen as the transfection system to utilize the large T antigen-
SV40 interaction to allow episomal replication of the transfected plasmid and 
facilitate large amounts of transient protein production. These cells were 
transfected with this plasmid with and without co-transfection with a pRC furin 
plasmid (a kind gift from Joop Gaken). The presence of protein of the correct 
molecular size was detectable in unconcentrated supernatant with Western 
blotting using the anti-denatured HLA-G antibody, 4H84. (Figure 5.6) However, 
staining with the anti-β2m, anti-myc and anti-His antibodies failed to detect 
protein. (Figure 5.6) The reasons for the non-binding of these antibodies was not 
completely clear although might possible have been due to refolding of the entire 
G-body molecule on the PVDF membrane resulting in epitopes for these 




In addition, immunoprecipitation experiments failed to show demonstrable 
binding to HLA-A2, either in the furin-cleaved or uncleaved molecule. (Figure 
5.6) The lack of binding of OGBv1 to HLA-A2 could have been due to 
insufficient affinity in its monomeric form, errors in the sequencing of the 
hybridoma or problems in folding of the ScFv domain. 
 
Recombinant B11 G-body (B11GBv1) 
 
To overcome the problem of ORIGBv1 not binding to HLA-A2, the ORIGBv1 
molecule was modified with removal of the VL mAb fragment, c-myc tag, furin 
cleavage site and VH mAb fragment to be replaced with an alternative anti-HLA-
A2 sequence proven to bind to its target when expressed as an ScFv fragment. 
(Figure 5.7) The sequence for the ScFv fragment was obtained from a published 
anti-HLA-A2 ScFv sequence, B11 developed using phage display technology 
and light-chain shuffling to enhance avidity. (218;219) 
 
Sequencing of B11 plasmid 
 
Sequencing of the B11pUC119 plasmid was undertaken to confirm that it 
matched the published sequence. The original B11 pUC119 plasmid (a kind gift 
from Dr Ouwehand and Dr Watkins) was transformed into TOP10 cells and 
plasmid DNA minipreps were made. Plasmid DNA was sent to a commercial 
company, Geneservice for sequencing with stock M13F, M13R and a custom 
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“AGGCGAGTCAGGACATTAGC” primer. Sequence data was compared with 
the published sequence, which confirmed a match. 
 
Synthesis of B11 insert to replace BB7.2 fragment 
 
The B11 ScFv insert was designed following the published sequence with (G4S)3 
linker arms at both ends and in between the two variable domains and with 
BspEI and BamHI restriction enzymes sites at the 5’ and 3’ ends to allow cloning 
into the original G-body. (Figure 5.7a) The design was submitted to Genscript, 
who further optimized the codons for expression in COS7 cells (using in-house 
software) and synthesized the B11 insert with cloning into a pUC57 vector. 
(Figure 5.7b) 
 
Cloning of the B11 insert into ORIGBv1 
 
The B11 pUC57 vector was transformed into TOP10 cells and plasmid minipreps 
generated. Both the ORIGBv1 and the B11 pUC57 plasmids were digested with 
BspEI and BamHI and run on an 0.8% agarose gel. (Figure 5.8) The digested G-
body fragment (without the BB7.2 portion) and the B11 insert were extracted 
from the gel and ligated. The ligated products were then used to transform 
TOP10 cells and plasmid minipreps were generated. 
 
DNA sequencing confirmed that the B11 insert had correctly replaced the 
original BB7.2 sequence in the ORIGBv1 plasmid. Sequencing primers used 
were T7F, bGHR and “ATGGAACCTTCCAGAAGTGG”. After confirmation 
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of the sequence, a plasmid maxiprep of the B11-Gbody version 1 (B11GBv1) 
construct was generated for transfection. 
 
Binding characteristics of B11GBv1 
 
Immunoprecipitation experiments showed that B11GBv1 was capable of binding 
HLA-A2. (Figure 5.9) Due to the relatively poor binding affinity of the 
monomeric HLA-G portion for its ligand, its conformational state was assessed 
by binding to anti-HLA-G mAbs. However, B11GBv1 was only bound weakly 
or not at all in repeat experiments by the conformational mAbs (87G, MEM-G9 
and W6/32). Figure 5.10a to 5.10d shows faint binding of B11GBv1 with the 
87G mAb; there was possibly better binding by MEMG/9 and the binding pattern 
for W6/32 was similar to that of 87G. 
 
In conclusion, these results showed that the B11GBv1 could bind HLA-A2 but it 
was not certain if the HLA-G portion was definitely in the correct conformational 
state. One possible explanation for this was that the expression of β2m at the end 
of the polypeptide chain attached to the anti-HLA-A2 ScFv was interfering with 
proper folding of the HLA-G heavy chain.  
 
Original G-Body version 2 (ORIGBv2) and B11 G-Body version 2 
(B11GBv2) 
 
Due to uncertainty of the HLA-G portion of the B11GBv1 not being in the 
correct conformational state, both ORIGBv1 and B11GBv1 were recloned 
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without the β2m portion of the molecule; with the intention of co-transfecting 
β2m separately in the expression system to determine if this would enable correct 
folding of the HLA-G portion.  
 
PCR cloning of ORIGBv2 and B11GBv2 
 
Further versions of the recombinant G-body without the β2m segment (and 
6xHis tag) “version 2” were generated by PCR cloning. (Figure 5.4) The 
ORIGBv1 and B11GBv1 plasmids were used as the template for PCR cloning. 
The new constructs were designed with 5’ NheI and 3’ BamHI restriction 
enzyme sites (underlined) to allow cloning into a pcDNA3.1(+) vector. The 
primers used for ORIGBv2 cloning were 5’-
CTGGCTAGCACCACCATGGTGGTC and 
ATAGGATCCTCACGGGGGTGTCGTACGGGCTG-3’; whereas the primers 




PCR conditions for the reaction were: denaturation at 98
o
C for 2 minutes, 30 
cycles of denaturation at 98
o
C for 10 seconds and extension at 72
o
C for 60 
seconds, and a final extension at 72
o
C for 5 minutes. PCR products were run on 
an 0.8% agarose gel and bands corresponding to the expected size were extracted 
from the gel (Figure 5.11a and 5.11b) and incubated with NheI and BamHI 
restriction enzymes prior to being purified with the Qiagen PCR product 




pcDNA3.1(+) plasmid was also incubated with NheI and BamHI restriction 
enzyme prior to being run on an 0.8% agarose gel. The corresponding linearized 
plasmid was extracted from the gel. The linearized vector and RE digested 
inserts were ligated and transformed into TOP10 cells. 
 
DNA sequencing confirmed that the ORIGBv1 and B11GBv1 plasmids had the 
intended sequence. Sequencing primers used were stock T7F and bGHR.  
 
Binding characteristics of ORIGBv2 and B11GBv2 
 
Immunoprecipitation experiments confirmed binding of B11GBv2 to HLA-A2. 
(Figure 5.9) Of interest, ORIGBv2 also showed weak binding to HLA-A2 unlike 
ORIGBv1. One possible explanation for this difference is that expression of β2m 
attached to the ScFV in the ORIGBv1 could have affected the conformational 
state of the anti-HLA-A2 ScFV portion of the molecule. 
 
In addition, both ORIGBv2 and B11GBv2 showed binding with the 
conformational monoclonal antibodies 87G and MEM-G/9 (Figure 5.10a 
to5.10d), although arguably the binding intensity was similar to that of the 
B11GBv1. The original Western blotting experiment was done with an 
unconjugated primary antibody (4H84) and a goat anti-mouse Fc HRP antibody 
as secondary layer. This resulted in some difficulty clearly identifying the GBv2 
bands as the secondary antibody also bound to the monoclonal antibodies used 
for immunoprecipitation, which has a similar molecular weight to the GBv2 
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products. Hence, the Western blot portion of the experiment was repeated using a 
biotinylated  primary detection antibody (4H84) and streptavidin-HRP as the 
secondary layer to avoid the problem of the immunoprecipitation antibody being 
seen on the Western blot.  
 
In summary, the B11GBv2 showed binding to HLA-A2 and had a HLA-G 
portion that had the correct conformational state. The ORIGBv2 had an HLA-G 
portion in the correct conformational state and probably had a degree of binding 
to HLA-A2 as well. 
 
Measurement of recombinant G-body concentrations 
 
Concentrations of the recombinant G-body were then measured using an ELISA 
kit to determine how much protein was actually being generated to allow 
planning of downstream experiments. This showed that the concentrations of the 
G-Body in the supernatant were all <20 ng/ml. (Table 5.1) Published literature 
suggested that it should be possible to obtain up to 1 μg/ml of protein using a 
COS7 expression system. (220) The reason for this discrepancy is not completely 
understood, although the expression system has not been fully optimised yet. In 
addition, it is possible that the signal peptide used for the G-body is not ideal for 






Design of the chemically conjugated GBody 
 
In view of the difficulty in generating a recombinant G-body, a chemically 
conjugated G-body (cGBOD) with both the requisite business ends was 
generated as described to allow quicker testing in functional experiments. 
Another advantage of the chemically conjugated molecule is that it would allow 
multimerisation of HLA-G, with potential to increase its effects. The chemically 
conjugated G-body was generated by exploiting the effectively irreversible 
biotin-streptavidin interaction. In summary, the anti-HLA-A2 antibody BB7.2 
was conjugated to streptavidin using a commercial kit. Biotinylated HLA-G was 
purchased and the two reagents were mixed to allow biotinylated HLA-G-BB7.2-
streptavidin complexes to form. 
 
However, biotinylated HLA-G purchased from the vendor was found to have 
significantly elevated levels of endotoxin. (Table 5.2) Consequently, this was 
removed to prevent interference with functional assays and the endotoxin levels 
remeasured. After buffer exchange, there was still some degree of endotoxin 
contamination although this was significantly less and expected to be lower still 
after dilution in culture medium prior to use in functional experiments. 
 
Binding characteristics of cGBOD 
 
K562 stably transfected with HLA-A2 (a kind gift from Mark Peakman) and 
LILRB2, the ligand with the highest affinity for HLA-G, were used in FACS 
experiments to test cGBOD binding. This confirmed that the conjugation process 
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had not affected the binding properties of both molecules. (Figure 5.12a and 
5.12b) 
 
Binding of the cGBOD was also tested on PBMCs of HLA-A2 positive and 
HLA-A2 negative individuals.  (Figure 5.12c) This showed binding to 
monocytes, assumed to be due to the myeloid-specific expression of HLA-G 
receptors LILRB1 and LILRB2, but not lymphocytes in HLA-A2 negative 
individuals. This is consistent with published flow cytometric data investigating 
the binding properties of HLA-G tetramers. (221) cGBOD binding was seen in 
both lymphocytes and monocytes of HLA-A2 positive subjects as expected due 
to interaction of the anti-HLA-A2 (BB7.2) portion of the construct with HLA-A2 
present on all cells. This confirmed that in addition to transfectants, the cGBOD 
could also interact with human cells that were to be used in functional 
experiments. 
 
An optimisations experiment with different molar ratios (4:1, 8:1 and 12:1) of 
biotinylated HLA-G to BB7.2 was performed (Figure 5.12d) to determine the 
best ratio for the cGBOD. This showed that there was greatest staining of 
LILRB2 transfectants with a ratio of 4:1. There was slightly less staining of 
HLA-A2 transfectants at this ratio compared to the other ratios. However, the 
MFI for LILRB2 staining at the other ratios were relatively close to the MFI for 







The results above indicate that both the recombinant and chemically conjugated 
G-bodies have been successfully generated. This represents the first step required 
for proof of concept that localisation of the HLA-G signal to the site of an 
allogeneic immune response confers additional immune suppression compared to 
just HLA-G alone. Functional experiments utilising the G-body are described in 
the following chapter. 
 
The recombinant G-body has been shown to bind to HLA-A2 unequivocally. As 
expected there is particularly strong affinity when the B11 ScFv sequence is used 
(218;219) but also some degree of binding with the original BB7.2 sequence is 
used. Additionally, this indicates that the ScFv fragment has folded correctly, at 
least for the ORIGBv2, B11GBv1 and B11GBv2 constructs. The addition of β2m 
with one shorter (G4S)1 segment may have resulted in the ORIGBv1 construct 
not folding in the correct conformational state and binding to HLA-A2. 
 
Proving that the HLA-G portion of the recombinant G-body bound to its target 
was more of a challenge. Monomeric HLA-G, despite being the highest affinity 
ligand for LILRB1 and LILRB2 still binds relatively weakly to its ligand 
(especially compared to antibody-antigen interactions). Surface plasmon 
resonance has been required to demonstrate binding (130) and additionally 
tetramerised HLA-G can also bind to its target. (222) As a surrogate to check 
whether the HLA-G portion of the recombinant G-body was folded correctly, 
binding to two different conformational anti-HLA-G antibodies was checked. 
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This showed that both the ORIGBv2 and the B11GBv2 bound two different 
conformational monoclonal antibodies, making it likely that the HLA-G portion 
in these two constructs had folded correctly. This does not necessarily constitute 
proof that the HLA-G portion would bind to its ligand but is sufficient evidence 
to try the molecule in functional experiments. 
 
Unfortunately, the transient transfection system did not generate sufficient 
quantities of protein for use in functional experiments. For future work, potential 
ways of addressing this would be generating the recombinant protein in large-
scale mammalian cell transfection systems, which would have the benefits of 
both ensuring appropriate folding of the protein in the cell machinery as well as 
glycosylation. The signal peptide used in the recombinant G-body was native 
human HLA-G and modification to an alternative signal peptide more suited to 
the cells used in the expression system (or using cells that might be more suited 
for a human signal peptide as COS7 cells are derived from monkey kidney 
tissue) might have increased the protein yield. A more economical way of 
producing the recombinant protein might be to use yeast or bacterial protein 
expression systems. However, it is likely in this instance that additional steps 
would need to be taken to obtain correct folding of the protein product. 
 
With additional time and resources, testing of different constructs using 
alternative HLA-G isoforms (i.e. HLA-G2, HLA-G3 or HLA-G4) instead of the 
full HLA-G1/G5 molecule would be useful to undertake. Another possibility for 
a molecule incorporating full length HLA-G with β2m and the ScFv portion as a 
single polypeptide chain might be to design the gene sequence as β2m-HLA-G-
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ScFv. β2m-HLA-G fusion protein constructs have recently been demonstrated to 
have functional tolerogenic effects in  murine allogeneic skin graft model. (216) 
These approaches might have allowed for both easier production and re-folding 
of the recombinant protein without sacrificing immunosuppressive potential. 
 
The chemically conjugated G-body, on the other hand, can be generated in 
sufficient quantity for functional experiments. Additionally the flow cytometric 
data confirms that both portions of the molecule bound to their respective targets, 
both in transfectants and primary cells. The process for generation of this is 
relatively quick and allows for production of large quantities of the G-body, with 
the only limitation being cost. On the negative side, however, the process used to 
make the chemically conjugated G-body does result in a variety of molecular 
species as it is not possible to control the exact stoichiometries of monoclonal 
antibody to streptavidin to biotinylated HLA-G. It might be possible that certain 
particular stoichiometries result in greater functional consequences although a 
means of separating or isolating the different species generated by the 
conjugation process would need to be undertaken. For future work, potentially 
mass spectrometry could be used to determine the make-up of the chemically 
conjugated G-body as well as isolating the fraction which is likely to have the 
greatest biological activity. 
 
The development of both the G-body products is exciting as it gives a new set of 
tools to test the therapeutic potential of manipulating the LILR molecules via 
HLA-G. The chemically conjugated G-body, although a crude mixture of 
different molecules allows rapid testing for proof-of-concept; the results of which 
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are described in the next chapter. The recombinant molecule on the other hand 
holds more potential as a therapeutic that might eventually have in vivo use, 















Concentration of HLA-G/G-body in the supernatant of various 
transfectants 
 
Supernatant from transfectant: HLA-G concentration (ng/ml) 
pcDNA3.1(+) 1.2 









Endotoxin levels in biotinylated-HLA-G before and after endotoxin removal 
and after buffer exchange into PBS 
 
Sample Endotoxin concentration (EU/ml) 
Biotinylated HLA-G, from supplier >250 
Biotinylated HLA-G, post ET removal 0.107 
Biotinylated HLA-G, post buffer 
exchange 
11.20 
Biotinylated BSA 1.135 
Streptavidin conjugated BB7.2 21.95 
Streptavidin conjugated MPC13 15.03 








The conceptual design for the recombinant G-body which would 






















1, 2, 3 and 2m are the 
extracellular domains of the 
HLA-G molecule
VHA & VLA are the variable 
domains of the heavy and light 










The ORIGBv1 construct consisting of a single polypeptide chain with a furin 





















1, 2, 3 and 2m are the 
extracellular domains of the 
HLA-G molecule
VHA & VLA are the variable 
domains of the heavy and light 

















The B11GBv1 construct consisting of a single polypeptide chain with the 
B11 ScFv fragment inserted in place of the BB7.2 ScFv fragment, and 6xHis 






















1, 2, 3 and 2m are the 
extracellular domains of the 
HLA-G molecule
VHA & VLA are the variable 
domains of the heavy and light 












Schematic for the ORIGBv2 and B11GBv2 constructs which consist of the 
HLA-G heavy chain linked to the anti-HLA-A2 ScFv fragment; with the 



















1, 2, 3 and 2m are the 
extracellular domains of the 
HLA-G molecule
VHA & VLA are the variable 
domains of the heavy and light 









DNA sequence for the ORIGBv1 construct cloned into pcDNA3.1(+). 













































Kozak sequence,Sig pep of HLA-G h chain,HLA-G alpha-
1,2 and 3 domains,HLA-G connecting stalk,Linker 
peptide (3X),VLA,Connecting peptide of Ig domain,C-myc 
tag (10aa),3X His tag,Furin site,VHA,Connecting 
peptide of Ig domain,Linker peptide (1X),Beta 2 m,6X 




Western blot showing immunoprecipitation using biotinylated HLA-A2 
bound to streptavidin beads (Lanes 1 and 2); and detection of ORIGBv1 in 
neat supernatant using different detection antibodies (Lanes 3 to 6). The 
primary detection antibody used in the immunoprecipitation experiments is 
4H84 (non-conformational anti-HLA-G). No binding of ORIGBv1 to 
biotinylated HLA-A2 is visible in lane 2. For lanes 3 to 6, detection of the 
ORIGBv1 (predicted molecular weight of 73 kDa) in neat supernatant is 
noted only when 4H84 is the detection antibody (Lane 3). No detection is 
noted with anti-β2m, anti-c-myc or anti-His antibodies (Lanes 4 to 6). 
1    2        3         4        5       6 
Lane bHLA-A2 Material Detection
antibody
1 - ORIGBv1 sup 4H84
2 + ORIGBv1 sup 4H84
3 Neat ORIGBv1 supernatant 4H84
4 Neat ORIGBv1 supernatant Anti-β2m
5 Neat ORIGBv1 supernatant Anti-c-myc




Original anti-HLA-A2 sequence derived from B11 ScFv clone used to 
replace the BB7.2 sequence in ORIGBv1, prior to optimisation for COS7 
























Anti-HLA-A2 sequence derived from B11 ScFv clone used to replace the 
BB7.2 sequence in ORIGBv1, after optimisation for expression in COS7 
























0.8% agarose gel of ORIGBv1 and B11 pUC57 plasmids digested with 
BspEI and BamHI showing two bands of approximately 800 bp 





Western blot showing immunoprecipitation using biotinylated HLA-A2 
bound to streptavidin beads. The primary detection antibody is 4H84 (non-
conformational anti-HLA-G). Faint binding of ORIGBv2 (predicted 
molecular weight of 62 kDa) and stronger binding of B11GBv1 (predicted 
molecular weight of 73 kDa) and B11GBv2 (predicted molecular weight of 






Western blot showing immunoprecipitation using anti-HLA-G (87G) bound 
to protein G beads. The primary detection antibody is 4H84 (non-
conformational anti-HLA-G). and the secondary antibody is goat-anti 
mouse Fc-HRP. Faint binding of B11GBv1 (predicted molecular weight of 
73 kDa) and very faint binding of ORIGBv1; stronger binding of ORIGBv2 
and B11GBv2/β2m (predicted molecular weight of 62 and 60 kDa 
respectively) is seen in the region of the yellow box. 
1   2  3  4   5 6   7   8
Lane Protein G 87G Supernatant
1 + - OriGBv2
2 + + -
3 + + OriGBv1
4 + + OriGBv2
5 + + OriGBv2/β2m
6 + + B11GBv1
7 + + B11GBv2




Western blot showing immunoprecipitation using anti-HLA-G (MEMG/9) 
bound to protein G beads. The primary detection antibody is 4H84 (non-
conformational anti-HLA-G). and the secondary antibody is goat-anti 
mouse Fc-HRP. Binding of B11GBv1 (predicted molecular weight of 73 
kDa) and very faint binding of ORIGBv1is seen in the region of the yellow 
box. Binding of GBv2 by MEMG/9 is less certain due to proximity to IgG 
heavy chain band. 
1   2  3    4  5  6  7
Lane Protein G MEMG9 
mAb
Supernatant
1 + + -
2 + + OriGBv1
3 + + OriGBv2
4 + + OriGBv2/β2m
5 + + B11GBv1
6 + + B11GBv2





Western blot showing immunoprecipitation using anti-HLA-G (87G) bound 
to protein G beads. The primary detection antibody is biotinylated 4H84 
(non-conformational anti-HLA-G). and the secondary antibody is 
streptavidin-HRP. Binding of B11GBv1 (predicted molecular weight of 73 
kDa); and of ORIGBv2 and B11GBv2 proteins (predicted molecular weight 
of 62 and 60 kDa respectively) is seen. There is also very faint binding of 
ORIGBv1.  
Lane Protein G 87G Supernatant
1 Neat OGBv1 supernatant
2 + - B11GBv2/b2m
3 + + -
4 + + OGBv1 250ul
5 + + OGBv2
6 + + OGBv2/b2m
7 + + B11GBv1
8 + + B11GBv2
9 + + B11GBv2/b2m
10 + + sol HLA-G/b2m
11 Neat B11GBv2/b2m supernatant






Western blot showing immunoprecipitation using anti-HLA-G (MEMG/9) 
bound to protein G beads. The primary detection antibody is biotinylated 
4H84 (non-conformational anti-HLA-G). and the secondary antibody is 
streptavidin-HRP. Binding of B11GBv1 (predicted molecular weight of 73 
kDa); and of ORIGBv2 and B11GBv2 proteins (predicted molecular weight 
of 62 and 60 kDa respectively) is seen. 
Lane Protein G MEMG/9 Supernatant
1 Neat OGBv1 supernatant
2 + - B11GBv2/b2m
3 + + -
4 + + OGBv1 250ul
5 + + OGBv2
6 + + OGBv2/b2m
7 + + B11GBv1
8 + + B11GBv2
9 + + B11GBv2/b2m
10 + + sol HLA-G/b2m
11 Neat B11GBv2/b2m supernatant




0.8% agarose gel showing the products of the ORIGBv2 PCR reaction. The 





0.8% agarose gel showing the products of the B11GBv2 PCR reaction. The 
expected product of 1758 bp highlighted by the yellow box, was extracted 





Overlay histogram showing binding of cGBOD to LILRB2 transfected K562 
cells. The detection antibody is goat anti-mouse FITC. The red histogram is 
detection antibody alone and the blue histogram is staining with cGBOD 








Overlay histogram showing binding of cGBOD to HLA-A2 transfected K562 
cells. The detection antibody is anti-HLA-G (87G) PE. The red histogram is 
detection antibody alone and the blue histogram is staining with cGBOD 







Overlay histograms showing binding of cGBOD to lymphocytes and 
monocytes (identified by light scatter on flow cytometry) in PBMCs of HLA-
A2 positive and HLA-A2 negative subjects. The red histogram represents 
detection antibody alone and the blue histogram represents addition of 
cGBOD followed by detection antibody. Binding was seen to monocytes in 
both HLA-A2 positive and negative subjects, as monocytes express the 
ligands for HLA-G. cGBOD binding was only seen in lymphocytes of HLA-
A2 positive individuals due to interaction of the anti-HLA-A2 portion of the 
molecule. 










Overlay histograms showing cGBod (at different ratios) binding to K562-
HLA-A2 transfectants (top) with an 87G-PE detection antibody; and 
binding to K562-LILRB2 transfectants (bottom) with an goat anti-mouse 












Chapter 6: Functional assays to determine the effect of ligation of LILRB2 




Engagement of the LILR molecules has been shown to influence the 
development of dendritic cells, early activation events in monomyelocytic cells, 
T cell responses and NK cell cytotoxicity. Some of these effects have been 
demonstrated with monoclonal antibodies directed against LILRB1, LILRB2 and 
LILRB4. (39;40;42) In addition, HLA-G (in various formats) has also been 
shown to have an effect on immune responses following engagement of its 
cognate ligands (which include LILRB1 and LILRB2). (39;40) 
 
In the original paper describing LILRB1, Colonna et al showed that LILRB1 was 
involved in downregulation of intracellular calcium mobilisation in monocytes 
and B cells, reduction in NK and T cell cytotoxicity as well as reduction in 
serotonin release from LILRB1-trasnfected rat basophilic leukaemia (RBL) cells. 
(39) Cytosolic calcium was measured using Indo-1 AM and calcium released 
was triggered by cross-linking of MHC I on B cells (using the mAb HP-1F7) or 
MHC II on monocytes (using the mAb 3.8B1). Co-cross linking of LILRB1 
(using the mAb HP-F1) resulted in downregulation of calcium mobilisation.  
 
Fanger et al have also shown that co-ligation of CD64 (FcγRI, using the mAb 
32.2) and LILRB1 (using the mAbs M402 and M405) resulted in inhibition of  
intracellular calcium mobilisation and tyrosine phosphorylation of associated Fc 
225 
 
receptor γ chain and Syk molecules, compared with crosslinking of CD64 alone. 
(44)  
 
LILRB1-transfected RBL cells were activated to release serotonin using plate 
bound mouse IgE (acting through FcεRI). Co-cross linking of LILRB1 using HP-
F1 bound to the plate resulted in clear reduction in serotonin release. (39) 
 
Addition of HP-F1 (directed against LILRB1) resulted in restoration of lysis of 
HLA transfected 721.221 cells by an NK cell line (NKL). (39) Lysis was 
restored in HLA-B*2702, B*2705 and B*5101 transfectants with addition of HP-
F1 and restored in HLA-A*0301, B*0702 and G1 transfectants in combination 
with an anti-CD94 mAb. These data were further tested in reverse ADCC 
experiments, where the FcR
+
 murine mastocytoma cell line P815 was killed by 
NKL in the presence of an anti-CD16 mAb which binds FcR on the target cell 
line and CD16 on the effector cell line. Addition of HP-F1 resulted in reduction 





 T cell cytotoxicity was also restored by addition of HP-F1. HP-F1
+
 T cells 
were sorted and cloned and then selected for expression of Vβ2 which binds the 
toxic shock syndrome toxin-1 (TSST-1) superantigen. Cytotoxicity was tested 
using 721.221 cells with or without a HLA-B*2705 transfection, pulsed with 
different concentrations of TSST-1. One of the T cell clones efficiently killed 
TSST-1 pulsed 721.221 cells but not the HLA transfected 721.221 cells. 
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Cytotoxicity against the transfected cells was restored by addition of HP-F1 mAb 
Fab fragments.  (39) 
 
Addition of the anti-LILRB1 mAb, HP-F1 has also been shown to result in an 
increase of interferon-γ production by NK-92 CD56+ cells after binding to HLA 
transfected 721.221 cells presumably by inhibition of the LILRB1-HLA 
interaction. (223) Fresh NK cells were also shown to downregulate interferon-γ 
production after exposure to polyI:C and suboptimal doses of IL-12 , when 
incubated in HP-F1 coated wells, although this effect was not seen with NK-92 
cells. (223) 
 
The anti-LILRB1 mAb, GHI/75 has been shown to block the interaction of 
recombinant HLA-G5 and G6 with LILRB1 on U937 cells resulting in reduction 
in TGFβ secretion. (224) However, a similar effect was not demonstrated when 
the anti-LILRB2 mAb, 27D6 was used, although LILRB2 is expressed on U937 
cells. 
 
LILRB1 ligation (with HP-F1 and protein G for cross linking) during the 
development of GM-CSF/IL-4 monocyte derived DCs in vitro has been shown to 
result in modulation of DC maturation and function. (99) DCs treated with anti-
LILRB1 had high levels of CD14 and low levels of CD1a, no CD83 and low 
levels of CD86. In addition, they also resulted in a reduced MLR when incubated 




Similar to LILRB1, co-ligation of LILRB2 (with the mAb 42D1) has also been 
shown to reduce intracellular calcium mobilisation in DCs triggered by FcγRII 
(CD32, with mAb IV.3) and HLA-DR (mAb 3.8B1). (40) Ligation of LILRB2 
on transfected RBL cells also resulted in a reduction of serotonin release, 
although the RBL cells were activated by incubation with HLA I transfected or 
untransfected 721.221 cells coated with TNP and mouse anti-TNP IgE. (40)  
 
Co-ligation of LILRB4 on monocytes and macrophages also resulted in a 
reduction in intracellular calcium mobilisation. (42) In this instance, calcium flux 
was triggered by engagement of CD11b (with mAb 44aabc), MHC II (with mAb 
B73.1) or (CD16, with mAb 3.8B1). Cella et al also showed that tyrosine 
phosphorylation in monocytes stimulated with anti-HLA DR was reduced with 
co-ligation with anti-LILRB4. (42) Lu et al confirmed a similar finding in THP-1 
cells, where co-ligation of CD64 (FcγRI) with LILRB4 using mAbs resulted in a 
80to 90% reduction in protein tyrosine phosphorylation seen on Western blot. 
(225) They further established that LILRB4 co-ligation specifically reduced 
protein tyrosine phosphorylation of the proximal signalling molecules, Lck and 
Syk, the downstream signalling molecules, LAT and ERK as well as the adaptor 
protein c-Cbl. However, protein tyrosine phosphorylation of α-actinin-4 was not 
reduced, indicating selectivity in LILRB4 mediated regulation of tyrosine 
dephosphorylation.   
 
Engagement of LILRB4 has also been demonstrated to possibly have 
downstream functional effects on monomyelocytic cells. Lu et al also showed 
inhibition of TNF-α production by LILRB4 co-ligation in both THP-1 cells and 
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monocytes activated by engagement of CD64. (225) Brown et al showed that 
ligation of LILRB4 (with the mAb ZM3.8 and protein G) during the 
development of GM-CSF/IL-4 monocyte derived DCs (both immature and LPS-
matured) resulted in upregulation of CD86. (177) There was no change in CD1a, 
CD80 or CD83. However, this had no effect on a MLR with allogeneic CD4
+
 
naïve T cells. LILRB4 ligation also resulted in increased IL-10 and reduced IL-8 
production by macrophages.  
 
HLA-G has also been shown to have various immunosuppressive properties both 
in vivo and in vitro. As previously discussed, HLA-G binds to LILRB2 and 
LILRB4 and is the highest affinity natural ligand known for these molecules. 
(14) It also interacts with KIR2DL4 and CD8. (134;135) 
 
HLA-G has been shown in vitro to have effects on allo-proliferative responses, 
cytotoxicity and cytokine secretion. Experiments have been done both by 
transfecting cells with HLA-G or by addition of some form of soluble HLA-G to 
culture medium, which is more directly comparable to the experiments 
performed in this chapter. 
 
In various published experiments, HLA-G has been transfected into 721.221, 
K562 or C1R cells. Riteau et al transfected HLA-G into 721.221 and K652 cell 
lines. (207) HLA-G transfected 721.221 cells were used as stimulator cells with 
PBMCs as responder cells; and reduced allo-proliferation when compared to 
vector only transfectants. Furthermore, HLA-G transfected K562 cells were able 
to reduce all-proliferation in an MLR with 721.221 cells as the stimulators and 
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PBMCs as the responders. (207) Bainbridge et al demonstrated that C1R cells 
transfected with HLA-G (rather than HLA-A2) also reduced the allo-proliferative 
response of PBMCs in an MLR. (226) Apps et al further extended this work to 
try to determine which cells were primarily affected by HLA-G in the reduction 
of allo-proliferative responses. (133) They tested the effect of co-culturing HLA-
G transfected 721.221 with MoDCs. This did not inhibit the upregulation of 
HLA-DR, co-stimulatory molecules (CD40, CD80, CD86) or the activation 
marker CD83, but did result in an increase in IL-6 and IL-10 (but not IL-8 or 
TNF-α) secretion. Additionally, they did one-way MLR reactions with PBMCs 
as responders and 721.221 cells as stimulators. HLA-G transfection resulted in 
reduced proliferation, which could be reversed with the addition of anti-
LILRB1/LILRB2 antibodies (HP-F1, M401 and M402). They then tested this 
again with depletion of HLA-DR
+
 cells (to remove APCs) and found that there 
was no additional inhibitory effect with HLA-G transfected stimulator cells, 
suggesting that most of the HLA-G effect was on the indirect stimulation of T 
cells by responder APCs. (133) 
 
Soluble HLA-G has also been shown to have immunomodulatory effects, similar 
to cell membrane-bound HLA-G, consistent with the hypothesis underpinning 
development of the G-body. Kapasi et al showed that HLA-G (isolated from 
placental tissue using anti-HLA-G, 4H84 mAb and anti-β2m affinity columns) 
modulated cytotoxic T lymphocyte activity at different doses, although in their 
experiments allo-proliferative responses were not affected by HLA-G. (227) Low 
doses of HLA-G (0.01 to 0.05 μg/ml) resulted in increased cytolytic activity 
whereas higher doses (>1 μg/ml) had a suppressive effect. There was however, 
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no effect seen when HLA-G was added to cells that had already been primed. 
They also found that IL-10 was increased and TNF-α and IFN-γ were reduced 
with decreased allo-CTL responses and that the converse was true when there 
was increased allo-responses. (227) 
 
Le Friec et al generated soluble HLA-G by transfecting HLA-G5 into LCL cells, 
and purified the supernatant using anti-HLA I (W6/32 mAb) columns. (228) The 
purified HLA-G5 was then incubated with MoDCs during their development and 
incubated with allogeneic CD3
+
 T cells. Again, there was no change in 
maturation markers with addition of HLA-G5, but there was a reduction in allo-
proliferation in a proportion of MLR responses (4/17 cases showed a strong 
reduction in proliferation, 5/17 showed a weak reduction and 8/17 showed no 
reduction). (228) Naji et al used recombinant HLA-G5 produced in SF9 insect 
cells, supernatant from M8 cells transfected with HLA-G1 or G5 or HLA-G5 
isolated from liver-kidney transplant patient’s plasma; they also demonstrated a 
reduction in allo-proliferative MLRs (using LCL as stimulator and PBMCs as 
responder cells) which could be blocked with addition of anti-LILRB1 or anti-
LILRB2 antibodies. (146) In addition, they demonstrated that blocking FasL 
restored HLA-G induced inhibition, suggesting that this pathway was important 
in the process.  
  
Addition of HLA-G tetramers has been shown to affect the development of 
MoDCs in vitro. Liang et al have shown a reduction in HLA-DR and 
costimulatory molecules (CD80, CD86) with addition of HLA-G tetramers. (229) 
Subsequent to that, Ristich et al demonstrated that addition of HLA-G tetramer 
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treated MoDCs to a MLR resulted in the generation of anergic and 




 T cells 
and raised CTLA-4
+
 cells in that population. (24) These cells were also more 
likely to produce IL-10. CD4
+
 T cells also showed a reduction in spontaneous 





 T cells with an increased capacity for IL-10 
production. Ristich et al also looked at gene profiles in HLA-G treated MoDCs 
and found that 11 genes (most of which were downregulated) were specifically 
affected. (24) These genes were mainly involved in remodelling of specialized 
antigen-processing compartments and in MHC Class II restricted antigen 
presentation. 
 
Experiments have also been done to try to improve the potency of soluble HLA-
G as an immunosuppressive molecule. In view of the increased potency of 
dimeric HLA-G, Zhong et al made a construct comprising IgG-Fc and soluble 
HLA-G in place of the variable regions of the IgG molecule, resulting in a 
divalent molecule. (230) They then demonstrated that compared to monomeric 





 T cells in an MLR using irradiated T1 cells as stimulators and non-
adherent PBMCs as responders. Additionally, the dimeric HLA-G molecule was 
also shown to suppress cytotoxic responses more than monomeric HLA-G, 
thought to be due to upregulation of LILRB1 on cytotoxic CD8
+
 T cells. (230) 
 
In summary, it is reasonably clear that engagement of the LILRB molecules does 
result in inhibition of cellular responses – although the magnitude of the 
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responses does vary between the subjects tested. The published data, however, 
has yet to address exactly how these molecules vary the magnitude of their 
influence on cellular immune responses. As these molecules are relatively non-
polymorphic structurally, one possible explanation is that the cell surface density 
of expression is responsible for modulating their immunological influence. 
 
The experiments in this chapter were undertaken to determine if the magnitude of 
response to LILR engagement was influenced by the density of surface 
expression of these molecules. First of all, experiments were undertaken to 
confirm that engagement of the LILR molecules did modulate immunological 
responses. Subsequently, the magnitude of LILR expression on the cell surface 
was compared with the effect on the immunological response being tested to 
determine if there was any relationship between the two. 
 
In this chapter, development of the assays used to test the effect of LILR 
engagement (by anti-LILRB2 monoclonal antibodies and by the G-body) is 
described. LPS (E Coli) and ssRNA are used to induce cytokine secretion from 
purified monocytes and the effect of modulation with anti-LILRB2 antibodies 
tested. Additionally, modulation of lymphocyte proliferation by anti-CD3/28 
beads, anti-CD3 or SEB is also used to determine if the G-body has any 
functional effect and whether there is a difference between HLA-A2 positive and 




The variation in the effect on the functional assays is then tested in different 
individuals; and the effect of the anti-LILRB2 monoclonal antibodies correlated 
with the cell surface expression of LILRB2. 
 
The anti-LILRB2 monoclonal antibody 42D1 was used for these experiments as 
proof of principle that LILR ligation would have functional immune effects as 
there was availability of a large amount of this particular antibody from the 
hybridoma. Although, there is more published functional data available on the 
effects of LILRB1 engagement, the hybridoma for this was not available and 
obtaining significant quantities of an anti-LILRB1 mAb for functional 
experiments was not feasible. In addition, despite there being more published 
data on LILRB1 compared to LILRB2, overall there was still a relative paucity. 
 
It should be noted that the exact functional effect (with regard to whether they 
are agonistic or blocking) of these antibodies is not completely certain. In the 
original paper describing the discovery of LILRB2 and generation of 42D1, these 
antibodies were shown to abolish intracellular calcium flux when co-ligated 
(using a secondary antibody) with the stimulatory anti-FcγRII or anti-HLA-DR 
monoclonal antibodies in dendritic cells. (40) The 42D1 antibody has also been 
shown to enhance HLA-G tetramer staining. (221) However, the same antibody 





 tolerogenic DCs results in return of their stimulatory 
capacity. (23) Similar results have been seen with anti-LILRB1 mAbs where the 
same mAb could result in activation or blockade of receptor function, depending 




Effect of anti-LILRB2 antibodies on LPS and ssRNA induced cytokine 
secretion 
 
The effect of LILR ligation on TLR-induced responses was tested as both sets of 
molecules function as part of innate immunity, with the TLRs primarily 
recognising microbial products and the LILRs probably recognising self. In 
addition, the LILR (and PIR) pathway has been shown to have effects on TLR 
stimulation. LILR and PIR-B receptors have been shown to bind S aureus with 
TLR2 and result in IL-10 release. (7) Inhibition of TLR2 signalling has also been 
shown to be impaired in PIRB-/- mice with exaggerated Th2 responses and 
impaired DC maturation. (60) The importance of LILR and PIR signalling as a 
counterbalance to TLR activation is also seen in PIRB-/- mice which are more 
prone to lethal Salmonella infection; interestingly, due to enhanced susceptibility 
rather than an excessive immune response. (81) Engagement of LILRA2 has 
been shown to result in reduced IL-12 production by TLRs in the context of 
leprosy. (161) Signalling through TLRs has also been shown to affect LILR 
expression. (177;231) Exposure to live and heat-inactivated Salmonella results in 
upregulation of LILRB4, thought to be mediated by LPS. (177) LILRA2 has 
been shown to inhibit TLR4 activity (232) and LILRA4 has been demonstrated 
to regulate TLR7/9 function in PDCs. (29) 
 
Purified monocytes were chosen as the cellular target as these cells expressed 
LILRB2 and were abundant, allowing easy testing in multiple individuals. 
Another consideration in design of the assay was the selection of an assay that 
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had a quantitative (or at least semi-quantitative) readout to allow more significant 
comparison with the cell surface expression levels of the LILR molecules. For 
this reason, ELISA measurement of cytokines was chosen. 
 
Optimisation of the concentration of antibody and stimulus for use in the assay 
 
A range of TLR ligands were initially tested to determine if they resulted in 
secretion of IL-6 from monocytes. The range of stimuli used included poly-I:C 
(TLR3), LPS (TLR4), imiquimod (TLR7), ssRNA40/LyoVec (TLR8) and CpG 
(ODN2006, TLR9). This showed that only LPS and ssRNA induced secretion of 
IL-6. (Figure 6.1) 
 
In view of this, LPS and ssRNA were then chosen for use in further optimisation 
experiments. Experiments were initially conducted to determine if there was any 
reduction in cytokine secretion when 42D1 was added compared to a rat IgG2a 
isotype matched control. This was done with a single stimulus (LPS) with 
cytokine levels measured for a single cytokine (IL-6) as a pilot experiment. This 
showed that there was a reduction in IL-6 secretion with addition of anti-LILRB2 
antibody compared to the rat IMC. There was a ~20% reduction in IL-6 secretion 
at a mAb concentration of 1 μg/ml, with a reduction of 40 to 45% at 
concentrations between 10 to 50 μg/ml. (Figure 6.2) This confirmed that 





Subsequently, experiments with a range of concentrations of antibody, TLR 
ligand and monocyte numbers were conducted to determine the optimum 
conditions for testing of the effect of 42D1 in a larger group of individuals. On 
the basis of these experiments (Figure 6.3), the experimental conditions for use in 
a larger group of individuals was set at 20,000 purified monocytes per well, with 
addition of 50 μg/ml of anti-LILRB2 or IMC and stimulated with either 1ng/ml 
of LPS or 1 μg/ml of ssRNA. 
 
Results of anti-LILRB2 antibodies on TLR ligand-induced cytokine secretion in 5 
individuals 
 
The assay was then performed on five healthy individuals, and this showed 
variation in levels of cytokine suppression with addition of 42D1 between 
different cytokines, different stimuli and between the individuals tested. (Figures 
6.4 and 6.5) 
 
There was suppression of all cytokines tested (IL-6, IL-8, IL-10 and TNF-α) 
when LPS was used as the stimulus. (Figure 6.4a) However, when ssRNA was 
used as the stimulus, there was no suppression of TNF-α, unlike the other 3 
cytokines tested. (Figure 6.4b) 
 
When comparing the different individuals tested, it can also be seen that there 
was quite a wide degree of variation both in the baseline cytokine secretion and 
in the reduction of cytokine secretion if 42D1 had been added. (Figure 6.5b)With 
LPS stimulation and addition of 42D1, there was a reduction in IL-6 of 13 to 
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68% (mean 41%), in IL-8 of 5 to 31% (mean 18%), in IL-10 of 39 to 90% (mean 
66%) and in TNF-α of 6 to 54% (mean 28%). When ssRNA was used as the 
stimulus, there was a similar reduction in IL-6 (mean 45%, range 25 to 58%) and 
a slightly greater reduction in IL-8 (mean 25%, range 10 to 37%). There was 
slight less reduction in IL-10 (mean 52%, range 43 to 80%, after exclusion of one 
significant outlier). A more significant difference seen was the lack of any 
suppression of TNF-α secretion by 42D1 when ssRNA was used as the stimulus, 
suggesting that an alternative pathway (not affected by LILRB2 inhibition) of 
activation compared to LPS might be involved. 
 
These findings confirmed that there was variation in a functional response 
following engagement of LILRB2; and consequently, it would be useful to 
determine if the expression levels of LILRB2 correlated with this functional 
response. 
 
Relationship to LILRB2 expression levels 
 
Cellular surface expression levels of LILRB2 were also measured on purified 
monocytes at baseline. Following this, the amount of cytokine suppression by 
42D1 was correlated with monocyte cell surface expression levels. (Figure 6.6) 
This, however, did not show any significant relationship. Baseline monocyte 
LILRB2 expression levels were similar for 4 of the subjects with one subject 
having markedly lower levels (<50% compared to the rest). However, the single 
subject with lower LILRB2 expression levels did not have functional data results 




Part of the reason for the lack of relationship between LILRB2 expression levels 
and functional effects might be due to the small numbers of subjects used; and 
consequently, it would have been interesting to determine if a correlation would 
have been detectable in a larger group of subjects. 
 
 
Effect of the chemically conjugated G-body in functional studies 
 
Effect of the chemically conjugated G-body on lymphocyte proliferation 
assays 
 
In order to determine if the chemically conjugated G-body had any effect on 
lymphocyte proliferation, initially more straightforward experiments using single 
defined stimuli on isolated PBMCs were undertaken. The cGBOD and 
appropriate controls (i.e. HLA-G tetramers, BB7.2, HLA-G tetramers and BB7.2 
combined without streptavidin linking, and mouse IgG2b as isotype matched 
control for BB7.2) were added to PBMCs (isolated from buffy coats) stimulated 
with an anti-CD3 monoclonal antibody (OKT3), anti-CD3/CD28 beads or SEB. 
PBMCs were incubated for 4 days and tritiated thymidine was added 18 hours 
prior to the cells being harvested. To test whether the localisation by the anti-
HLA-A2 monoclonal antibody had any effect, both cells that were HLA-A2 
positive and HLA-A2 negative were used. In total, five HLA-A2 positive donors 




Effect of the chemically conjugated G-body in lymphocytes stimulated with anti-
CD3/CD28 beads 
 
When stimulated with anti-CD3/28 beads, addition of the cGBOD resulted in 
suppression of lymphocyte proliferation compared to untreated cells, although 
this effect was only seen in individuals who were HLA-A2 positive. This result 
was statistically significant compared to untreated cells and with the addition of 
HLA-G tetramers. (Figures 6.7)  A similar suppression of proliferation was not 
seen in HLA-A2 negative individuals. (Figures 6.8) There was not much 
difference in proliferation seen when any of the other reagents (anti-HLA-A2, 
HLA-G tetramers or a combination of those two) were used in both HLA-A2 
positive and negative individuals 
 
Effect of the chemically conjugated G-body in lymphocytes stimulated with SEB  
 
When stimulated with SEB, addition of the cGBOD resulted in more marked 
suppression of proliferation compared to that seen when cells were stimulated 
with anti-CD3/CD28 beads (average of 48% vs. 75% proliferation compared to 
control). Again, this finding was present in HLA-A2 positive individuals but not 
HLA-A2 negative individuals. (Figure 6.7 and 6.8)  
 
With SEB stimulation, suppression of proliferation was also seen with HLA-G 
tetramers and HLA-G tetramers + anti-HLA-A2. The amount of suppression was 
slightly less than that seen with the cGBOD, although the differences were not 
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significant. Again, this suppression was only seen in HLA-A2 positive 
individuals. 
 
Effect of the chemically conjugated G-body in lymphocytes stimulated with anti-
CD3 mAbs 
 
When stimulated with the anti-CD3 monoclonal antibody, addition of the 
cGBOD resulted in a similar degree of suppression of proliferation compared to 
stimulation with SEB, in HLA-A2 positive individuals. (Figure 6.7) There was 
also a similar effect with addition of HLA-G tetramers or HLA-G tetramers + 
anti-HLA-A2. In the HLA-A2 negative individuals tested, there was slight 
reduction in proliferation with addition of cGBOD, HLA-G tetramers or HLA-G 
tetramers + anti-HLA-A2, although less than that seen in HLA-A2 positive 
individuals, and not statistically significant. (Figure 6.8) 
 
These experiments have been performed in a larger group of 26 HLA-A2 
positive and HLA-A2 negative individuals each by Pedro Vieira, a post-doctoral 
researcher in the same laboratory. These results are similar to the ones done in a 
smaller group of samples and indicate that the cGBOD results in suppression of 
proliferation with all 3 stimuli (anti-CD3/CD28 beads, anti-CD3 and SEB). The 
reduction in proliferation was greater than that seen with HLA-G tetramers or 
HLA-G tetramer + anti-HLA-A2, and only present in HLA-A2 positive 
individuals. In the larger group of HLA-A2 negative individuals, suppression of 
the proliferative response was seen with the cGBOD, HLA-G tetramers and 
HLA-G tetramers + anti-HLA-A2, although these were a similar level with no 
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added suppression seen with the cGBOD (data not shown). These findings 
confirmed the added effect of combining anti-HLA-A2 into the same construct as 
HLA-G.  
 
Effect of the chemically conjugated G-body on allo-proliferation reactions 
 
As the cGBOD was shown to bind to the appropriate ligands on both ends 
(Chapter 5, Figure 5.12a to 5.12d), the molecule was tested in an MLR to 
determine if it had any functional properties. However, addition of the cGBOD 
(or its controls) did not have any difference in an MLR with HLA-A2 positive 
MoDCs as the stimulator population with two different sets of HLA-A2 negative 
responder PBMCs as the responder population. (Figure 6.9, representative of 
both experiments) It can be concluded that at least with this set of conditions, the 
cGBOD did not affect thymidine incorporation by T cells although various other 
parameters (e.g. whether different concentrations of G-body have an effect or 
whether cytokine production is different) remain to be tested. 
 
 
Effect of anti-LILRB2 antibodies on lymphocyte proliferation assays 
 
In view of the effect of the cGBOD and HLA-G tetramers on lymphocyte 
proliferation induced by anti-CD3/CD28 beads, anti-CD3 and SEB, the effect of 
anti-LILRB2 in the system was tested, both using the monoclonal antibody alone 
or with the addition of protein G as a cross linker. However, this did not show 






Cytokine suppression by anti-LILRB2 antibodies 
 
The data showed that there was no significant relationship (in the 5 individuals 
tested) in the amount of cytokine suppression following ligation with anti-
LILRB2 antibodies and the cell surface expression of these molecules. The most 
likely explanation for this is that there were an insufficient number of individuals 
to demonstrate any effect. Ideally, it would be preferable to conduct the analysis 
on a larger number of samples to increase the power of the study, but this was 
not plausible/practical/feasible. 
 
It should be noted, however, that although there was significant variability in the 
suppression of cytokine secretion between the various individuals, there was a lot 
more homogeneity in the expression levels of LILRB2. This raises the possibility 
that cell surface density of the LILRB2 molecules does not play that significant a 
role in influencing downstream immune responses. Alternatively, the limited 
number of structural polymorphisms that exist may play a larger role than 
expected. Differences in the downstream signalling pathway or the TLRs being 
stimulated may also be involved in these differences. 
 
In addition, although previously thought that these molecules interact with the 
non-polymorphic portions of the HLA molecule (the distal D1 and D2 regions of 
LILRB1 and LILRB2 interacting with the α3 domain of the MHC and β2m), 
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there is data showing that the LILR molecules possess different binding affinities 
for different HLA species. (5) The difference in the binding affinity was thought 
to be due to LILR interactions with the peptide groove on the MHC. These more 
recent findings suggest that the LILR molecules do interact with the polymorphic 
regions in the HLA molecule and that HLA haplotype might well influence the 
subsequent immunological responses following binding to the LILRs. (5) It is 
possible that in vivo this represents a more important mechanism by which the 
magnitude of the LILR response is controlled. 
 
In the set of experiments involving cytokine secretion, purified monocytes rather 
than dendritic cells were used. It is possible that the effect of the anti-LILRB2 
antibodies on dendritic cells (purified from whole blood) or monocyte-derived 
dendritic cells (using GM-CSF and IL4) might have been different to purified 
monocytes. This is potentially relevant as dendritic cells are the most potent 
antigen presenting cells and have the greatest influence on subsequent immune 
responses. 
 
Although it is uncertain if the 42D1 clone used to bind the LILRB2 receptor is an 
agonistic or blocking antibody, the reduction in inflammatory cytokines (e.g. IL-
6, IL-8 and TNF-α) would suggest that it is most likely agonistic, at least in the 
set of experiments here. However, it should also be noted that there was a 
concomitant reduction in IL10, which is typically seen as an immunosuppressive 
cytokine. In addition, there is data indicating that engagement of LILR molecules 
on DCs by HLA-G resulted in increased IL10 production. (133) The reason for 
these differences is not entirely clear although there are a number of differences 
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in the experiments conducted. The experiments done here used monocytes 
whereas published data was with monocyte-derived DCs. Furthermore, in this set 
of experiments, only LILRB2 was engaged, whereas the published data mainly 
used HLA-G, which would engage other molecules apart from LILRB2. Also, 
IL10 has been reported to result in secretion of proinflammatory cytokines when 
administered to humans. (233) Taken together, in this context, it is most likely 
that the anti-LILRB2 mAb is suppressing the total cytokine response to the TLR 
stimulus via LILRB2. 
 
In addition, it should be noted that this set of experiments have not yet addressed 
the downstream effect of monocytes exposed to LILRB2 engagement during 
TLR ligand stimulation on the T cell compartment. In terms of next steps, further 
experiments exploring the effect of exposure of anti-LILRB2 treated monocytes 
or dendritic cells on T cells should be done. 
 
Effect of the G-body on lymphocyte proliferation 
 
The assays used to investigate the effect of the G-body on proliferation were 
used initially chosen for simplicity to gauge if more complicated experiments 
would be useful. These have shown that binding of the G-body to its ligands does 
reduce lymphocyte proliferative responses particularly in HLA-A2 positive 
individuals. In addition, the G-body had a greater suppressive effect in 
proliferation compared to either HLA-G tetramers alone or HLA-G tetramers 
mixed with anti-HLA-A2, suggesting that localisation of the G-body to the 
surface of HLA-A2 positive cells had added effects. The effects due to the G-
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body were not seen in HLA-A2 negative individuals. Although only 5 HLA-A2 
positive and 2 HLA-A2 negative individuals were tested in this set of 
experiments, a postdoctoral researcher working in the same laboratory (Pedro 
Vieira) has carried out the same set of experiments on a larger group of samples 
(26 each HLA-A2 positive and negative). These experiments have confirmed the 
findings in this small set of results. 
 
The particularly exciting finding is that localisation of the G-body by means of 
the anti-HLA-A2 portion of the molecule significantly enhances its 
immunosuppressive effect, consistent with the hypothesis. The reasons and 
means by which this occurs is not clear, although several different mechanisms 
may be involved, with both cis- and trans- effects.  
 
It is possible that the G-body binding to dendritic cells and other APCs may 
influence the stimulatory capacity of the APC by interaction with LILRB1 and 
LILRB2 on the cell surface in a cis- fashion. There could also be trans- 
interactions with T cells which express LILRB1; as suggested by the fact that 
stimulation with anti-CD3/28 beads which only rely on the T cell is also 
suppressed. The G-body binding to T cells is also likely to play a role as well 
both through a trans- interaction with APCs as well as cis- interactions with 
LILRB1 on the same cell. 
 
Interestingly, the same effect is not seen in cells which are HLA-A2 negative 
suggesting that there is an additional benefit to localisation via the anti-HLA-A2 
portion as opposed to the effect of pure HLA-G alone. It is possible that binding 
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of multiple G-body molecules on the cell surface allows localisation and delivery 
of a significantly greater immunosuppressive HLA-G signal. To an extent, this 
possibility is supported by the published data indicating that HLA-G multimers 
possess a greater effect compared to HLA-G monomers. (130;230) 
 
However, when the G-body was tested in an allo-proliferative MLR, it had no 
effect when HLA-A2 positive MoDCs were used as stimulator cells with 2 
different sets of HLA-A2 negative PBMCs as the responder populations. The 
reasons for this are not clear – although it should be noted that in published data, 
not all individuals have suppressed allo-proliferative and in one paper, 
approximately half the individuals tested did not show any reduction in an MLR 
when HLA-G was added. (228) In addition, a lower concentration of G-body was 
used in the allo-proliferation experiments (Gbody containing a concentration of 
0.5 μg/ml mAb) compared to those used in the non-allo lymphocyte proliferation 
(Gbody containing a concentration of 2.5 μg/ml mAb) and anti-LILRB2 
experiments (10μg/ml of anti-LILRB2 mAb). This might have contributed to the 
lack of suppression of the proliferative response. Furthermore, MoDCs are 
inherently an extremely potent stimulus and it might be that this was too strong 
for the G-body to overcome. 
 
To further the work and test the potential usefulness of the G-body in a 
therapeutic setting, more complicated experiments involving different 
alloreactive donors should be performed to determine if there is any effect on 
proliferation, cytokine secretion, formation of memory T cells and the 
development of regulatory cells. It would also be useful to determine if exposure 
247 
 
to the G-body resulted in modification of antigen-presenting cells/T cells once 
the original stimulus was no longer present. 
 
Experiments looking at the functional effect of the G-body on NK cytotoxicity 
and function, CD8
+
 T cell cytotoxicity and early signalling events (e.g. calcium 
flux and protein tyrosine phosphorylation) would also be worth doing to fully 




In summary, the data presented in this chapter does support published literature 
indicating that engagement of LILRB2 receptors results in immunosuppressive 
effects. The exact mechanisms underlying this remain to be fully worked out. 
However, the effect on TLR signalling pathways in monocytes has not been 
explored previously and the data showing cytokine suppression in purified 
monocytes does provide additional information about how LILRB2 influences 
immunological outcomes. The data showing differential suppression of cytokine 
secretion (due to TLR agonists) on engagement of LILRB2 has also not been 
described in published literature and warrants further exploration. 
 
The data from the G-body experiments is also encouraging although further 
experiments (particularly involving allogeneic systems) need to be done to 
confirm its immunosuppressive properties. Initial data does suggest that the 
compound (and the theoretical concept) has significant translational potential. 
Although these G-body experiments were done with the chemically conjugated 
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compound, with more resources it would also be useful to determine the 
functional properties of the recombinant G-body although larger quantities would 






IL-6 secretion by purified monocytes after addition of a variety of TLR 
ligands. Bars represent the mean of 3 replicates and the error bars represent 
one standard deviation from the mean. The data represents the results of 


































Effect of addition of anti-LILRB2 vs. rat IgG2a (as IMC) to IL-6 concentration secreted by purified monocytes stimulated with LPS. 

























































Titration experiments showing the effect of varying the dose of TLR ligand (LPS), antibody concentration and monocyte numbers on 
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Percentage reduction in cytokine (IL-6, IL-8, IL-10 and TNF-α) secretion of 
purified monocytes stimulated with LPS after addition of anti-LILRB2 mAb 
compared to addition of a rat IgG2b IMC in healthy individuals (n=5). The 
diamonds represent the mean value and error bars represent 1 standard 
deviation. 
Cytokine











































































Percentage reduction in cytokine (IL-6, IL-8, IL-10 and TNF-α) secretion of 
purified monocytes stimulated with ssRNA after addition of anti-LILRB2 
mAb compared to addition of a rat IgG2b IMC in healthy individuals (n=5). 
The diamonds represent the mean value and error bars represent 1 
standard deviation. 
Cytokine

















































































Difference in cytokine (IL-6, IL-8, IL-10 and TNF-α) secretion by purified monocytes after stimulation with LPS or ssRNA in 



































































































































































































































































































































Correlation between suppression of cytokine secretion (IL-6. IL-8, IL-10 
and TNF-α) by stimulation with LPS and ssRNA after addition of anti-
LILRB2 mAb compared to addition of a rat IgG2b IMC; and LILRB2 
expression levels (in median fluorescence intensity, MFI) for 5 different 













































































































































































































































































































Percentage proliferation compared to control of lymphocytes from buffy 
coats of healthy HLA-A2 positive donors (n=5). Cells were stimulated with 
either anti-CD3/CD28 beads, SEB or anti-CD3 mAb. An anti-HLA-A2 
isotype matched control (IMC), anti-HLA-A2 mAb, G-body, HLA-G 
tetramers or HLA-G tetramers and anti-HLA-A2 mAb were added to 
culture medium to determine if any of these reagents resulted in suppression 
of proliferation. The circles with the bars represent the mean and one 
standard deviation respectively. The red horizontal bars indicate a 
statistically significant difference at p<0.05. 































































































































Percentage proliferation compared to control of lymphocytes from buffy 
coats of healthy HLA-A2 negative donors (n=2). Cells were stimulated with 
either anti-CD3/CD28 beads, SEB or anti-CD3 mAb. An anti-HLA-A2 
isotype matched control (IMC), anti-HLA-A2 mAb, G-body, HLA-G 
tetramers or HLA-G tetramers and anti-HLA-A2 mAb were added to 
culture medium to determine if any of these reagents resulted in suppression 
of proliferation. The circles with the bars represent the mean and one 
standard deviation respectively. There were no statistically significant 
difference between the groups. 































































































































Mixed lymphocyte reaction with MoDC “C” as the stimulator cells and 
PBMCs “F” as the responder population; the cGBod and its controls were 
added at 3 fold successive dilutions (C1 being the highest concentration 
containing 0.5μg/ml mAb). The beads are anti-CD3 anti-CD28 microbeads 
(Invitrogen). Samples were repeated in triplicate and the error bars 
represent one standard deviation. No significant difference was seen 
between any of the groups with addition of the cGBod or any of the control 
reagents. MPC11 is a mouse IgG2b isotype matched control for the anti-



































































































































































Absolute counts per minute (cpm) and percentage of maximum proliferation 
on addition of anti-LILRB2, protein G (pG) or anti-LILRB2 and protein G 
to lymphocytes stimulated with either SEB, anti-CD3/CD28 beads or anti-
CD3. 





































































Chapter 7: Discussion 
 
At present, the LILR molecules represent a potentially exciting area of as yet 
untapped discovery. Their presence and conservation on many different immune 
cells indicate that they are likely to play a significant role in regulating immune 
responses. In particular, myelomonocytic antigen presenting cells, including DCs 
express many different members of the family of these molecules. This suggests 
that they may well play a significant role in fine tuning and controlling immune 
responses, particularly as DCs are the most potent ‘professional’ antigen-
presenting cells.   
 
Despite this inference, relatively little research has been conducted since these 
molecules were first identified more than 15 years ago. These have largely been 
in vitro studies and have demonstrated that the LILR molecules play a role in 
early calcium signalling events, (39;40;42) protein tyrosine phosphorylation, 
(42;225) NK and CD8
+
 T cell cytotoxicity, (39) DC maturation and 
allostimulatory capacity. (99) There have also been a limited number of in vivo 
murine studies showing that LILR molecules (and the PIR homologues) have 
roles in transplantation (68;79) and infection. (7;81) However, most of the 
studies have not been repeated and are relatively few in number. 
 
In addition to laboratory data, there is also some published clinical data showing 
that the LILR molecules are associated or might a play a role in immune-
mediated disease.  
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These have particularly been in the field of transplantation (142;173) and more 
recently, in infectious disease and HIV. (20;159) There is also data showing the 
significance of the LILR molecules in auto-immune and rheumatological disease. 
(28;172) 
 
There have also been a few authors who have suggested the use of the LILR 
system as a therapeutic target. (122;230) However, most experiments looking to 
manipulate the LILR system in the laboratory have utilised HLA-G (as the high 
affinity ligand for LILRB1 and LILRB2); there have also been a few papers 
using monoclonal antibodies against specific LILRs. The majority of the 
experiments have been in vitro, with far fewer efforts to develop in vivo models. 
Murine experiments have utilised the homologous PIR system, although there 
have also been some experiments conducted in mice transfected with HLA-G 
and LILRs. 
 
Given the widespread distribution of this family of molecules and the data 
emerging that they do play a role in a multitude of clinical conditions, it is 
important that steps are taken to increase our understanding. In particular, there is 
currently limited knowledge of their function, role in the immune response and 
potentially whether these molecules do represent a suitable target for therapeutic 
manipulation. To this end, this project has focused on trying to improve 
understanding of this potentially important group of molecules; in particular, the 
work described in earlier chapters has focused on understanding non-coding 
genomic variation in these molecules and their functional impact, as well as 






The first set of experiments conducted was to assess the variability in expression 
of a subset of these molecules and explore whether this variation might be due to 
differences in non-coding DNA. The data showed that there was significant 
variability in expression levels of the LILR molecules. There were differences in 
mean expression levels between different cell types, as well as differences in the 
variability of the same receptor on different cell types. Additionally, variation in 
expression between different individuals was also evident. The response to a 
dynamic stimulus (different cytokines were used in this project) was also tested 
and this too, showed differences between different cell types and between 
different individuals. 
 
A degree of biological variation in the expression of any receptor is not 
surprising; however, the differences in variability on the surface expression of 
the same receptor on different cell types does suggest that expression levels can 
be varied and may potentially have a role to play in determining immune 
responses. The variability in expression levels between different individuals also 
has implications for any therapeutic modality that might be developed in the 
future to utilize this group of molecules. 
 
Subsequently, following measurement of protein expression levels in a larger 
group of individuals, DNA sequencing of the non-coding region of LILRB2 was 
undertaken as proof of principle that genomic variation in this region could affect 
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LILR expression levels. Published data had shown that different haplotypes or 
SNPs for LILRB1 and LILRB2 could affect receptor expression levels. 
(172;194) However, in these studies, some of the variation occurred within 
coding regions of the protein. In this project, several SNPs were identified, 
although no significant relationships were found between expression levels of 
LILRB2 (either at baseline or following cytokine stimulation) and any of the 
SNPs. The reason for this remains to be determined, but is most likely due to the 
relatively small number of subjects tested. In a larger group looking at SNPs in 
more of the LILRs, it is likely that associations between genomic variation and 
LILR expression levels might become more apparent. 
 
In an attempt to address the relatively small numbers in the study, the putative 
promoter region for LILRB2 was cloned into luciferase expression vectors to 
determine if the SNPs present in different haplotypes would affect luciferase 
activity.  This too did not identify any relationship between SNPs/haplotypes or 
protein expression levels. Possible explanations for this include the small number 
of haplotypes tested and non-inclusion (in the cloned promoter region) of SNPs 
that might have effects on protein expression. In addition, the luciferase assay 
had a large amount of inherent variability which could have hidden small 
differences due to SNPs. 
 
In addition to looking at relationships between genomic variation and LILR 
expression levels, the relationship between surface expression levels of LILRB2 
and functional effects was also explored. In the process of developing assays to 
test the effect of LILR expression, it was discovered that ligation of LILRB2 
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resulted in suppression of cytokine secretion due to TLR4 and TLR8 engagement 
(by LPS and ssRNA/LyoVec respectively). This finding has not been previously 
demonstrated and would suggest that LILRB2 ligation can affect both signalling 
initiated by surface receptors and intracellular receptors. In addition, the 
suppression of cytokine responses varies between the two TLR receptors, 
suggesting that there are alternate pathways for secretion of some of the cytokine 
that are less affected by LILRB2 inhibition. 
 
Despite this, however, no relationship between the magnitude of surface 
expression of LILRB2 and functional effect due to its ligation were seen. This 
might have potentially been due to the small numbers of subjects tested in this 
set of experiments and it would be important to repeat this on a larger number of 
subjects to determine if LILR expression levels do affect functional outcomes as 
hypothesized.  
 
The assay for testing LILR expression levels is robust, and given more resources, 
it would have been interesting to measure values in patients with specific disease 
states, both at baseline and in response to stimuli, to determine how these 
molecule are affected in various immunological (and non-immunological) 
conditions. Additionally, there also remains scope to test if particular SNPs (or 
haplotypes) are associated with disease as well. This has been demonstrated in a 
few clinical conditions (Table 1.2) but by and large, remains unascertained for 




In parallel to the experiments done to evaluate LILR expression levels and their 
relationship with genomic variation, work was also carried out to develop 
constructs that could be used to harness the therapeutic potential of these 
molecules. Both a ‘crude’ conjugation of biotinylated HLA-G to streptavidin-
coated anti-HLA-A2 mAbs and a more elegant recombinant single polypeptide 
molecule were created. Binding of both constructs to their cognate ligands was 
demonstrated, showing that these constructs were fit for use in downstream 
functional experiments. Unfortunately, it was not possible to generate sufficient 
quantities of the recombinant construct within the resources of the project and 
hence, the chemically conjugated molecule was used for further experiments. 
However, it would be important to upscale production of the recombinant 
molecule for functional testing, as this format would be more directly applicable 
for use as a therapeutic product. 
 
What is quite promising is the data that the G-body does have an effect in 
functional experiments. Although the effect was only seen in single population of 
cells rather than an MLR, it is noteworthy that was significant additional 
suppression of proliferation with addition of the G-body in the presence of HLA-
A2 positive cells. This strongly suggests that localisation of HLA-G to the cell 
surface by binding to HLA-A2 does confer added immunosuppressive properties.  
 
However, further work with the G-body needs to be done in experiments with an 
allo-specific stimulus. Although initial experiments in a small number of subjects 
did not show any significant effect with addition of the G-body, it might be that 
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an effect would be seen if a larger number of subjects were tested and/or the 
experimental conditions were modified.  
 
The in vitro data also suggests that there is merit in progressing on to mouse 
experiments. This would possibly be best tested in some form of murine allo-
transplantation model e.g. skin grafting. In support of this, a similarly 
constructed molecule comprising an avidin-linked mAb (33D1, which binds to 
DCIR2 on conventional DCs) bound to biotinylated K
d
 monomer has been used 
in a mouse model of allogeneic skin transplantation. (234) The idea behind this 
construct was to allow targeting of intact MHC molecules to quiescent dendritic 
cells, which inhibited the indirect alloresponse against allo-mismatched skin 
grafts. The authors managed to induce indefinite skin graft survival by using this 





The conjugate molecule used by Tanriver et al is similar in principle to the 
concept underpinning the G-body in that it combines two properties. However, 
Tanriver et al delivered the mismatched class I MHC combined with a targeting 
antibody for immature DCs. This allowed the localisation of the high 
concentration of a target antigen to immunosuppressive cells. Additionally, the 
conjugation system used by Tanriver et al is much the same as the technology 
employed for generation of the chemically conjugated G-body, thus providing 





In summary, this project has shown that LILR expression levels can be 
accurately quantified on different cell types. Furthermore, engagement of 
LILRB2 modulates the cytokine response generated by TLR4 and TLR8 
signalling, which is a novel finding.  
 
The generation of a construct combining the immunosuppressive properties of 
HLA-G and the targeting function of an anti-HLA-A2 mAb has been successful. 
This has also been shown to have effects on lymphocyte proliferation, 
particularly more so in individuals who are HLA-A2 positive compared with 
those who are HLA-A2 negative; confirming that there is additional 
immunosuppressive potential to be gained by target-specific localisation of the 
HLA-G. 
 
So far, however, it has not been possible to prove the hypothesis that genomic 
variation affects the expression levels of the LILR molecules, or that the 
magnitude of expression of the LILR molecules has functional significance. 
However, this set of experiments was done on relatively small numbers of 





Several areas in this project merit further exploration based on the data 





1. Sequencing of the coding and non-coding regions for all 4 LILR 
molecules assessed in this study 
2. Use of bioinformatics to analyse the genetic data generated to determine 
the effect of various SNPs on LILR expression levels 
3. Comparison of LILR expression levels between different disease groups 
with healthy controls 
4. Testing the effect of engagement of LILRB2 on other parameters 
a. Activation markers on cells 
b. Ability of APCs to stimulate a T-lymphocyte response, in an 
autologous and allogeneic setting 
5. Testing the effect of engagement of other LILR molecules on cytokine 
secretion and other functional properties as described above 
6. Up-scaling production of the recombinant G-body for use in in vitro and 
in vivo experiments 
7. Further testing of the G-body 
a. To determine its effect on other parameters apart from 
proliferation e.g. cell activation markers, calcium flux, tyrosine 
phosphorylation, cytokine secretion 
b. In MLR reactions 






In conclusion, this project has generated some exciting data – in particular, the 
development of a robust method for quantifying the expression of LILR 
molecules on different cell types, demonstration that engagement of LILRB2 can 
affect functional effects due to cell surface and intracellular TLR signalling; and 
development of the G-body and proof of principle that the construct does have an 
HLA-A2-specific immunosuppressive effect. 
 
However, more work does remain to be done, both in terms of basic science and 
its potential clinical application. The regulation, function and role of the LILR 
molecules remain poorly understood, despite their widespread expression on 
many immune cells. They had been previously thought to act as innate sensors 
for ‘self’ especially with their recognition of MHC molecules; however, their 
recognition of bacteria (7)  suggests that they may have additional roles in the 
recognition and response to microbial pathogens as well. From the point of view 
of this project, the G-body represents a novel development in using MHC 
molecules for localisation of an immunosuppressive/tolerogenic signal and this 
concept may yet prove useful, particularly in the transplantation setting. In this 
regard, further development of the G-body is likely to be rewarding with the 





In summary then, the LILR molecules do indeed represent an area rich with 
potential for future discovery, both in terms of helping us to better understand 
innate immune responses as well as manipulation for therapeutic benefit; and 
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Appendix 1: International Union of Pure and Applied Chemistry (IUPAC) 








R Purine (A or G) 
Y Pyrimidine (C, T, or U) 
M C or A 
K T, U, or G 
W T, U, or A 
S C or G 
B C, T, U, or G (not A) 
D A, T, U, or G (not C) 
H A, T, U, or C (not G) 
V A, C, or G (not T, not U) 
N Any base (A, C, G, T, or U) 
 
 
 
